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ABSTRACT 
Prismatomeris malayana Ridley of Rubiaceae was investigated for its anti-
inflammatory properties by evaluating their inhibition of the hyaluronidase and 
lipoxygenase activity and of TPA-induced inflammation in mice. The leaf was found 
to be the most active in the three selected assays. From bioassay guided fractionation 
and isolation, ursolic acid 60 was isolated and found to be the compound responsible 
for the hyaluronidase inhibitory activity. The  isolation work on the leaves yielded five 
pentacylic triterpenoids (PTC) (3β-hydroxyurs-12-en-28-oic acid 60 [ursolic acid],  3β, 
19, 24-trihydroxyurs-12-en-28-oic acid 61 [barbinervic acid], 3β,23-dihydroxyurs-12-
en-28-oic acid 62, 28-O-β-glucopyranosyl-3α,19α,23-trihydroxyurs-12-en-28-oic acid 
63 and 3β-hydroxyurs-11-en-13,28-olide 65); three iridoids (asperulosidic acid 68,  
scandoside 70 and prismalayanoside 66). Compound 66 (prismalayanoside) is novel 
with an unprecedented spiro-octa-lactone ring. The ten compounds isolated from the 
roots are; one PTC (3β-hydroxyolean-12-en-28-O-acetoate 64); eight anthraquinones 
(lucidin-3-methyl ether  71, rubiadin-1-methyl ether 11, damnacanthol 72,  rubiadin 
10, 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-anthraquinone 73, 2-methoxy-3-
oxyhydroxymethyl -9,10-anthraquinone 74, and lucidin-ω-methyl ether 21) and one 
iridoid (asperulosidic acid 68). Further investigation of the stems led to the isolation of 
lucidin-ω-methyl ether 21 (an anthraquinone) and asperuloside 69 (an iridoid). Seven 
analogues (75-81) were prepared by structural modification of ursolic acid 60. The 
quantitative structure activity relationship study (QSAR) was carried out to correlate 
the selected twenty two ursolic acid analogues with their hyaluronidase inhibitory 
activity.  The statistical characteristic provided by the best multi linear model gave R
2
 
value of more than 0.9 thus indicating good predictive ability. 
 
 
  
ABSTRAK 
Prismatomeris malayana Ridley dari Rubiaceae telah di kaji untuk ciri-ciri anti-
radangnya dengan mengenal pasti perencatannya terhadap aktiviti hialuronidas dan 
lipoksigenas  dan juga terhadap keradangan ditingkatkan-TPA dalam tikus.  Daun 
didapati adalah paling aktif dalam ketiga-tiga essei terpilih. Dari fraksinasi dan isolasi 
berpandukan essei, asid ursolik 60 telah diasingkan dan didapati adalah sebatian yang 
bertanggungjawab untuk perencatan aktiviti hialuronidas.  Pengasingan keatas daun 
menghasilkan lima triterpenoids pentasiklik (PTC) (3β-urs-12-en-28-oic acid 60 (asid 
ursolik),  3β, 19, 24-trihidroksiurs-12-en-28-oic acid 61 [asid barbinervik], 3β,23-
dihidroksiurs-12-en-28-oic acid 62, 3β-hidroksiurs-11-en-13,28-olide 65  dan 28-O-β-
glukopiranosil-3α,19α,23-trihidroksiurs-12-en-28-oic asid 63) dan tiga iridoid [asid 
asperulosidik 68,  skandosida 70 dan prismalayanoside  66). Sebatian 66 
(prismalayanosida) adalah nobel dengan gelang “spiro-octa-lactone”. Sepuluh sebatian 
dari akar adalah satu PTC [3β-hidroksiolean-12-en-28-O-acetoate 64], lapan 
antrakuinon [lucidin-3-metil eter 71, rubiadin-1-metil eter 11, damnakantol 72, 
rubiadin 10, 1-etill-3-hidroksimetil-4-hidroksi-9,10-antrakuinon 73  dan 2-metoksi-3-
oksohidroksimetil -9,10-antrakuinon 74]  dan satu iridoid [asid asperulosidik 68]. 
Kajian lebih lanjut keatas batang berjaya mengasingkan dua sebatian antrakuinon 
[lucidin-ω-metil eter 21] dan iridoid [asperulosida 69]. Tujuh terbitan  (75-81) telah 
disediakan dari struktur modifikasi ke atas asid ursolik 60. Kajian perhubungan 
kuantitatif struktur activity (QSAR) telah dilakukan untuk menghubungkan dua puluh 
dua terbitan asid ursolik 60 terpilih dengan aktiviti perencatan hialuronidas mereka. 
Ciri-ciri statistik telah dihasilkan melalui model multi linear terbaik yang memberikan 
nilai R
2
 lebih dari 0.9 seterusnya menunjukkan keupayaan ramalan yang memuaskan. 
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Chapter 1:  
Introduction 
 
 
 
 
 
 
 
 
 
 
  
 
1.1 General 
 
There are three different types of medicine: traditional, herbal and pharmaceutical (de 
Padua et al., 1999). The same plant may be consumed as a medicinal tea or it may be 
cultivated and processed into a herbal medicine alternatively formulation in different 
communities or countries. It may provide a lead compound for pharmaceutical 
development. These systems of medicine are complementary in health care and can in 
no way substitute for one another. 
 
Since ancient times people have been exploring nature, and plants in particular have 
been one of the major foci in the search of new drugs (Verpoorte, 1999). As of today, 
plants have provided many novel natural compounds (Graham, 2005) with potent 
activities and biological properties such as taxol 1, artemisinin 2, vinblastin 3, quinine 
4, morphine 5. In order to find new leads from plants, random screening of plant 
species is presently widely used based on chemotaxonomy, traditional use or plant 
ecological observations. In 1995, Pimn et al. reported that there are about 250,000 
different plant species of which 70% have not been investigated at all while the other 
30% have only been partially investigated. This means that more than 70% of higher 
plants have not been adequately studied for potentially useful biological activity and 
the plant kingdom has not received sufficient attention as a resource for possible 
medicinal agents (Pimn et al., 1995).  
 
In 1988, the database NAPRALERT was reported to contained more than 88,000 
secondary metabolites, and every year some 4000 new ones are being reported 
(Verpoorte, 1999). In addition, over half of the world’s 25 best selling pharmaceuticals 
for 1991 owed their origin to a natural source material (O’Neil & Lewis, 1993) and 
  
120 plant-derived compounds are currently used as drugs (Farnsworth et al., 1985). In 
another extensive review of new drugs introduced between 1981 and 2002 (Newman et 
al., 2003),  28% of the 868 new chemical entities were natural products or derived 
from natural products, while another 28% of drugs were created around a 
pharmacophore  from a natural product. 
 
Several natural anti-inflammatory drugs were identified in plant extracts that have been 
used in traditional medicine for the relief of pain, fever and inflammation related 
diseases (Maria et al., 2010) such as curcumin 6, resveratrol 7 and lupeol 8.  
Inflammation has been recognized as a common mechanism of disease in neurological 
and neuropsychiatric diseases; therefore, interest in anti-inflammatory drugs has 
increased among investigators. Natural compounds are currently being considered for 
treatment of chronic inflammatory and neurodegenerative diseases due to the serious 
adverse effect of modern drugs used to treat inflammation.   
 
The most frequently prescribed drugs in modern medicine were non-steroidal anti-
inflammatory drugs (NSAIDS) which are very effective in the alleviation of pain, fever 
and inflammation (Inger et al., 2010). The term NSAID refers to structurally diverse 
chemical compounds that share the ability to inhibit the activity of the prostaglandin 
biosynthetic enzymes, the cyclooxygenase (COX) isoforms 1 and 2 (Maria et al., 
2010).  By 2010, about fifty different NSAIDS preparations were available in the 
market with main indications from mild to moderate pain of somatic origin (Inger et 
al., 2010).  NSAIDS may be classified as salicylates, arylalkanoids acids (diclofenac, 
indomethacine, nabumethone, sulindac), 2-arylpropionic acids or profens (ibuprofen, 
flurbioprofen, ketoprofen, naproxen), N-arylanthranilic acids or fenamic acids 
(mafenamic acid, meclofenamic acid), pyrazolidine derivatives (phenylbutazone),  
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oxicams (piroxicam, meloxicam), sulfonilides (nimesulide) and others.  However, the 
mechanisms underlying their beneficial effects remain largely unknown.   
 
One important development was the discovery of selective COX-2 inhibitors (coxibs) 
which were introduced into clinical practice because of their reduced risk of 
gastrointestinal bleeding compared to non-selective COX inhibitors. Unfortunately, 
these compounds later shown to posses significant cardiovascular adverse effects, thus 
leading to the withdrawal from the market of one drug of this class, (rofecoxib) 
(Imbimbo et al., 2009).  The selective NSAIDS also have the same adverse effect such 
as diclofenac, ibuprofen and piroxicam.  NSAIDS also show gastrointestinal toxicity 
mediated by the inhibition of COX-1 effects on the gastric mucosa resulting in 
heartburn, dyspepsia, nausea, abdominal pain (subjective symptoms), erosions, 
asymptomatic ulcers (superficial gastro duodenal mucosal lesions) and perforation, 
symptomatic ulcers, bleeding (serious gastro duodenal ulcers) (Inger et al., 2010).   
 
In Malaysia, the plant Prismatomeris malayana has not been extensively investigated 
for the chemical constituents even though it is widely used in traditional medicine, 
especially in relation to anti-inflammatory aspects. Therefore, the objectives of the 
study are: 
 
1. To evaluate the anti-inflammatory activity of this plant using three assays;  
hyaluronidase, lipoxygenase and TPA mouse ear oedema inhibitory activity. 
2.        (a)  To conduct bioassay guided fractionation and isolation on this plant in order                   
to isolate and elucidate the structure of the active anti-inflammatory chemical 
compound/s 
 
  
(b) To isolate and elucidate structure of the other chemical compounds from 
this plant and also evaluate them. 
3.  To synthesize analogous of the active compound from 2(a) for quantitative 
structure activity relationship (QSAR) study. 
4. To construct a QSAR model that relates the structure with the bioactivity 
values on the active compound and the analogues. 
 
1.2 Rubiaceae: Distribution and habitat 
 
Rubiaceae is distributed worldwide but found mainly in tropical countries with about 
500 genus and 6000 species (Ng, 1990). It was an important component of the lower 
strata of the rain forest.  In terms of stem density, has great variation from 0.1 stem per 
acre to 14 stems per acre (Ng, 1990). Distribution of some known species are Gardenia 
carinata in northen part of Peninsular Malaysia while Timonius wallichianus in south 
of Peninsular Malaysia. 
 
The plants of this family with the most economic use are coffee (Coffea Arabica L., C. 
liberica bull., C. robusta Linden) and quinine (Cinchona ledgeriana Moens, C. 
succirubra Pavon) which are natives to Peru (Keng, 1969). The gambier, a tanning 
material from Uncaria gambier Roxb. was at one time an important crop on Singapore 
Island.    
 
The Rubiaceae family is used in traditional medicine as an exceptional source of anti-
malarial herbs (Milkyas et al., 2013) such as Pentas micrantha. Decoctions of Rennelia 
elliptica are taken as aphrodisiac, body aches and as post natal tonic (Osman et al., 
2010) whereas the famous Morinda citrifolia has been used for a broad range of 
  
therapeuthic uses such as to treat diabetic (Kohei et al., 2010). Phytochemical   
investigation have shown that many Rubiaceous plants have been found to contain 
napthtohydroquinones and anthraquinones both free and as glycosides (Su-ching et al., 
1995) such as Galium verum (Derek et al., 1995), Rubia lanceolata Hayata (Su-Chin et 
al., 1995), Pentas micrantha (Milkyas et  al., 2013) and Ophiorrhiza pumila (Mariko et 
al., 1998).  The anthraquinones, in particular the 9,10-anthraquinones, were reported to 
posses anti-plasmodial, anti-viral, anti bacterial, anti-fungal, protein cleaving, anti-
cancer and anti-malarial properties  (Endale et. al., 2012; Koyama et al ., 2008;  Singh 
et al., 2006; Chan et al., 2011; Suzuki et al., 2005; Wang et al., 2008; Winter et al., 
1995) 
 
1.3 General appearance and morphology 
 
The Rubiaceae are trees, shrubs, or infrequently herbs comprising about 450 genera 
and 6,500 species, including some lianous forms. Common plants included gardenia, 
cinchona, weet woodruff, partridgeberry, gambier, ixora, and noni (Keng, 1969).  The 
leaves are simple and usually entire, opposite or sometimes whorled and stipules are 
present and interpetiolar (Keng, 1969, Ng, 1990, Corner, 1988). The flowers are nearly 
always bisexual and actinomorphic, often heterostylous, and usually are in cymose 
inflorescences. The calyx is mostly somewhat reduced four to five lobes.  Sometimes 
the lobes are obsolete, rarely greatly expanded and brightly colored. The sympetalous 
corolla is mostly four to five lobed, occasionally with three or up to ten lobes. The 
androecium consists of as many stamens as corolla lobes and is adnate to the corolla 
tube or epigynous zone, alternate with the lobes. The gynoecium consists of a single 
compound pistil of two or seldom more carpels, a single style, and a nearly always 
inferior ovary with the number of locules equaling the number of carpels, each with  
  
one many axile ovules. An epigynous nectary disk is usually present. The fruit is 
variable and sometimes forming multiples. 
 
1.4 Taxonomy of Rubiaceae 
 
The botanical classification of the family is most intricate, depending chiefly on the 
minute structure of the ovary, stamens and seeds (Corner, 1988). Hsuan Keng (1969) 
was divided the order rubiales into two families; rubiaceae and caprifoliaceae. The key 
to the rubiaceae family was opposite and stipulate leaves and regular flower. The 
family members are either herbs, shrubs or trees and some times climbers. The 
subfamilies Rubioideae and Cinchonoideae, are generally recognized mainly by the 
number of ovules in an ovary–locule.   
 
Bremer et al. (2000), suggests the classification of the Rubioideae through their 
phylogenetic analyses based on molecular data i.e  protein coding rbcL gene, the 
spacer sequence between atpBand and rbcL and the third, non-coding intron marker 
(rps16) from Andersson and Rova (1999). The classification is under the genus 
Prismatomeris under subtribe Prismatomerinae and tribe Morindeae. Scheme 1.4 
summarized the classification of the Rubiaceae family.  The list of Prismatomeris 
species, as retrieved on in 
http://iphy10.org/~rpage/theplantlist/A/rubiaceae/Prismatomeris, were listed in table 
1.4  together with their reference. The list also included the varieties and subspecies of 
Prismatomeris.  
 
 
 
  
 
 
 
 
 
 
Scheme 1.4:   Classification of Rubiaceae 
 
 
 
 
 
 
 
 
 
 
Species 
Genus 
Subtribe 
Tribe 
Subfamily 
Family 
Genus Rubiales  
Rubiaceae 
Robioideae 
Monondeae 
Prismatomerinae 
Prismatomeris 
Prismatomeris sp. 
Cinchonoideae 
Caprifoliaceae 
  
Table 1.4: The list of Prismatomeris species and reference. 
 
Species References 
P.  albidiflora Thwaites Hooker’s J. Bot. Kew Gard. Misc. 8: 269 
1856 
P. albidiflora var. fergusonii  
(Thwaites ex Bedd.) Trimen 
Handb. Fl. Ceylon 2: 356 1894 
P. albidiflora var javanica Valeton Bijdr. Boomsoort. Java 8: 199 1902 
P. andamanica Ridl. Bull. Misc. Inform. Kew 1939: 607 1940 
P. beccariana (Baill. Ex K. Schum.) 
J.T. Johanss 
Opera  Bot. 94: 57 1987 
P. brachypus Ridl. Bull. Misc. Inform. Kew 1939: 602 1940 
P. brevipes Hutch. Pl. Wilson. 3: 413 1916 
P. connata Y.Z. Ruan Acta Phytotax. Sin. 26: 447 1988 
P. euphlebia Merr. Mitt. Inst. Allg. Bot. Hamburg 7:301 1937 
P. Thwaites ex Bedd. Fl. Sylv. S. India 134/10 1871 
P. filamentosa Craib Bull.  Misc. Inform. Kew 1932: 436 
P. fragrans Geddes Bull. Misc. Inform. Kew 1927: 173 
P. fragrans subsp. andamanica (Ridl.) 
J.T. Johanss. 
Opera Bot. 94: 45 1987 
P. glabra (Korth) Valeton Bot. Jahrb. Syst. 44: 569 1910 
P. grifthii Ridl. J. Fed. Malay States Mus. 10: 96 1920 
P.harmandii Pit. Fl. Indo-Chine 3: 429 1924 
P. henryi (H. Lév.) Rehder J. Arnold Arbor. 16: 328 1935 
P. javanica (Valeton) Ridl. Bull. Misc. Inform. Kew 1939: 606 1940 
P. kinabaluensis J.T. Johanss. Opera Bot. 94: 40 1987 
P. labordei (H. Lév.) Merr. Ex Rehder J. Arnold Arbor. 18: 249 1937 
P. lepidophloia (Miq.) Ridl. Bull. Misc. Inform. Kew 1939: 601 1940 
P. linearis Hutch. Pl. Wilson. 3: 414 1916 
P. malayana Ridl. J. Fed. Malay States Us. 10: 142 1920 
P. memecyloides Craib Bull.  Misc. Inform. Kew 1932: 437 
P. mollis Craib Bull.  Misc. Inform. Kew 1932: 437 
P. multiflora Ridl. Bull.  Misc. Inform. Kew 1939: 603 
P. neurophylla (Miq.) Ridl. Bull.  Misc. Inform. Kew 1939: 606 
P. obtusifolia Merr. Philipp. J. Sci. 26: 492 1925 
P. ovalifolia Ridl. Bull.  Misc. Inform. Kew 1939: 605 
P. parkinsonii Ridl. Bull.  Misc. Inform. Kew 1939: 605 
P. parviflora  Ridl. Bull.  Misc. Inform. Kew 1939: 605 
P. robusta J.T. Johanss. Opera Bot. 94: 40 1987 
P. sessiliflora Pierre ex Pit. Fl. Indo-Chine 3: 429 1924 
P. subsessilis King & Gamble J. Asiat. Soc. Bengal, Pt. 2, Nat. Hst. 73: 91 
1904 
P. tetrandra (Roxb.) K. Schum. Nat. Pflanzenfam. 4(4): 138 1891 
P. tetrandra subsp. malayana (Ridl.) 
J.T. Johanss. 
Opera Bot. 94: 40 1987 
P.  tetrandra subsp. tetrandra unknown 
P. tetrandra var. multiflora (Ridl.) Y.Z. 
Ruan 
Acta Phytotax. Sin. 26: 447 1988 
P.  tetrandra var. philippinensis Ridl. Bull.  Misc. Inform. Kew 1939: 603 
  
1.5 The genus: Prismatomeris 
 
 The genus Prismatomeris comprises twenty five species in the world, of which 
approximately grow in tropical Asia (Lemmens & Bunyapraphatsara, 2003). It is 
classified in the tribe Morindeae, together with Morinda and Renellia; it seems closely 
related to the latter genus. However some authors have placed it in a separate tribe 
Prismatomerideae (Lemmens & Bunyapraphatsara, 2003).  
 
The genus Prismatomeris is a small shrub tree, glossy pale brown bark flaking off 
when dry, each inter node with a median longitudinal ridge ending between each pair 
of leaf stalks. The leaves are ovate to elliptic or slightly obovate.  Secondary veins are 
known to inarch to form a series of marginal loops while tertiary veins are reticulate or 
obscure. The stipules of the leaves are triangular, bifid at the tip and the apices are 
either looks like two cusps or fine points (Ridley, 1967). Its flowers are stalked or 
sessile, in terminal and axillary clusters of two to ten bisexual and heterostylous. The 
calyx cup fringed by four to six teeth or sub truncate. The colour is white (Ridley, 
1967). The ovary are two-celled while ovules one per cell.  It attached to ovary cross 
wall with filiform style and two-lobed stigma. The fruit are globose to ellipsoid with 
one or two seeded. The seed are globose, with a narrow lateral groove at its point of 
attachment. 
 
1.6 The species: Prismatomeris malayana 
 
P. tetrandra (Roxb.) K. Schum (figure 1.6.1-1.6.4) is also synonym to P. malayana 
Ridley and P. albidiflora King (Lemmens & Bunyapraphatsara, 2003). Locally it is 
  
known as tongkat aji samat. This species can be found in north-eastern India, Sri 
Lanka, Bangladesh, Burma, southern Laos, Vietnam, southern China, Thailand, 
Peninsular Malaysia, Singapore, Anamas Island (Indonesia) and Philipines (Luzon).  
The distribution mainly in lowlands regions up to 500m altitude, but sometimes in 
montane forest up to 1700 m altitude, in humid evergreen forest as well as dry forest, 
scrub vegetation, on dunes, also on shale and limestone . 
 
P. malayana is a shrub or small tree up to 7 m tall; young branches with 2 prominent 
longitudinal ridges (Lemmens & Bunyapraphatsara, 2003). It will flowering at 5 ft. 
tall. (Corner, 1988).  It has dark grey brown colored bark. The twigs are brittle. The 
leaves decussately opposite on vertical branches, distichously opposite on horizontal 
branches, simple and entire. The petiole are 2-25 mm long while the stipules are 
interpetiolar, narrowly triangular, up to 7.5 mm long and either caduceus or persistent 
(Lemmens & Bunyapraphatsara, 2003). Figure 1.2 illustrates the flower (Corner, 1988) 
and the flowering and fruiting branch of P. malayana (Lemmens & Bunyapraphatsara, 
2003). The flowers are bisexual, heterodistylous, strongly scented. Its pedicel is up to 
3.5m long while calyx is tubular with up to 2.5mm long and usually denticulate. Its 
corolla is hypocrateriform with tube up to 3cm long and lobes up to 2.5cm long. The 
colour of flower is white with stamens inserted above the middle of the corolla tube.  
The disk of flower is annular with two celled inferior ovary which is filiform style and 
it has 2-lobed stigma.  
 
The fruits are sub globose drupe with 7-11 mm in diameter and the colour is blackish-
purple to blackish-blue and it is 1-seeded. The seed is almost spherical, up to 9 mm in 
diameter with dark reddish-brown testa and endosperm corneous (Lemmens & 
Bunyapraphatsara, 2003). 
  
1.7 Medicinal significance and known biological importance of Prismatomeris 
species. 
 
In the traditional medicinal system, every part of Prismatomeris malayana is very 
useful. In Peninsular Malaysia and Thailand traditional medicinal system, the leaves 
have been applied as a poultice to fresh wounds (Burkill, 1966). In Cambodia, a 
decoction of the leaves, made by extended boiling with coconut palm and lawsonia 
roots, is used to treat bronchitis. In Thailand, the macerated roots in water are used to 
treat snakebites whereas in Indochina, the decoction has been used in a mixture with 
coconut and henna to treat bronchitis (Lemmens & Bunyapraphatsara, 2003).   
 
The wood is considered a tonic and depurative in herbal tea drink after childbirth in 
Indochina. People in Thailand will use the decoction of the mixture of roots or stem 
with other herbal plant to treat bloody vomiting (Lemmens & Bunyapraphatsara, 
2003). The author interviewed a few traditional medicinal practioners and found out 
that the root of P. malayana is one of the ingredients in a tonic containing also 
Eurycoma longifolia (tongkat ali) used as a preparation for improving blood circulation 
and providing energy. 
 
Past reports have illustrated that there has been a few biological activity studies on 
Prismatomeris sp.  An extract of P. tetrandra was found to be cytotoxic in brine 
shrimp lethality bioassay and on human tumor cell line (Dey et al., 2003).  Kartsen et 
al. (2007) reported on the isolation and determination of absolute configuration of the  
 
  
 
 
Figure 1.6.1:   Prismatomeris malayana Ridley 
 
Figure 1.6.2: The leaves and roots of Prismatomeris malayana Ridley 
 
 
Figure 1.6.3:  The flowering and fruiting 
branch of Prismatomeris malayana Ridley 
(Lemmens,R.H.M.J.& Bunyapraphatsara N., 
2003) 
 
 
 
 
 
 
 
 
 
Figure 1.6.4:  The flower of                                              
Prismatomeris malayana   Ridley 
(Corner E.J.H, 1988) 
  
 
new cytotoxic iridoids from Prismatomeris tetrandra namely as prismatomerine 9.  A 
number of anthraquinones, iridoids, triterpenoids and steroids were isolated from this 
species (Jiang et al., 2005; Zi-Ming et al., 2005). Kwanjai et al. (2005), reported on the 
biological activity such as anti-plasmodial, anti-tuberculosis, anti-fungal and 
cytotoxicity of the isolated anthraquinones and triterpenoids from Prismatomeris 
fragrans. Their preliminary study revealed that the hexane and dichloromethane 
extracts of the root and stem exhibited anti-plasmodial activity against Plasmodium 
falciparum (IC50 range 3.1- 3.7 μg/mL), anti-mycobacterial activity against 
Mycobacterium tuberculosis (MIC range 25-100 μg/mL), anti-fungal activity against 
Candida albicans (IC50 range 11-17 μg/mL) and cytotoxicity against BC and NCI-
H187 cell lines (IC50 range 2-8 μg/mL).   
 
The root methanol extracts of Prismatomeris sessiflora Pierre ex Pitard showed 
significant anti-malarial potential against T9/94 Plasmodium falciparum (Kittisak et al., 
1999). However, the isolated rubiadin 10 and rubiadin-1-methyl ether 11 
(anthraquinones) revealed weak activity on the anti-malarial assay with IC50 range 
13,000 ng/mL and 1,560 ng/mL respectively.   
O
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O
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10  R1=R3= OH   R2=CH3
11  R1= OCH3   R2= CH3   R3= OH 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 2:   
General chemical aspects 
 
 
 
 
  
2.1 Introduction 
 
Plants can be classified based on their physical characteristics and are hierarchically 
divided into kingdom, sub-kingdom, division, class, sub-class, order, family, genus and 
species. Besides that, through observations on reported findings, it may be expected 
that similar types of chemical constituents could be found in similar plant orders or 
family. This expectation is based on the assumption that similar plant orders or family 
contain similar types of enzymes, and that these enzymes can probably catalyse similar 
biotransformations ultimately leading to similar chemical structures (Vierhuis et al., 
2001; Umezawa, 2003).   
 
2.2      Chemical constituents of Prismatomeris  
  
Examination of the literature has demonstrated that Prismatomeris species produces 
mainly anthraquinones, iridoids and triterpenoids (Lee, 1968, Kittisak et al., 1999, Zi-
Ming et al., 2005, Kwanjai et al., 2005 and Kartsen et al., 2005).  The iridoids and 
triterpenoids are classified under the terpenes groups while the anthraquinones are 
considered as phenolics. Further discussion will be carried out on these three groups of 
chemical constituents to understand their classification, structures, biogenetic pathways 
in plants and to list down their medicinal properties.   
 
Lee (1968), Kittisak et al. (1999) and Zi-Ming et al. (2005) reported on the isolation of 
two anthraquinones i.e. rubiadin-1-methyl ether 11 and rubiadin 10 from 
Prismatomeris malayana, P. sessiflora and P. tetrandra respectively. The two 
anthraquinones were also isolated from P. fragrans (Kwanjai et al., 2005).  Besides 
these two anthraquinones, Zi-Ming et al. (2005) also reported another six 
  
anthraquinones from P.tetrandra as following: 1-hydroxy-2,3-dimethoxy-7-methyl-
9,10-anthraquinone 12, 1,3-dihydroxy-5,6-dimethoxy-2-methyl-9,10-anthraquinone 
13, 3-hydroxy-1,5,6-trimethoxy-20-methyl-9,10-anthraquinone 14, 1-hydroxy-2-
methyl-9,10-anthraquinone 15, 1,3-dihydroxy-2-methoxy-9,10-anthraquinone 16 and 
2-hydroxy-3-hydroxmethyl-9,10-anthraquinone 17.  Another six anthraquinones were 
identified from P. fragrans i.e. 1,3-dihyroxy-2-methyl-5,6-dimethoxyanthraquinone 
18, nordamnacanthal 19, damnacanthal 20, lucidin-ω-methyl ether 21 and 1-hydroxy-
2-hydroxymethyl-3-methoxyanthraquinone 22 (Kwanjai et al., 2005).  A complex 
iridoid, prismatomerin 9 has been isolated from P. tetrandra together with 
gaertneroside 23 (Kartsen et al., 2005). 
 
A biological activity investigation on P. fragrans by Kwanjai et al. (2005) reported on 
the isolation of two triterpenoids, β-acetylolean-12-en-28-olic acid 24 and 3β-O-acetyl-
11α, 12α-epoxyolean-28, 13-olide 25 and β-sitosterol 26.   
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2.3           Terpenoids 
 
Terpenes are one of the most important classes of natural products. These compounds 
are widely distributed in nature. Terpenes often possess a five carbon unit, known as 
isoprene unit 33 and is commonly represented by the symbol C5 (Ruzicka, 1953). The 
number of isoprene units 33 incorporated in the particular terpenes, serves as basis for 
the classification of these group of compounds as listed in table 2.3 (Grisehach, 1965). 
Thus, monoterpenes are composed of two isoprene units and have the molecular 
formula C10H18, sesquiterpenes contains three isoprene units; C15H28, diterpenes have 
four isoprene units ; C20H34 and triterpenes are composed of six isoprene units; C30H50. 
 
 
 
  
 
Table 2.3:  Classification of terpenoids 
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2.3.1 Biosynthesis of triterpenoids and iridoids  
 
The mode of synthesis of compounds in plants will be discussed in this part. Two 
terms that usually used in this field are “biogenesis” and “biosynthesis.  However, it is 
customary that the former term is used for a hypothesis, and the latter for an 
experimentally proven route (Nakanishi et al., 1974). The immense variety of 
structural types found in the terpenoids was rationalized by the isoprene rule of 
Ruzicka (Ruzicka, 1921).  The biogenetic isoprene rule implies the involvement of an 
isoprene’s branched five carbon units in the biosynthesis of terpenoids.  The isoprene 
units 33 could be linked together in a head-to-tail, tail-to-tail or head-to-head manner. 
During the biosynthesis, terpenoids could be formed by a linear arrangement of 
isoprene units 33 followed by various cylisations, rearrangements of the carbon 
No. of 
Carbon 
Name Parent Subclass Occurence 
10 Monoterpenoids GPP  27 Iridoids Oils 
15 Sesquiterpenoids FPP  28 Abscesic Oil, Resins 
20 Diterpenoids GGPP 29 Gibberellins Resin, Bitters, 
Heartwood 
25 Sesterpenoids GFPP 31 - Resin. Bitters, 
Heartwood 
30 Triterpenoids Squalene  30 Phytosterols, 
Cardenolides, 
Saponins 
Resin. Bitters, 
Heartwood, 
Latex 
40 Carotenoids 34 Phytones 32 - Gene tissues, 
Root and Fruit 
10
13
-10
14
 Rubbers GGPP 29 - Latex, root 
  
skeleton and by the loss or addition of carbon atoms.  However, the isoprene is not a 
precursor of the triterpenoids 
 
Triterpenoids constitute a large and diverse group of natural products.  The 
biosynthesis proceeds via the formation of 15-C atom farnesyl pyrophosphate (FPP) 28 
from the linkage of three isoprene 33 unit in a head-to-tail manner (scheme 2.3.1).   
Two FPP 28 linked in a tail-to-tail manner to give squalene 30, a 30-C atoms (Holstein 
et al., 2004). Squalene 30 is oxidized to oxidosqualene 35 or squalene 2,3-epoxide 
(Abe et al., 1993, Haralampidis et al., 2002). Cyclization of oxidosqualene 35 to 
saponins can proceed in two ways, either via ‘chair-chair-chair conformation’ or via 
‘chair-boat-chair’ conformation (Vincken et al., 2007). The stereochemistry clearly 
showed the configuration of the C8 and C14 atoms. Cyclisation via the ‘chair-chair-
chair’ conformation resulted in the methyl group at the C8 atom pointing upwards 
while the one at C14 atom is pointing downwards, whereas the opposite is the case 
after cylization of the ‘chair-boat-chair’ conformation (Vincken et al., 2007).  
Oxidosqualene 35 is further converted to cyclic derivatives via protonation and 
epoxide ring opening, which creates a carbocation which can undergo several types of 
cyclization reactions. After these cyclizations, subsequent rearrangements can proceed 
in different ways by a series of hydride shifts and/or methyl migrations, which lead to 
the formation of new carbocations. Finally, the carbocations are neutralized by proton 
elimination to give a double bond or a cylopropanyl ring, or by reaction with water to 
give a hydroxyl group. Scheme 2.3.2 illustrates the cyclisation of oxidosqualene to the 
various triterpenes skeletons.   
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Scheme 2.3.1:  General scheme of terpenoid biosynthesis 
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Scheme 2.3.2:  The cyclization of oxidosqualene to the various saponins skeletons 
  
  
Iridoids are usually found as glycosides (Biswanath et al., 2007).  Structurally they are 
cylopentano [c] pyran monoterpenoids which is also known as the iridane 36 skeleton 
cis-2-oxa-bicyclo-[4,3,0]-nonane (Jean, 1995).   
O
C
OC
C
36  
Iridoids generally have ten carbon atoms. The eleventh carbon is generally part of a 
carbomethoxyl group (loganin 37, geniposide 38) or part of carboxylic acid group 
(monotropein 39) or by an aldehyde or methyl group (lamioside 40). Sometimes the 
eleventh carbon is absent (aucubin 41, catalpol 42).  Secoiridoids and plumeria iridoids 
is another group with a different skeleton (Jean, 1995; Biswananth et al., 2007).   
Secologanin 43, gentiopicroside 44 and oleoside 45 are examples of secoiridoids while 
plumericin 46 is an example for plumeria. 
 
Biogenetically and chemotaxonomically of iridoids provide a structural link between 
terpenes and alkaloids (Biswananth et al., 2007). The incorporation of labeled 
mevalonic acid and geraniol derivatives into iridoid-type structures demonstrated the 
terpenoid character of iridoids (Jean, 1995). One of the proposed mechanisms involves 
the cyclisation of 10-oxo-geranial 47 to iridodial 48 or to 8-epi-iridodial 49. The 
glucosylation and oxidation of iridodial 48 leads to loganin 37, the lead precursor of 
most iridoids. The same process also applies to 8-epi-iridodial 49 to lead, via 8-
epiloganin, to antirrhinoside 50, and gardenoside 51.  Loganin 37 will undergo a ring 
opening which leads to the secoiridoids via the secologanin 43; the precursor of all the 
secoiridoids.  Scheme 2.3.3 shows the proposed simplified biogenesis of iridoids. 
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Scheme 2.3.3:  Simplified biosynthesis of iridoids
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2.4    Aromatic or benzenoid compound. 
 
The fundamental structural element that characterizes phenolics is the presence of one 
or more aromatic rings substituted by at least one hydroxyl group, free or engaged in 
another function such as ether, ester or glycoside (Jean, 1995). Plant phenolic 
compounds are widely distributed in plant kingdom. Recently, polyphenols have 
gained an importance due to their potential use as prophylactic and therapeutic agents 
in many diseases, as well as their anti oxidant properties (Venketeshwer, 2012). Table 
1.2.2 illustrates the classification of the phenolic constituents in plants which provided 
by Harbone & Simmons (1964). 
 
 
 
Table 2.4:  The classification of the phenolic constituents in plants 
Carbon Families of phenols 
C6 Simple phenols 
C6 Phenolic acids and related compounds 
C6-C1 Acetophenones and phenylacetic acids 
C6-C2 Cinnamic acids and related compounds 
C6-C3 Coumarins, isocoumarins and chromones 
C15 Flavones 
C15 Isoflavones and Isoflavonoids 
C15 Flavonols, dihydroflavonols and related compounds 
C15 Anthocyanidins 
C15 Chalcones, aurones and dihydrochalcones 
C30 Biflavonyls 
C6-C1-C6 Benzophenones, xanthones and stilbenes 
C6-C2-C6 Quinones 
C6-C10-C14 Betacyanins 
C18  
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2.4.1 Biosynthesis of anthraquinones 
 
Anthraquinones 52 is a good example of a class of natural products incooporating a 
quinine moiety. It is naturally occurred when the dione 53 conjugated to two 
condensed polycyclic aromatic system (Jean, 1995). Generally, quinones arise from the 
oxidation of phenols.   
O
O
O
O
52 53
1
2
3
4
10
9
5
6
7
8
1 2
345
6
A B C
 
One of the remarkable features of anthraquinone biosynthesis in higher plants is that 
they are derived from a variety of different precursors and pathways (Leistner, 1981).  
The two main biosynthetic pathways leading to anthraquinones are the polyketide 
pathway (Van Den Berg & Labadie, 1989) and the chorismate pathway (Leistner, 
1985).  However, anthraquinones in the family Rubiaceae such as those from Morinda, 
Rubia and Galium species are considered to be biosynthesised via the chorismate acid 
pathway (Scheme 2.4.1). The shikimic acid and chorismic acid pathway shall be 
discussed in the next paragraph. 
 
Thus, it was established that rings A and B of anthraquinones 52 in Rubia (Leistner, 
1981), Morinda  (Leistner, 1967) and Galium (Bauch & Leistner, 1978, Inoue et al., 
1984) are derived from shikimic acid 54 (Leistner & Zenk, 1967), α-ketoglutarate 57 
via o-succinylbenzoate 56 whereas ring C of Rubia type is derived from mevalonic 
acid (MVA) 58 (Leistner, 1981, 1985) or 2-C-methyl-D-erithritol-4-phosphate 
pathway (MEP) 59 in Cinchona (Ying-Shan et al., 2002).   
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E-4-P=erythrose 4-phosphate, P=phosphate residue, PEP=phosphoenolpyruvate, TCA=tricarboxylic acid, TPP=thiamine 
diphosphate. 
 
 
Scheme 2.4.1:  Biosynthetic pathway leading to anthraquinones in the Rubiaceae 
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Chapter 3:  
Results and discussion 
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3.1 Introduction  
 
 
 In this study, seventeen compounds were successfully isolated, purified and finally the   
structures were fully elucidated. The structures were determined by a combination of 
spectroscopic methods; 1D-NMR (
1
H, 
13
C, DEPT), 2D-NMR (COSY, HMQC and 
HMBC), IR, MS (LCMS/MS). The structures of the compounds were also elucidated 
by comparison with previous work. 
 
3.2      Structural elucidation of isolated compounds from Prismatomeris malayana 
Ridley. 
 
The isolated compounds from this plant species could be classified into three type; 
pentacylic triterpenoids (60-65), iridoids (66, 68, 69, 70) and anthraquinones (71, 
11,72, 10, 73, 74, 21).  Compound 73 and74 are new while compound 66 was novel. 
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3.2.1 Compound A:  3β-hydroxyurs-12-en-28-oic acid (Ursolic acid ) 
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60 
 
Ursolic acid (3β-hydroxyurs-12-en-28-oic acid) 60 (compound A) was obtained as a 
white amorphous powder and produced a pseudo-molecular ion peak [M+Na]
+
 at m/z 
479.35059 by ESI-MS which  is consistent with the molecular formula of C30H48O3. Its 
IR spectrum gives strong peaks at 1686cm
-1
 corresponding to the stretching of a C=O, 
a broad and sharp absorption band between 3866 and 3188 cm
-1
, and 2860 cm
-1
 
indicate the presence of a COOH functional group (Silverstein et al.,1991). 
 
 The 
1H NMR (figure 3.2.1.1) gives two sets of doublet (δ0.99, J=5.2 Hz, 3H, H-30 
and δ1.03, J= 4.8 Hz, 3H, H-29) of two secondary methyl groups, five tertiary methyl 
groups (δ1.25, H-23; 1.08, H-26; 1.04, H-24; 1.28, H-27 ;0.90, H-25) and a tri 
substituted olefinic double bond (δ5.54, brs) for H-12. The presence of an oxymethine 
proton resonating at δ3.50 (brt, J=8.5) for H-3, was revealed in the 1H-NMR of 
compound A. The configuration of 3β-secondary hydroxyl group was in agreement 
with the observed coupling constant, for 3β–urs-12-en-28-oic acid (Chien-Ya et. al., 
2001).  The occurrence of doublet at δ2.68 (J=11.8Hz), for H-18 as well as a 
characteristic doublet of triplets signal (δ2.17, J1=4.4, J2=8.6 Hz, 1H) for H-16 
suggested that compound A is an urs-12-en derivative (Chien-Ya et al., 2001). 
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Moreover, the chemical shifts of the carbon and proton were identical to those reported 
for 3β-urs-12-en-28-oic acid (table 3.2.1).   
 
The
 13
C NMR spectrum (figure 3.2.1.2) combined with analysis of the DEPT spectrum 
(figure 3.2.1.3) allowed to differentiate thirty resonances into seven methines, nine 
methylenes, seven methyls and seven quarternary carbons, of which were assigned to a 
pentacyclic triterpene skeleton. The presence of an olefinic group at δ139.0 and 125.4 
(C-13 and C-12) in 
13
C spectrum of compound A, were the characteristic of ursane 
type skeleton (Naidu et. al, 1988). A signal at δ180.0 (C-28) indicated the presence of 
carboxylic acid. Another significant signal was revealed at δ77.6 (C-3) which belongs 
to the hydroxylated carbon.   
 
Figure 3.2.1.4 showed the HMQC spectrum of compound A which help to correlate the 
proton and carbon which are bonded together. The structure was further confirmed by 
the correlations detected in the HMBC spectrum (figure 3.2.1.5a and b) between H-18 
(δ 2.68) and C-12 (δ 125.5), C-19 (δ 39.2), C-29 (δ17.3), C-17 (δ 47.9), C-16 (δ 24.7), 
C-13 (δ 139.1), C-14 (δ 42.3) and another set of correlations between H-12 (δ 5.54) 
and C-11 (δ 23.4), C-10 (δ 37.2), C-14 (δ 42.3) and C-18 (δ 53.3). These two sets of 
correlations giving and evidence that the double bond at C-12 and C-13 and carboxyl 
geoup at C-28. Another set of correlation between H-3 (δ 3.50) and C-4 (δ 39.3), C-23 
(δ 28.6), C-24 (δ 16.4) support the assignment on the position of hydroxylated C-3.  
Figure 3.2.1.6 illustrates the selected HMBC correlation of compound A. 
 
Hence the complete assignments of compound A was achieved. As a result, with 
comparison of the spectroscopic data obtained from compound A with the literature 
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values, the former was confirmed to be 3β-hydroxyurs-12-en-28-oic acid (ursolic acid) 
60 (Werner et al., 2003, Simone et al., 2007).   
 
Table 3.2.1: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 60 in 
C5D5N 
 
Position 
13
C* 
13
C 
1
H(J,H)* 
1
H(J,H) 
1 39.2 38.9 1.00 
1.58 
0.95 
1.30 
2 28.2 28.4 1.81, 
1.81 
1.80 
1.80 
3 78.2 77.7 3.44dd 3.50 (brt, J=8.5) 
4 39.6 39.3 - - 
5 55.9 55.6 0.88d 1.10 
6 18.8 18.5 1.58 1.50 
7 33.7 33.3 1.59 
1.39 
1.60 
8 40.1 39.8 - - 
9 48.1 47.9 1.65 1.55 
10 37.5 37.2 - - 
11 23.7 23.4 1.96 1.90 
12 125.7 125.5 5.49s 5.54s 
13 139.3 139.1 - - 
14 42.6 42.3 - - 
15 28.8 27.8 1.22 
2.33t 
1.15 
2.30 
16 25.0 24.7 2.14 t δ 2.19 (dt, J1= 4.4,   
J2= 8.6) 
17 48.1 47.9 - - 
18 53.6 53.3 2.63d 2.68 (d, J=11.8) 
19 39.5 39.2 1.49 1.25 
20 39.4 39.2 1.05 1.00 
21 31.1 30.8 1.40 1.50 
22 37.4 37.0 1.97 1.75 
23 28.8 28.6 1.24s 1.25 
24 16.5 16.4 1.02s 1.04 
25 15.7 15.5 0.92 0.90 
26 17.5 17.2 1.06 s 1.08 
27 24.0 23.7 1.24s 1.28 
28 179.7 180.0 - - 
29 17.5 17.3 1.02d 1.03 (d, J1=4.8) 
30 21.4 21.2 0.97d 0.99 (d, J1=5.2) 
*
13
C NMR [150 MHz in C5D5N]   Werner et al., 2003 
*
1
H NMR [600MHz in C5D5N]      Werner et al., 2003 
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Figure 3.2.1.1:  
1
H NMR spectrum of ursolic acid 60 
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Figure 3.2.1.2:  
13
C NMR of ursolic acid 60  
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Figure 3.2.1.3:  DEPT spectrum of ursolic acid 60 
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Figure 3.2.1.4:  HMQC spectrum of ursolic acid 60 
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Figure 3.2.1.5a: HMBC spectrum of ursolic acid 60 
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Figure 3.2.1.5b: HMBC spectrum expansion of ursolic acid 60  
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3.2.2 Compound B: 3α,19α,24-trihydroxyurs-12-en-28-oic acid  
(barbinervic acid) 
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Barbinervic acid (3α, 19α, 24-trihydroxyurs-12-en-28-oic acid) 61 (compound B) was 
isolated as colorless amorphous solid. It produced a pseudo-molecular ion peak 
[M+Na]
+
 at m/z 511.34012 by ESI-MS which is consistent with the molecular formula 
C30H48O5. The IR spectrum gives strong peak at 1688cm
-1
 for C=O, a broad and strong 
peak between  3691 and 3208 cm
-1
, and 2937  cm
-1
 for COOH absorptions (Silverstein 
et al., 1991).   
 
Its 
1
H NMR (figure 3.2.2.1) is almost similar to compound A. It possess one set of 
doublets (δ1.16, J=9.6 Hz, H-30) which indicate the presence of secondary methyl, 
five singlets of tertiary methyl at (δ1.65, H-23; 1.0, H- 25; 1.14, H-26; 1.68, H-27; 
1.46, H-29) a tri substituted double bond (δ5.64, brs, H-12) and two oxymethine 
protons (δ4.5, bs, 1H)  for  H-3 and (5.08,bs, 1H) for OH-19. It showed differences in 
the total number of methyl groups compared to 60. The presence of two doublets 
(δ4.13, J=10.8 Hz and δ3.84, J=10.8 Hz, H-24) suggested the exocylic methane with 
geminal coupling (CH2-).   The H-α is deshielded by the electronegative oxygen atom 
(-OH) and thus shifted downfield in the spectrum. The occurrence of a singlet signal at 
3.02 for H-18 as well as a characteristic doublet of triplet signal (δ3.14 dt, J1=12.7 and 
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J2= 4.0 Hz) assignable to H-16α, which is shifted downfield by the anisotropic effect 
due to a 19α-hydroxyl group, similar to those reported on 3α, 19α,24-trihydroxyurs-12-
en-28-oic acid (Jie-Ping et al., 2006).   
 
The analysis on 
13
C NMR (Figure 3.4.2.2) and DEPT spectrum (Figure 3.2.2.3) 
differentiate thirty resonances into eight quarternary carbons, six methines, ten 
methylenes and six methyls. The presence of olefinic group was demonstrated by the 
peaks at δ128 and δ139.7 (C-12, C-13), while three hydroxylated carbon signals at 
δ69.8, 72.5 and 65.4 (C-3, C-19, C-24). The carboxylic carbon signal was revealed at 
δ180.6.    
 
The HMQC spectrum (figure 3.2.2.4a and 3.2.2.4b) showed the correlation between 
proton and carbon bonded together. The structural assignment was further confirmed 
by the HMBC spectrum illustrated in figure 3.2.2.5a and b. The correlation between H-
30 (δ 1.16) and C-19 (δ 5.08) supported the hydroxylated C-19. Another set of 
correlation between proton H-24 (δ 4.13) and C-4 (δ 43.69) giving an evidence that 
exocylic methane was position at C-24. Selected HMBC correlation was presented in 
figure 3.2.2.5. 
 
As a result, with comparison of the spectroscopic data obtained from compound B and 
the literature, the former was confirmed to be 3α,19α,24-trihydroxyurs-12-en-28-oic 
acid of 19α-hydroxyursane-type triterpenoids 61. 
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Table 3.2.2: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 61 in 
C5D5N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
13
CNMR [500MHz, DMSO-d6]  
Jie-Ping et al., 2006 
 
 
 
 
 
 
 
 
 
Position 
13
C* 
13
C 
1
H(J,H) 
1 33.3 33.8 1.35m 
2 25.7 26.7 1.8 m 
3 68.9 69.7 4.50 bs 
4 42.9 43.7 - 
5 49.4 48.1 1.80 m 
6 18.7 18.9 1.75 m 
7 33.6 33.6 1.2 m 
8 40.0 41.8 - 
9 47.1 47.5 1.4 m 
10 36.9 37.2 - 
11 23.7 24.0 2.2 m 
12 127.4 128.0 5.64 s 
13 139.0 139.7 - 
14 41.6 40.3 - 
15 28.5 29.05 2.14 m 
16 25.7 26.2 3.14 (dt, 12.6, 4.0 Hz) 
17 47.4 47.5 - 
18 53.7 54.4 3.02 s 
19 72.1 72.5 5.08bs 
20 41.9 42.2 2.3 m 
21 26.4 26.2 2.1 m 
22 37.7 38.3 2.5 m 
23 23.1 23.4 1.65s 
24 64.6  65.5  4.13 (d, 10.8 Hz) 
3.84 (d, 10.8 Hz) 
25 15.8 15.8 1.0 s 
26 16.9 16.9 1.14 s 
27 24.5 24.4 1.68 s 
28 179.4 180.6 - 
29 26.9 26.9 1.46 s 
30 16.8 16.6 1.16 (d, 9.6 Hz) 
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Figure 3.2.2.1: 
1
H NMR spectrum of barbinervic acid 61 
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Figure 3.2.2.2: 
13
C NMR spectrum of barbinervic acid 61  
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Figure 3.2.2.3: DEPT spectrum of barbinervic acid 61 
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Figure 3.2.2.4a: HMQC spectrum of barbinervic acid 61 
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Figure 3.2.2.4b: HMQC spectrum expansion of barbinervic acid 61 
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Figure 3.2.2.5a:  HMBC spectrum of barbinervic acid 61 
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Figure 3.2.2.5b:  HMBC spectrum expansion of barbinervic acid 61 
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Figure 3.2.2.6:   Selected HMBC correlation in barbinervic acid 61 
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3.2.3    Compound C: 3β, 23-dihydroxyurs-12-en-28-oic acid  
(23-hydroxyursolic acid) 
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23-hydroxyursolic acid (3β,23-dihydroxyurs-12-en-28-oic acid ) 62 (compound C) was 
isolated as white powder. It produced a pseudo-molecular ion peak [M+Na]
+
 at m/z 
495.34546 by ESI-MS which is consistent with molecular formula C30H48O4. Its IR 
spectrum gives sharp peak at 1689 cm
-1
 for C=O, a broad and sharp peak between 
3736 and 3066 cm
-1
, and 2933 cm
-1
 for OH absorption (Silverstein et al., 1991).   
 
The 
1
H NMR (figure 3.2.3.1) revealed the presence of two secondary methyl groups 
with two sets of doublet (δ0.99, J=5.0 and 0.94, J=5.0 Hz, 3H) and four tertiary methyl 
groups (δ1.05, H-24; δ 0.97, H-25; δ1.03, H-26; δ1.18, H-27). The tri substituted 
olefinic double bond (δ5.48) for H-12 was overlapped with the water signal. The 
presence of an oxymethine proton resonating at δ4.12 (dd, J=5.9, 10.0 Hz, H-3), could 
be observable in the 
1
H NMR of compound 62. The large coupling constant of H-3 in 
compound C is similar to that reported by Dong-Hyun et al. (2005) indicated that the 
H-3 of compound C was α orientated and thus the OH was β orientated. 
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The occurrence of a doublet at δ2.50, J=11.6 Hz, for H-18 as well as a characteristic 
doublet of triplets signal at δ2.22 (J1=2.7, J2=7.8 and J3=15.0 Hz, 1H) for H-16 
suggested that compound C is an urs-12-ene derivative (Chien-Ya et al., 2001). The 
presence of two doublets (δ4.09, J=10.5 Hz and δ3.65, J=10.4 Hz, H-23) which 
represent an AB system, suggested the exocylic methane with geminal coupling (CH2-) 
attached to an asymmetric centre. The H23-α was deshielded by the electronegative 
oxygen atom (OH) and therefore shifted downfield in the spectrum.   
 
The analysis on 
13
C NMR spectrum (figure 3.2.3.2) together with the DEPT spectrum 
(figure 3.2.3.3) enable us to distinguish and classify the thirty signals into seven 
methines, ten methylenes, six methyls and seven quarternary carbons. The 
13
CNMR 
spectrum also showed the presence of an olefinic carbon at δ125.2 and δ138.8 (C-12, 
C-13), two hydroxylated carbons at δ73.8 and δ67.0 (C-3, C-23) and a carboxylic 
carbon at δ179.7 (C-28).    
 
This was further corroborated by the HMBC spectrum (figure 3.2.3.5a and b) whereby 
the H-3 (δ4.12) correlated with C-23 (δ62.3), C-24 (δ12.9) which confirmed the 
assignments of methylene hydroxy in the ring A. Figure 3.2.3.6 summarized the 
selected HMBC correlations. 
 
Finally, after comparison between the spectroscopic data of compound C and the 
literature data of the known compound, this compound was confirmed to be 3β, 23-
dihydroxyurs-12-en-28-oic acid 62 (Dong-Hyun  et al., 2005).   
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Table 3.2.3: 
1H NMR [400MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 62 in 
C5D5N 
 
Position 
13
C*
 
 
13
C 
1
H(J,H)*  
1
H (J,H) 
 
    
1 38.4 38.7   1.05m 
2 27.2 27.3  1.47 m 
3 72.8 73.0 4.22(dd, 9.6, 6.0 
Hz) 
4.12 (dd, 5.9, 10.0 
Hz) 
4 42.4 42.7  - 
5 48.0 48.2  1.50 m 
6 18.1 18.3  1.80 m 
7 30.6 30.8  1.45 m 
8 39.5 39.2  - 
9 47.5 47.8  1.70 m 
10 36.6 36.8  - 
11 23.2 23.4  1.85 m 
12 125.0 125.4 5.48 brs 5.48  
13 138.7 139.0  - 
14 42.0 42.3  - 
15 28.2 28.4  1.24 m 
16 24.5 24.6  2.22 (dt, 2.7, 7.8, 
15.0 Hz) 
 
17 47.5 47.8  - 
18 53.1 53.3 2.20 (d, 11.0 Hz) 2.50 (d, 11.6 Hz) 
19 39.0 39.7  1.60 m 
20 38.9 39.2  1.15 m 
21 37.0 37.2  1.40 m 
22 32.8 33.0  1.65 m 
23 67.3 67.3  4.18(d, 10.4 Hz) 
3.72(d, 10.4 Hz)  
4.09( d,10.5 Hz)  
3.65 (d,10.5 Hz) 
24 12.7 12.9 1.04 s 1.05 s 
25 15.7 15.9 0.96 s 0.97s 
26 17.1 17.3  1.06 s 1.03s 
27 23.4 23.7 1.17 s 1.18s 
28 178.7 179.9  - 
29 17.1 17.3 0.98 (d, 6.4Hz) 0.99 (d, 5.0Hz ) 
30 20.9 21.2 0.92( d, 6.4Hz) 0.94(d, 5.0Hz ) 
      
 
*
1
HNMR [400MHz, C5D5N]  
*
13
CNMR [100MHz, C5D5N] 
(Dong-Hyun et al., 2005) 
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Figure 3.2.3.1:  
1
H NMR spectrum of 3β-23-dihydroxyurs-12-en-28-oic acid 62
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Figure 3.2.3.2:  
13
C NMR spectrum of 3β-23-dihydroxyurs-12-en-28-oic acid 62. 
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Figure 3.2.3.3:  DEPT spectrum of 3β-23-dihydroxyurs-12-en-28-oic acid 62. 
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Figure 3.2.3.4:  HMQC spectrum of 3β-23-dihydroxyurs-12-en-28-oic acid 62 
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Figure 3.2.3.5a:  HMBC spectrum of 3β,-23-dihydroxyurs-12-en-28-oic acid 62 
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Figure 3.2.3.5b:  HMBC spectrum of 3β-23-dihydroxyurs-12-en-28-oic acid 62 
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Figure 3.2.3.6: Selected HMBC correlation in 3β-23-dihydroxyurs-12-en-28-oic acid 62 
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3.2.4 Compound D:  
28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs-12-en-28-oic acid 
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28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs-12-en-28-oic acid 63 (compound D) 
was isolated as brown solid. It produced pseudo-molecular ion peak [M+Na]
 +
 at m/z 
673.39362 with ESI-MS which is consistent with molecular formula C36H58O10.   Its IR 
spectrum showed a sharp peak at 1724 cm
-1
 for C=O group and broad signal between 
3716 and 3018 cm
-1
 for the OH group (Silverstein et al., 1991). 
 
The 
1
H NMR spectrum (figure 3.2.4.1) showed one doublet (1.09, J1=9.6 Hz, 3H) 
which corresponded to secondary methyl H-30 and five singlet peaks for tertiary 
methyls (δ 1.64, H-27; δ 1.40, H-29; δ 1.54, H-23; δ 1.06, H-25; δ 1.26, H-26).  It also 
showed a singlet signal at δ2.95 for H-18 as well as a characteristic doublet of triplet 
signal (δ2.50 , J1 =5.8, J2=8.8 and J3=13.1 Hz, 1H) assignable to H-16α, which is 
caused downfield by the anisotropic effect due to a 19α-hydroxyl group strong 1,3 
diaxial interaction (Jie-Ping et al., 2006). The singlet signal at δ5.60 with an AB2 
patterns H-12 characteristic of tri substituted olefinic proton H-12. A doublet (J=7.9 Hz) 
of an AB system belongs to anomeric proton H-1’ of glucose unit observed at δ 6.33.  
The H-3 broad singlet was appeared at δ4.39 overlapped with glucose protons signals 
(H-2’- H-6’). 
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 The 
13
C NMR spectrum (figure 3.2.4.2) together with DEPT  (figure 3.2.4.4) 
distinguished  the carbon of compound D into six methanes, ten methylenes, six 
methyls and eight quarternary carbons for the aglycon skeleton. Another five methanes 
and one methylene peak was characteristic of the glucose moiety. The signal of 
carbonyl carbon presence at δ177.5 while the free hydroxylated carbons signal observed 
at δ69.8 (C-3) and δ73.1 (C-19). Another methylene hydroxy carbon was observed at 
δ65.5 which was assigned as the C-24.  The signal of the glucose and other remaining 
carbon was listed in table 3.2.3.  
 
The arrangement of the sugar unit which was connected to C-28 was determined by 
HMBC correlation (figure 3.2.4.5a and b) between H-1’ (δ 6.33, d) and C-28 (δ177.5).  
Another set of correlations was between H-24 (δ 65.5) and C-23 (δ23.4). 
Correlation between H-29 (δ1.40) and C-18 (δ54.9), C19 (δ 73.1) and C-20 (δ42.6) 
confirmed the position of quarternary hydroxyl to be at C-19.  The selected correlation 
was shown in figure 3.2.4.6. 
   
The HMQC assignment was shown in figure 3.2.4.4a and b.  The analysis of the 
accumulated data and comparison with literature values confirms that compound D was 
28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs-12-en-28-oic acid 63 that was reported 
previously as kakisaponin A (Chen et al., 2007)  but was first time reported isolated 
from this plant. 
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Table 3.2.4: 
1H NMR [400 MHz, δH (J, Hz)] and 
13C NMR [100 MHz, δC] of 63 in 
 
C5D5N. 
 
 
Position 
13
C 
13
C*
 1
H (J,H) 
1
H (J,H)*
 
1 33.8 34.0 1.40m 1.47m 
2 26.8 26.1 1.85m 1.82m 
3 69.8 70.0 4.39m 4.37m 
4 44.4 43.9 - - 
5 50.6 50.2 1.95 (bd, 12.4 Hz) 1.90 (bd, 12.1 Hz) 
6 19.1 19.3 1.72m 1.65m 
7 33.8 34.1 2.05m 2.05m 
8 41.2 40.8 - - 
9 48.3 47.9 2.02m 2.01m 
10 37.9 37.5 - - 
11 24.3 24.4 2.05m 2.02m 
12 128.9 128.5 5.60bs 5.55 brs 
13 139.7 139.3 - - 
14 42.6 42.2 - - 
15 29.0 29.2 2.50 (dt, 8.8, 5.8, 
13.0 Hz),  
 
1.82m 
16 26.5 26.5 3.10 (dt, 8.8, 5.8, 
13.0 Hz) 
2.46m 
17 49.1 48.7 - - 
18 54.9 54.5 2.95s 2.91s 
19 73.1 72.7 - - 
20 42.6 42.2 1.40m 1.33m 
21 26.5 26.7 1.26m 1.26m 
22 37.5 37.5 1.92m 2.04m 
23 23.4 23.6 1.54m 1.58s 
24 65.5 65.8 3.88 (d, 10.9 Hz) 
4.14(d, 11.0 Hz) 
3.82 (d, 10.8 Hz)  
4.08 (d, 10.8 Hz) 
25 15.9 16.1 1.06s 1.02s 
26 17.2 17.4 1.26s 1.22s 
27 24.3 24.5 1.64 1.60 s 
28 177.5 177.0 - - 
29 26.8 27.0 1.40 1.36s 
30 16.5 16.7 1.09 (d, 9.6 Hz) 1.04 (d, 6.1 Hz) 
1' 95.7 95.9 6.33 (d, 8.1 Hz) 6.28 (d, 8.1 Hz) 
2' 73.8 74.1 4.14 (t, 8.2 Hz) 4.19 m 
3' 78.8 79.0 4.25 (t, 8.7 Hz) 4.21m 
4' 71.0 71.3 4.33 (t, 9.2 Hz) 4.29m 
5' 79.1 79.3 4.11m 4.02 m 
6' 62.1 62.4 4.45 (d, 8.5 Hz) 
4.50 (d, 8.5 Hz) 
 
4.43 (d, 9.2 Hz)  
4.34 (d, 9.2 Hz) 
* 
13
CNMR [100MHz, C5D5N] 
*
1
HNMR [400MHz, C5D5N] 
Chen et al., 2007
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Figure 3.2.4.1:  
1
H NMR spectrum of 28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs 
-12-en-28-oic acid  63 
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Figure 3.2.4.2:  
13
C NMR spectrum of 28-O-β-glucopyranosyl-3α,19α,24-
trihydroxyurs-12-en-28-oic acid 63 
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Figure 3.2.4.3:  DEPT spectrum of 28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs-
12-en-28-oic acid 63 
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Figure 3.2.4.4a:  HMQC spectrum of 28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs-
12-en-28-oic acid 63 
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Figure 3.2.4.4b:  HMQC spectrum of 28-O-β-glucopyranosyl-3α,19α,24-
trihydroxyurs-12-en-28-oic acid 63 
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Figure 3.2.4.5a: HMBC spectrum of 28-O-β-glucopyranosyl-3α,19α,24-trihydroxyurs-
12-en-28-oic acid 63 
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Figure 3.2.4.5b: HMBC spectrum expansion of 28-O-β-glucopyranosyl-3α,19α,24-
trihydroxyurs-12-en-28-oic acid 63 
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Figure 3.2.4.6:  Selected HMBC correlation in 28-O-β-glucopyranosyl-3α,19α,24-
trihydroxyurs-12-en-28-oic acid 63 
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3.2.5  Compound E: 3β-acetylolean-12-en-28-oic acid 
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3β-acetylolean-12-en-28-oic acid 64 (compound E) was isolated as colorless crystal.  It 
produced pseudo-molecular ion peak [M-H]
 -
 at m/z 497.36142 with ESI-MS which is 
consistent with molecular formula C32H50O4. Its IR spectrum showed two sharp peaks 
at 1722 cm
-1
 and 1694 cm
-1
 for C=O and 2947 cm
-1
 for OH group (Silverstein et al., 
1991). 
 
The 
1
H NMR spectrum (figure 3.2.5.1) indicate the presence of seven quarternary 
methyls at (δ1.02,H-30; δ0.99, H-29; δ1.30, H-27; δ0.86, H-26; δ0.94, H-25; δ0.96, H-
24; δ0.91, H-23) and one additional methyl at 2.07 (s, 3H) of the acetyloxy group. An 
AX2 spin system could be observed at 3.35 (dd, J1=4.6 and J2=13.3 Hz, 1H) was 
indicative of H-18 which is next to H19. As compare to ursolic acid 60, the secondary 
methyl signals were not observed in the 
1
H NMR proton, thus suggested that the 
structure was oleanane type instead of ursane.  
 
The 
13
C NMR and DEPT spectrum (figure 3.2.5.2 and 3.2.5.3) showed five methines, 
ten methylenes, eight methyls and nine quarternary carbons on compound E. It 
exhibited down field signal at δ180.1 and δ170.2 attributable to the carbonyl carbon of 
 70 
 
C-28 and C-31 respectively. The methyl carbon of C-29 gave rise to a downfield peak 
at δ33.0 due to the deshielding effect of carbonyl carbon C-31. The methane carbon C-
19 experienced the deshielding effect from the carbonyl carbon to give a down field 
signal at δ46.4. The other signals are similar to those of ursolic acid 60. 
 
The HMQC spectrum was showed in figure 3.2.5.4 (a) and (b). This compound was 
further confirmed by the correlations detected in the HMBC spectrum (figure 3.2.5.5 
(a) and (b)) between H-11 (δ1.79) and C-12 (δ 123.6), C-13 (δ 139); H-21(δ 1.8 ) and 
C-30 (δ 23.5) and  C20 (δ 30.7 ). Complete assignments were shown in the HMBC 
spectrum (figure 3.2.5.5a and b) and the selected correlation was presented in figure 
3.2.5.6.  
 
Finally, after extensive comparison of the spectroscopic data obtained from compound 
E with the literature values (Kazuhito et al., 1997), the former was confirmed to be 3β-
acetylolean-12-en-28-oic acid 64. 
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Table 3.2.5.: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 64 in 
C5D5N 
 
Position 
13
C* 
13
C 
1
H(J,H)
*
 
1
H(J,H) 
1 38.0 38.0  1.50,1.15m 
2 23.5 23.5  1.45 m 
3 80.9 80.5 4.5 (dd, 7,1Hz) 4.73 (dd, 5.0,11.1Hz) 
4 37.6 37.6  - 
5 55.2 55.3  1.00 m 
6 18.1 18.2  1.50 m 
7 32.4 33.0  1.65 m 
8 39.2 39.4  - 
9 47.5 47.6  1.20 m 
10 36.9 36.9  - 
11 22.8 23.4 1.97 (dt, 3.5,14.0 Hz) 1.85 m 
12 122.5 123.6 5.27 (t, 3.5Hz) 5.5 bs 
13 143.6 139.0  - 
14 41.5 41.7  - 
15 27.6 28.0  1.40 m 
16 23.3 23.6  2.10,1.90 m 
17 46.5 46.2  - 
18 40.8 41.0 2.82 (dd, 4.5,13.5Hz) 3.35 (dd, 4.6,13.3Hz) 
19 45.8 46.4  1.91 m 
20 30.6 30.7  0.90 m 
21 33.7 33.9  1.50 m 
22 32.4 32.8  1.90 m 
23 28 27.9 0.86s 0.94 s 
24 16.6 16.7 0.87s 0.86 s 
25 15.3 15.1 0.87s 0.91 s 
26 17.1 17.1 0.74s 0.97 s 
27 25.8 25.9 1.13s 1.30 s 
28 184.3 180.1  - 
29 33 33.0 0.94s 1.02 s 
30 23.5 23.5 0.97s 1.04 s 
32 21.3 20.9 2.05s 2.07s 
31 171.1 170.5  - 
*
1
HNMR [90 and 270MHz] in CDCl3 
*
13
CNMR [25 and 67.5MHz] in CDCl3 
(Kazuhito et al., 1997) 
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Figure 3.2.5.1:  
1H NMR spectrum of 3β-acetylolean-12-en-28-oic acid 64 
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Figure 3.2.5.2:  
13
C NMR spectrum of 3β-acetylolean-12-en-28-oic acid 64  
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Figure 3.2.5.3:  DEPT spectrum of 3β-acetylolean-12-en-28-oic acid 64 
 
 
 
 
 
 
 
 
20 40 60 80 100 
3 5 9 18 30 
32 
25 
24 
26 
29 
27 
23 
6 
2,16,11 
15 
22,7 
21 
1 
19 
18 9 5 3 
32 
3 5 
9 
19,
17 
18 
1 
4,10 
14 
21 
7,22,29 
20 
23 
27 
2,16 
6 
26 
24 
25 15 
30 
11 
 75 
 
COOH
H3COCO
31 3
29 30
11
12 18
16
2324
32
1
2
64
5
7
8
9
10
14
13
15
17
19 20 21
22
25 26
27
 
 
 
 
 
 Figure 3.2.5.4 (a):  HMQC spectrum of 3β-acetylolean-12-en-28-oic acid 64 
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Figure 3.2.5.4 (b):  HMQC spectrum of 3β-acetylolean-12-en-28-oic acid 64 
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Figure 3.2.5.5(a):  HMBC spectrum of 3β-acetylolean-12-en-28-oic acid 64 
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Figure 3.2.5.5(b):  HMBC spectrum expansion of 3β-acetylolean-12-en-28-oic acid 64 
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Figure 3.2.5.6:  Selected HMBC correlation in 3β-acetylolean-12-en-28-oic acid 64 
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3.2.6         Compound F: 3β-hydroxyurs-11-en-13,28-olide 
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3β-hydroxyurs-11-en-ursane-13,28-olide 65 (compound F) was isolated as white 
amorphous powder. It produced pseudo-molecular ion peak [M+Na]
+
 at m/z 477.33621 
with ESI-MS which is consistent with molecular formula C30H46O3. It showed strong 
signal at 2884cm
-1
 in the IR spectrum for OH group and a sharp signal at 1687 cm
-1
 for 
the stretching C=O (Silverstein et al., 1991).  
 
Its 
1
H NMR (figure 3.2.6.1) exhibited two sets of doublets (table 3.2.6.1) resonated at δ 
0.88 (d, J =6.1 Hz, H-29, 3H), δ 1.08 (d, J =6.1 Hz, H-30, 3H) and five singlet of 
tertiary methyl protons (δ1.29,H-23; δ1.26, H-27; δ1.23,H-24; δ1.08,H-26; δ0.94, H-
25). It also showed two sets of broad doublets of tri substituted olefinic protons at 
δ6.10 (brd, J=10.3 Hz, H-11, 1H) and δ5.70 (brd, J=10.3 Hz, H-12, 1H). The presence 
of an oxymethine proton resonating at δ3.50 (brt, J=8.4 Hz), was revealed in the 1H 
NMR of compound F. Compared to compound A, the signal for H-18 was shifted to 
the upper field due to the steric effect of the lactone ring. However, the doublet of 
triplets signal (δ 2.15, J1=5.6, J2=13.7 and J3=19.5 Hz, 1H) and δ2.05 (m, 1H) could be 
assigned to be of the H-16 protons.  
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The 
13
C NMR (fig. 3.2.6.2) showed thirty resonances. It showed the lactone carbon 
signal at δ180.7 and one C-O bonded qarternary carbon signal resonated at δ90.7, two 
olefinic carbons resonated at δ130.6 and δ135.0 which assignable to be of C-11 and C-
12, respectively. The 
13
C NMR spectrum showed five sp
3
 quarternary carbon signals 
resonated at δ46.4, δ43.4, δ43.2, δ40.7 and δ37.8 of C-17, C-14, C-8, C-4 and C-10 
respectively. A hydroxylated carbon was revealed at δ77.6 (C-3) together with other 
five sp
3
 methine carbon resonated at δ1.7, δ56.3, δ54.6, δ41.5 and δ39.4 attributable to 
be C-5, C-18, C-9, C-19 and C-20 respectively.   
 
Finally, after thorough comparison on the empirical data of compound F together with 
the known compounds (Masaaki et al., 1983), this compound was identified as 3β-
hydroxyurs-11-en-ursane-13,28-olide 65 with additional double bond between C-11 
and C-12 (Mulholland et al., 2011) 
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Table 3.2.6: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 65 in 
C5D5N 
 
Position 
13
C* 
13
C 
1
H(J,H)  
1 39.1 39.8   
2 27.4 29.1   
3 79.0 79.2 3.5 (t, 8.4 Hz)  
4 38.9 40.7 -  
5 55.3 56.3   
6 17.8 19.3   
7 34.2 32.7   
8 42.3 43.4 -  
9 51.4 54.6   
10 37.1 37.8 -  
11 18.9 125.5 6.1 (d, 10.3 Hz)  
12 34.7 130.6 5.7 (d,10.3 Hz)  
13 93.2 90.7 -  
14 43.3 43.2 -  
15 27 27.1   
16 22.9 24.4 2.15 (dt, 5.5, 13.7, 19.5 Hz), 2.05m 
17 45.7 46.4 - 
18 61.2 61.7   
19 38.7 40.7   
20 39.9 39.4   
21 30.8 31.2   
22 31.6 31.2   
23 28 29.6 1.29s  
24 15.3 17.1 1.23 s  
25 16.4 19.2 0.94 s  
26 18.5 20.4 1.09 s  
27 17.4 19.4 1.26 s  
28 180.6 180.8 -  
29 17.6 19.4 0.88 (d, 6.1 Hz)  
30 19.5 20.6 1.08 (d, 6.1 Hz)  
     
*
13
CNMR [22.5MHz] 
*
1
HNMR [89.55MHz] CDCL3 
(Masaaki et al., 1983) 
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Figure 3.2.6.1:  
1
H NMR spectrum of 3β-hydroxyurs-11-en-13,28-olide 65 
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Figure 3.2.6.2:  
13C NMR spectrum of 3β-hydroxyurs-11-en-13, 28-olide 65  
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3.2.7  Compound G: Prismalayanoside  
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Prismalayanoside 66 (compound G) was isolated as yellowish amorphous solid.   It 
produced pseudo-molecular ion peak [M+Na]
+
 at m/z 685.17523 (calcd. 685.16944) 
with ESI-MS which is consistent with the molecular formula of C31H33O16 (figure 
3.2.7.0).   The UV spectrum showed maximum absorption at 234, 292 and 314 nm 
typical for the iridoid of plumerin type (Biswanath et al., 2007).  The IR absorptions 
band at 3375 cm
-1
 (strong and broad signal) and 1686 cm
-1 
(strong signal) show the 
presence of α,β-unsaturated carboxylic acid (Silverstein et al., 1991), whereas, the 
absorptions at 1754 and 1639 cm
-1
 suggested the presence of an iridoic enol ether 
system conjugated with an ester carbonyl group (Wu et al., 2009). 
 
The 
1
H NMR spectrum in MeOD (figure 3.2.7.1 a) was characterized by a doublet for 
H-1 at δ5.25 (d, J=5.1 Hz) which was split by proton H-9 at δ3.00 (dd, J1=5.2 and J2= 
7.2 Hz), an olefinic proton at δ7.60s (d, J1=1.4 Hz, H-3) and carbomethoxy group 3.80 
(s, H-20) (table 3.2.7).  These signals were consistent with the characteristic structural 
features of an enol ether system conjugated with a carbomethoxy group of iridoid 
skeletons (Wu et al., 2009). An AB spin system between cis-olefinic protons, H-7 and 
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H-6 showed by the two doublet signals resonated at δ5.62 (dd, J1=5.5 and J2=2.0 Hz) 
and δ6.50 (dd, J1=5.5 and J2=2.3 Hz) respectively. The small coupling constant of these 
disubstituted protons, H-6 and H-7, indicated that the double bonds were located in a 
five membered ring (Wu et al., 2009). The anomeric proton of glucose, H-1’ was 
resonated at δ4.80 (d, J=7.8 Hz). The big coupling constant value of H-1’ substantiated 
the β-configuration of the glucopyranose unit (Kim et al., 2006). The signals for the 
other glucose protons (H-2’, H-3’, H-4’, H-5’ and H-6’) were resonated between 3.2-4.0 
ppm and overlapped with the proton signals of H-5, H-17, H-18. The 
1
H NMR spectrum 
in C5D5N showed a better resolution for the H-2’, H-3’, H-4’, H-5’, H-6’, H-5, H-17 
and H-18 (figure 3.2.7.1b). The coupling constant values of the sugar unit further 
supported the glucose type of sugar in this compound (table 3.2.7).   
 
Besides the above mentioned signals of cylopentanopyran ring system with a sugar 
moiety, other peaks were of an isolated olefinic protons at δ7.70s (H-10) and a 
downfield singlet at δ4.12 which is attributable to the isolated H-14 (figure 3.2.7.1a, 
MeOD). A pair of doublet signal at the aromatic region of δ7.35 (d, J=8.5 Hz) and δ 
6.80 (d, J=8.5 Hz) were the signal of two sets of chemically equivalent protons of the 
para-substituted aromatic ring; H-2’’, H-6’’ and H-3’’, H-5’’, respectively. The spin 
system AA’BB’ was indicated by the presence of a pair of dd signal at δ2.60 (dd, J=6.7, 
12.9 Hz) and δ2.10 (dd, J=8.5, 13.6 Hz) which is attributable to H-16. Three sets of 
protons were found overlapped with the glucose protons signals: H-5 (4.05, m), H-17 
(3.83, m) and H-18 (4.0, m).   
 
In the 
1
 H NMR (C5D5N) however, the signals of H-5, H-17 and H-18 could be 
observed at 3.98 (bd, 7.8 Hz), [4.09 (dd, 13.7, 4.1), 3.87 (m)] and 4.65m, respectively.  
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The signal for H-5 was split into the broad doublet by H-6 and H-9. The multiplicity of 
H-18 because of its correlation with H2-17 and H2-16.  
 
Combined analysis of the 
13
C NMR (figure 3.2.7.2, MeOD) and the DEPT (figure 
3.2.7.3, MeOD) spectra showed thirty one carbon signals which consisted of one 
methyl, three methylene, eighteen methine and nine quartenary carbons.  In comparison 
with prismatomerin 63 and gaertneroside 21 (Krohn et al., 2007), prismalayanoside 66 
showed three additional peaks which are shifted down field at δ79.4 (C-15), δ62.3C-17) 
and δ77.9 (C-18), probably due to the deshielding effect of the electronegative oxygen 
atom (table 3.2.7).   
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The other additional signals were methine carbon at δ46.7 of C-14, methylene carbon at 
δ34.9 (C-16) and two carbonyl carbons at δ178.7 and δ173.3 of C-13 and C-19, 
respectively. The downfield chemical shift of C-8 (δ 98.5) indicated that this quaternary 
carbon is oxygenated.   
 
The analysis on COSY (figure 3.2.7.4 a) and HMQC (figure 3.2.7.5) spectra showed the 
correlations between H-6 (δ 6.50), H-7 (δ 5.62), H-5 (δ 4.05), H-9 (δ 3.00)  and H-1(δ 
5.25), thus supported the cis-fused cylopentanopyran ring sytem found in iridoid 
skeletons which particularly the plumieride type iridoids (Kuigoua et al., 2010). In 
figure 3.2.7.4 b (C5D5N), the COSY correlation between H-18 (δ 4.66) and H-16a (δ 
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3.87), H-16b (δ 3.13) and H-17 (δ 4.10), H-17b (3.87) suggested the presence of the 
five membered ring D.   
 
The structure was further confirmed with the HMBC spectrum (figure 3.2.7.6a and b, 
MeOD). The expected 
1
JCH and 
2
JCH correlation for the aglycon cylopentanopyran ring 
(ring A and B) were observed. It showed correlation between H-3 (δ 7.6) and C- 1 (δ 
94.6), C-4 (δ 111.0), C-5 (δ 40.6), C-11 (δ 168.8); H-5 (δ 4.05) and C-9 (δ 51.0), C-4 (δ 
111.0), C-7 (δ 130.1), C-6 (δ 141.8), C-3 (δ 152.6); H-6 (δ 6.5) and C-5 (δ 40.6), C-9 (δ 
51.0), C-8 (δ 98.5) C-7 (δ 130.1); H-7 (δ 5.62) and C-5 (δ 40.6), C-9 (δ 51.0), C-8 (δ 
98.5), C-6 (δ 141.8); H-9 (δ 3.0) and C-8 (δ 98.5). The cross peak between H-1’ (δ 4.80) 
and C-1 (δ 94.6) confirmed the site of attachment of the glucose moiety at C-1.   
 
The unusual seven-membered unsaturated spiro lactone ring (ring C) attached to C-8 
was constructed by the long range correlations in the HMBC spectrum between H-10 (δ 
7.7) and C-14 (δ 47.8), C-8 (δ 98.5), C-13 (δ 174.5), C-12 (δ 131.8); H-14 and C-18, C-
1”, C-12, 2”, 6”, C-10 (δ 151.5), C-13 (δ174.5); H-16 (δ 2.10) and C-17 (δ 62.8), C-18 
(δ 78.1) , C-15 (δ 77.8) (figure 3.2.7.7). The HMBC spectrum (figure 3.2.7.6 c, C5D5N), 
showed better view on the  correlation between H-18 and C-14, H-17 and H-17 and C-
16, C-15 thus further supported the five-membered ring D unit. 
 
 
The ROESY / NOESY experiment (figure 3.2.7.9, CD3OD) showed interactions 
between H-9 and H-5, H-6 and H-5, H-7, thus indicated that all these protons are 
cofacial (Krohn et al., 2007). The H-10 was of α-position relative to C-8 as the chemical 
shift of C-9 was δ 51.0 (Kanchanapoom et al., 2002).  Thus, the cross peaks between H-
1/H-10 and H-5/H-9 confirmed that the linkage between C-8 and C-10 was α-oriented, 
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H-1 was α and in equatorial conformation whereas H-5 and H-6 were β-oriented. The 
correlations were summarized in figure 3.2.7.8. 
 
From the 3D minimization of the molecular structure of prismalayanoside resulted in a 
skewed/pleated octalactone ring. Therefore, the methylene proton of H-16b was 
oriented within the proximity to H-10. The ROESY confirmed the configuration from 
the interaction between H-16b and H-10 thus implied that C-16 is β-oriented (figure 
3.2.7.8).                   
 
Thorough examination of all spectral data obtained led to the conclusion that 
prismalayanoside 66 was assigned as the novel compound having unprecedented spiro-
hepta-lactone ring. 
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Table 3.2.7: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 66 in 
CD3OD
a 
and C5D5N
b
. 
 
 
1
H (J,H)
a
 
1
H (J,H)
b 13
C
a
 
13
C
b 
1 5.25 (d, 5.1 Hz) 6.01 (d, 3.2 Hz) 94.6 94.3 
3 7.60(d, 1.4) 7.75 (d, 0.9 Hz) 152.6 152.2 
4 - - 111.0 110.9 
5 4.05m 3.96 (brd, 7.8 Hz) 40.6 39.5 
6 6.50 (dd, 2.3, 5.5 Hz) 6.50 (dd, 5.5, 2.8 
Hz) 
141.8 140.5 
7 5.62(dd, 5.5, 2.3 Hz) 5.51 (dd, 5.5, 1.8 
Hz) 
130.1 130.2 
8 - - 98.5 97.6 
9 3.0(dd, J=5.2, 7.2 Hz) 3.38 (dd, 8.2, 3.6 
Hz) 
51.0 50.6 
10 7.70s 8.30s 151.5 151.2 
11 - - 168.8 167.2 
12 - - 131.8 133.8 
13 - - 174.5 173.3 
14 4.12s 4.83s 47.8 48.5 
15 - - 79.4 79.5 
16 2.60 (dd, 7.7, 13.8 Hz),  
2.10 (dd, 7.7, 13.8 Hz) 
2.87(dd, 13.7, 7.5 
Hz), 3.13 (dd, 13.7, 
7.5 Hz) 
35.9 38.5 
17 3.85m 4.10(dd, 13.7, 4.1 
Hz), 3.87m 
62.3 62.6 
18 4.0m 4.66m 77.9 78.7 
19 - - 179.9 178.0 
20 3.80s 3.59s 52.2 51.7 
1’ 4.80 (d, 7.8 Hz) 5.36 (d, 7.8 Hz) 100.3 101.4 
2’ 3.37-3.50m 4.12 (brd, 8.2 Hz) 74.6 75.0 
3’ 3.37-3.50m 4.24 (t, 9.1 Hz) 79.2 79.0 
4’ 3.37-3.50m 4.42 (bd, 8.7 Hz) 71.3 71.4 
5’ 3.37-3.50m 3.89m 79.0 79.4 
6’ 3.7(dd, 4.3, 12.8Hz), 
3.55 (dd, 4.3, 12.8 Hz) 
4.45 (dd, 11.9, 1.8 
Hz),4.4(dd, 11.9, 
5.5Hz) 
63.9 63.8 
1” - - 127.5 127.7 
2” 7.35 (d, 8.5 Hz) 7.67 (d, 8.7 Hz) 130.9 132.3 
3” 6.80 (d, 8.5 Hz) 7.14 (d, 8.7 Hz) 116.6 116.6 
4” - - 157.5 159.1 
5” 6.80 (d, 8.5 Hz) 7.14 (d, 8.7 Hz) 115.5 116.6 
6” 7.35 (d, 8.5 Hz) 7.67 (d, 8.7 Hz) 130.9 132.3 
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Figure 3.2.7.0:  Mass spectrum of prismalayanoside 66 
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Figure 3.2.7.1a:  
1
H NMR spectrum of prismalayanoside 66 in MeOD 
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Figure 3.2.7.1b:  
1
H NMR spectrum of prismalayanoside 66 in C5D5N 
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Figure 3.2.7.2a:  
13
C NMR spectrum of prismalayanoside in MeOD 66 
 
 
 
Figure 3.2.7.3:  DEPT spectrum of prismalayanoside in MeOD 66 
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Figure 3.2.7.2 b:  
13
C NMR spectrum of prismalayanoside 66  in C5D5N 
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Figure 3.2.7.4a:  COSY spectrum of prismalayanoside 66 in MeOD 
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Figure 3.2.7.4b:  COSY spectrum of prismalayanoside 66 in C5D5N 
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Figure 3.2.7.5a:  HMQC spectrum of prismalayanoside 66 in MeOD 
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Figure 3.2.7.5b:  HMQC spectrum of prismalayanoside 66 in C5D5N 
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Figure 3.2.7.6a:  HMBC spectrum of prismalayanoside 66 in MeOD 
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Figure 3.2.7.6b:  HMBC spectrum expansion of prismalayanoside 66 in MeOD 
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Figure 3.2.7.6c:  HMBC spectrum expansion of prismalayanoside 66 in C5D5N 
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Figure 3.2.7.7:  Selected HMBC correlation of prismalayanoside 66 
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Figure 3.2.7.8:  Selected NOESY correlation of prismalayanoside 66 
 
 103 
 
 
 
 
 
O
O
COOCH3
OH
OH
OH
HO
O
OO
O
OH
HO
COOH
1
3
5
6
7
15
16
17
18
8
10
12
13
14
19
1"
1' 6'
9
11 20
 
 
 
 
 
 
 
Figure 3.2.7.9:  NOESY spectrum of prismalayanoside 66 in MeOD 
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3.2.8  Compound H: Asperulosidic acid 
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Asperulosidic acid 68 (compound H) was isolated from the roots and leaves as brown 
amorphous powder. It produced the pseudo-molecular ion peak [M-H]
+
 at m/z 
431.11816   with ESI-MS which is consistent with molecular formula C18H24O12. The 
IR spectrum indicated the presence of OH groups (3365 cm
-1
) and the conjugated enol-
ether system characteristic of an iridoid (1688 cm
-1
 and 1636 cm
-1
) (Ling, 2003; 
Silverstein et al.,1991).    
 
The 
1
H NMR spectrum (figure 3.2.8.1) was characterized by a doublet for the H-1 at 
δ5.09 (J=9.0 Hz), a singlet for the H-3 (δ7.70), a doublet for the H-10 (δ4.85, J=15.8 
Hz) (table 1.4.8.1). Another proton, H-5 and 9 resonated at δ3.01 (t, J=6.3 Hz) and 
δ2.65 (t, J=8.3 Hz), respectively. The anomeric proton of glucose (δ 4.77, J=7.8 Hz, H-
1’) and a singlet for H-7 (δ6.05). A strong peaks resonating at δ2.10 corresponding to 
three protons were attributable to the methyl protons attached to the carbonyl carbon.     
 
The 
13
C NMR (figure 3.2.8.2) and DEPT spectra (figure 3.2.8.3) indicate the presence 
of seventeen carbons; three quarternary carbons, eleven methines, two methylenes and 
one methyl group. A signal at δ170.6 corresponding to the carbonyl carbon attached to 
the methyl carbon the signal for which resonated at δ20.7 (table 3.2.8). Another 
carbonyl carbon resonated at δ172.6 could be assigned to C-11. The peaks at δ155.4 and 
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δ131.8 might be attributable to the methine sp2 carbons at position C-3 and C-7, 
respectively.   
 
The quartenary carbon of C-4 and C-8 resonated at δ108.1 and δ145.8 respectively.  
The peaks at δ101.2 and δ75.3 corresponded to the methine carbon type which were 
deshielded due to the oxygen neighbouring atom. Another signal at δ46.1 and δ42.3 and 
δ63.7 could be assigned to methine carbon C-9, C-5 and methylene carbon C-10 
respectively. The former was deshielded due to the attachment to the oxygen atom.    
The HMQC spectrum (figure 3.2.8.4) of compound H shows the complete assignments 
of 
1
H and 
13
C signals.  
 
As a result, by comparison of the spectroscopic data obtained from compound H with 
the literature values (Inouye et. al., 1969, Ling S.K., 2003), the former was confirmed to 
be asperulosidic acid 68.   
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Table 3.2.8: 
1
H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 68 in 
CD3OD. 
 
Position 
13
C* 
13
C 
1
H(J,H) 
1
H(J,H)* 
1 101.1 101.1 
 
5.09 (d, 9.0 Hz) 5.05 
3 154.9 155.4 7.70s 7.62d 
4 109.0 108.1 - - 
5 42.6 42.3 3.00t 3.02t 
6 75.4 75.2 4.90s 4.90s 
7 131.8 131.8 6.05s 6.01d 
8 145.9 145.8 - - 
9 46.3 46.1 2.65t 2.62t 
10 63.7 63.7 4.85, 4.94, m. 4.85d 
 
 
 
 4.94d 
11 172.5 172.5 - - 
12 
COOCH3 172.5 172.5 - - 
COOCH3 20.8 20.8 2.10 2.09 
1' 100.5 100.4 4.75 4.72d 
2' 74.9 74.8 3.25-3.50m 3.24m 
3' 78.5 78.3 3.25-3.50m 3.38m 
4' 71.5 71.4 3.25-3.50m 3.26m 
5’ 78.5 78.1 3.25-3.50m 3.26m 
6’ 62.9 63.0 3.65, 3.90m 
3.85(dd, 1.8, 12.0 Hz), 
3.62 (dd, 6.0,12.0 
 
* 
1
H NMR [300 MHz, CD3OD] 
*
13
CNMR [75MHz, CD3OD] 
Ling, 2003
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Figure 3.2.8.1:  
1
H NMR spectrum of asperulosidic acid 68 
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Figure 3.2.8.2:  
13
C NMR spectrum of asperulosidic acid 68 
 
 
 
Figure 3.2.8.3:  DEPT spectrum of asperulosidic acid 68 
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Figure 3.2.8.4:  HMQC  spectrum of asperulosidic acid 68 
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3.2.9 Compound I:  Asperuloside 
 
O
O
O
H3COOC O
A B
C
OH
OH
OH
HO
O
6
7
8 9
10
4
3
1'
6'
3'
11
12
 
69 
 
Asperuloside 69 (compound I) was isolated as white amorphous powder.   It produced 
pseudo-molecular ion peak [M+K]
+
 at m/z 453.11 with ESI-MS which is consistent 
with molecular formula C18H22O11.  Its IR spectrum showed the presence of OH groups  
(3360cm
-1
) and a conjugated enol-ether system of an iridoid (1689 cm
-1
 and 1635cm
-1
) 
(Ling, 2003) .    
 
The 
IH NMR (figure 3.2.9.1) showed a broad singlet signal at δ7.35 for H-3 which is 
characteristic for the iridoids (table 3.2.9). Another signal resonated at δ5.98 (bs, 1H), 
δ5.74 (bs, 1H), δ5.59 (d, J =6.2 Hz) which assigned to H-1, H-7 and H-6 respectively.  
The signal for H-1 was shifted to lower field due to the steric effect of ring C. The steric 
effect also shifted the signal of H-5, H-9 and H-10 at δ3.70 (m, 1H), δ3.50 (m, 1H) and 
δ4.95 (d, J=14.7 Hz) and δ4.72 (d, J=14.7 Hz) respectively. The signal of H-10 was 
overlapped with the CD3OD signal.   
 
The anomeric proton, H-1’, resonating at δ4.74 (d, J=7.8 Hz) clearly indicated that the 
dissacharide moiety should be in a pyranoside form. Other signals for the glucose 
protons (H-2’, H-3’, H-4’, H-5’) resonated between δ4.0 – δ3.2.   
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Finally, by comparison of the obtained spectroscopic data with the literature review 
(Briggs, 1963, Inouye, 1970, Ling, 2003), compound I was identified as asperuloside 
69.   
 
 
 
Table 3.2.9: 
1H NMR [300 MHz, δH (J, Hz)] and 
13
C NMR [75 MHz, δC] of 69 in 
CD3OD. 
 
 
13
C* 
13
C 
1
H(J,H)
*
 
1
H(J,H) 
1 93.3 92.3 5.95(brs, J=1.5 Hz) 5.98bs 
3 150.3 153.7 7.29 (d, J=2.1 Hz) 7.35bs 
4 106.1 105.1 - - 
5 37.4 36.4 3.64m 3.70m 
6 86.3 85.3 5.56 (d, J=6.3 Hz) 5.59 (d, J=6.2 Hz), 
7 128.9 127.9 5.73 bs 5.74 bs 
8 144.2 143.2 - - 
9 45.2 44.2 3.34m 3.5m 
10 61.9 60.3 4.9 (d, J=15.3 Hz), 
4.8 (d, J=15.3 Hz) 
4.95 (d, J=14.7 Hz), 
4.72 (d, J=14.7 Hz) 
11 172.2 171.4 - - 
12 172.2 171.6 - - 
OCH3 20.6 19.7 2.08s 2.10s 
1' 100 98.9 4.67 (d, J=8.1 Hz) 4.74(d , J=7.8 Hz) 
2' 74.6 73.6 3.19 (dd, J= 8.1, 9.0 
Hz) 
3.19m 
3' 77.8 76.8 3.38 (t, J=9.0 Hz) 3.40m 
4' 71.5 70.5 3.27 (t, J=9.0 Hz) 3.3m 
5’ 78.3 77.3 3.3m 3.4m 
6’ 62.5 61.7 3.92 (dd,  J= 2.1, 12.0 
Hz),    
3.67 (dd, 6.0,12.0Hz) 
3.97m, 3.69m 
     
 
* 
1
H NMR [300 MHz, CD3OD] 
*
13
C NMR [75MHz, CD3OD] 
(Ling, 2003)
Chapter 3: Results and Discussion 
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Figure 3.2.9.1:  
1
H NMR spectrum of asperuloside 69 
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Figure 3.2.9.2:  
13
C NMR spectrum of asperuloside 69 
 
 
 
 
Figure 3.2.9.3:  DEPT spectrum of asperuloside 69 
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3.2.10 Compound J: Scandoside 
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Scandoside 70 (compound J) was isolated as brown amorphous powder. It produced 
pseudo-molecular ion peak [M-H]
 -
 at m/z 389.10745 with ESI-MS which is consistent 
with molecular formula C16H22O11. Its IR spectrum showed a broad signal at 3369 cm
-1
 
for OH and a sharp signal at 1635 cm
-1
 for the presence of C=O group (Silverstein et 
al.,1991).   
 
The 
1
H NMR (figure 3.2.10.1) showed a broad singlet (table 3.2.10) for the H-3 
characteristic of iridoids at δ7.66. Another signals observed at δ5.09 (d, J=9.0 Hz, H-1), 
δ2.55 (t, J=8.0 Hz, H-9). An oxymethylene proton of H-10 appear at δ4.50 and δ4.25 as 
two doublet (J=15.8 and J=15.6 Hz). The anomeric proton resonating at δ4.76 (H-1’, d, 
J=7.8 Hz) clearly indicated that the sacharide moiety should be in a pyranoside form 
(Ling, 2003). The sequential trans diaxial relationship of H-1’ to H-5’ (J=9.0-9.5 Hz), 
with the corresponding carbon signals established that the sugar unit was that of a                       
β-glucopyranosyl moiety. Other signals for the glucose resonated at δ3.89 and δ3.67 (H-
6’, 2xd, J=11.8 Hz). 
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The 
13C NMR (figure 3.2.10.2, table 3.2.10) indicated the glucose signals at δ99.2, 
δ77.4, δ76.8, δ73.9, δ70.6 and δ61.8 represent C-6’, C-1’, C-3’ ,C-2’, C-4’ and C-5’ 
respectively which experience the deshielding effect due to the neighbouring oxygen 
atom. The two sp
2
 carbons i.e C-3 and C-7 gave signals at δ150.3, δ128.8 respectively.  
The C-3 experienced a deshielding effect from the C=O of the carboxylate moiety due 
to its β position from the group. The C-6, C-1 and C-10 gave rise to down field signal at 
δ74.4, δ100.4 and δ60.7 respectively due to the deshielding effect of the next oxygen 
atom. The signals at δ41.7, δ44.8, δ150.4 and δ107.6 could be attributable to C-5, C-9, 
C-8 and C-4 respectively. 
 
Figure 3.2.10.3 showed the DEPT spectrum of compound J. This spectrum 
distinguished the C, CH, CH2 and CH3 signals present in this compound.  Figure 
3.2.10.5 showed the COSY spectrum of compound J and this provides further support 
for the proton assignments from the 
1
H NMR spectrum.  The 
1
H-
1
H COSY correlation 
was shown in figure 3.2.10.4. HMQC spectrum in figure 3.2.10.5 showed the C-H 
correlation of compound J.   
 
Analysis of all spectral data obtained and comparison with literature (Inouye et al., 
1968, Ling, 2003) led to the conclusion that compound J was assigned as scandoside 70. 
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Table 3.2.10: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 70 in 
CD3OD 
 
 
13
C* 
13
C 
1
H(J,H) 
1
H(J,H)* 
1 101.1 100.4 5.09 (d, 9.0 Hz) 4.97 (d, 9.0 Hz) 
3 153.2 150.3 7.66s 7.48 (d, 1.5Hz) 
4 111.6 107.6 - - 
5 43.4 41.7 3.05bt 3.04 (ddt, 1.5, 6.3, 8.4 Hz) 
6 75.8 74.4 4.90m 4.88m 
7 129.7 128.8 6.03s 5.98 (d, 2.1 Hz) 
8 151.5 150.4 - - 
9 46.2 44.8 2.55 (t, 8.0 Hz) 2.52 (dd, 8.1, 8.4 Hz) 
 
10 61.8 60.7 4.50 (d, 15.8 Hz) 4.45 (d, 15.9 Hz) 
  
 
4.25 (d, 15.6 Hz) 4.20 (d, 15.9 Hz) 
11 173.9 - - 
1' 75.0 70.6 4.76 (d, 7.7 Hz) 4.72 (d, 8.1 Hz) 
2' 77.8 76.8 3.40(d, 9.0 Hz) 3.23 (dd, 8.1, 9.3 Hz) 
3' 71.6 73.9 3.2-3.2 m 3.4 (t, 9.3 Hz) 
4' 78.5 77.4 3.2-3.2 m 3.26m 
5' 62.8 61.8 3.2-3.2 m 3.26m 
 
6' 100.3 99.2 
 
3.89 (d, 11.7 Hz),    
3.67 (d, 11.8 Hz) 
 
3.84 (dd, 2.0, 12.0 Hz)   
3.65 (dd, 5.4, 12.0 Hz) 
* 
1
H NMR [300 MHz, CD3OD] 
*
13
CNMR [75MHz, CD3OD] 
(Ling, 2003)
Chapter 3: Results and Discussion 
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Figure 3.2.10.1:  
1
H NMR spectrum of scandoside 70 
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Figure 3.2.10.2:  
13
C NMR spectrum of scandoside 70 
 
Figure 3.2.10.3:  DEPT spectrum of scandoside 70  
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Figure 3.2.10.4:  COSY spectrum of scandoside 70 
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Figure 3.2.10.5:  HMQC spectrum of scandoside 70  
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3.2.11 Compound K:  Lucidin-3-methyl ether 
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Lucidin-3-methylether (4-hydroxy-2-hydroxymethyl-3-O-methoxy-9,10-anthraquinone)  
71 (compound K) was isolated as yellow amorphous powder. It produced pseudo-
molecular ion peak [M - H]
- 
at m/z 283.05963  with ESI-MS which is consistent with 
molecular formula C16H12O5.  The UV spectrum recorded in methanol showed 
maximum absorption at 283, 247, 203 nm.  The IR spectrum exhibits absorption due to 
OH groups (3306 cm
1
)   and a strong signal of C=O (1647 cm
-1
) (Silverstein et al., 
1991).   
 
The 
1H NMR (figure 3.2.11.1) showed one methoxy peak at δ 3.64 (s, 3H), one 
oxymethylenes at δ 4.86 (s, 3H), aromatic proton signals at δ8.9 (dd, J1=2.1, J2=8.1 Hz, 
H-5), 8.18-8.27m (H-6, 7) and 8.40 (dd, J1=2.1, J2=8.1 Hz, H-8). The data demonstrate 
a similarity to those of damnacanthol 69 but with additional one singlet peak resonated 
at δ13.17. It was the chelated proton from the hydroxyl group attached to C-1. Thus, it 
makes this compound different from damnacanthol 71.    
 
Its 
13
C NMR (figure 3.2.11.2) showed 16 signals for all the carbons present in this 
anthraquinone. The complete assignments were summarized in table 3.2.11 also similar 
to those of damnacanthol 71. The 
13
CNMR spectrum of this compound indicated the 
presence of eight quarternary carbons, six methines, one methylene and one methyl 
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group. The methine carbon which resonated at lower field of 109.7 was seen to have J2 
correlation to OH-1 in the HMBC spectrum (figure 3.2.11.3), thus supported its position 
at C-2. Another important J2 correlation was between the oxymethylene (CH2OH) and 
methoxy (CH3OH) proton and carbon. The complete HMBC correlation was 
summarized in figure 3.2.11.4.   
 
Hence, this compound was demonstrated to be 4-hydroxy-2-hydroxymethyl-3-O-
methoxy-9,10-anthraquinone 71 (Kitajima et. al., 1998).   
 
 
 
Table 3.2.11: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 71 in 
DMSO-d6 
 
 
13
C 
1
H (J/H) 
1
H (J/H)* 
1 108.4 13.17s 13.14s 
2 109.7   
3 164.9   
4 164.5 7.50s 7.45s 
4a 134.5   
5 127.5 8.90 (dd, J=2.1, 8.1 Hz) 8.28-8.32m 
6 135.3 8.18-8.27m 7.78-7.84m 
7 135.2 8.18-8.27, m 7.78-7.84m 
8 127.1 8.40 (dd, J=2.1, 8.1 Hz) 8.28-8.32m 
8a 133.5   
9 182.3   
9a 117.4   
CH2O 58.4 4.86s 4.89s 
OCH3 61.9 3.64s 4.06s 
10a 133.6   
10 186.8   
 
*
 1
H NMR [125.65MHz, DMSO-d6], 
13
C NMR [500 MHZ, DMSO-d6] 
Kitajima et al., 1998 
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Figure 3.2.11.1:  
1
H NMR spectrum of lucidin -3-methyl ether 71 
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Figure 3.2.11.2: 
13
C NMR spectrum of lucidin-3-methyl ether 71 
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 Figure 3.2.11.3a:  HMBC spectrum of lucidin-3-methyl ether 71 
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Figure 3.2.11.3b:  HMBC spectrum expansion of lucidin-3-methyl ether 71 
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Figure 3.2.11.4:  Selected HMBC correlation in lucidin-3-methyl ether 71 
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3.2.12 Compound L: Rubiadin-1-methyl ether 
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Rubiadin-1-methylether 11 (compound L) was isolated as yellow amorphous powder 
from two fractions, it produced pseudo-molecular ion peak [M-H]
 -
 at m/z 267.06534 
with ESI-MS which is consistent with molecular formula C16H12O4. The UV spectrum 
recorded in MeOH showed maxima absorptions at 280, 238 and 204 nm. In the IR 
spectrum, important absorptions were observed at 3306 cm
-1 
for OH groups and 1650 
cm
-1
 for C-H aromatics group (Silverstein et al., 1991). The strong signal which is 
attributable to C=O group could be observed at 1672 cm
-1
.   
 
Its 
1
H NMR (figure 3.2.12.1) showed an A2B2 type of aromatic proton signals at δ8.18 
(dd, J1=7.4 and J2=1.8 Hz, H-8), δ8.12 (dd, J1=7.4 and J2=1.8 Hz, H-5), δ7.90 (dt, 
J1=7.4 and J2=1.8 Hz, H-6) and δ7.80 (dt, J1=7.4 and J2=1.8 Hz, H-7) for the ring (table 
3.2.12). A singlet δ7.48 for an isolated aromatic proton could be attributable to proton 
H-4. Another signal resonated at δ3.83 (s, 3H) and δ2.13 (s, 3H). The former was a 
signal for the methoxy protons as it resonated at lower field due to the deshielded effect 
of the oxygen atom, while the latter was the signal for the aromatic methyl protons.   
 
The 
13
C NMR (figure 3.2.12.2) together with the DEPT spectrum (figure 3.2.12.3) 
distinguished sixteen carbons into nine quarternary carbons, five methines and two 
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methylenes groups. Two quarternary carbonyl carbons at δ182.8 and δ180.3 were 
assigned to be C-10 and C-9 respectively. The C-10 was deshielded interspace by the 
neighboring oxygen atom of the methoxy group at C-1. Peaks at position δ126.1- 
δ134.7 were indicative of the sp2 carbons of the benzene ring. The quarternary carbon 
resonated at δ161.8 (C-3), δ160.8 (C-1), δ134.7 (C-4a), δ133.9 (C-8a), δ132.2 (C-10a), 
δ126.3 (C-2) and δ118.1 (C-9a). The C-3 and C-1 experience a deshielding effect from 
the neighbouring oxygen atom. The methoxy and methyl carbon resonated at δ60.8 and 
δ9.2 respectively.   
 
Consequently, comparison of the empirical data with the literature values (Lee, 1968; 
Kohei et. al, 2010) of a known compound led to the conclusion that compound L was 
rubiadin-1-methylether 11.   
 
 
Table 3.2.12: 
1
H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 11 in 
DMSO-d6 
 
 
13
C 
13
C* 
1
H(J,H) 
1
H (J,H)* 
     1 160.8 161.1 - - 
2 126.3 126.6 - - 
3 161.8 162.3 - - 
4 109.2 109.5 7.48s 7.51s 
4a 134.7 135.0 - - 
5 126.2 126.5 8.12 (d, J=7.4, 1.8 Hz) 8.1 (dd, J=7.4, 1.4 Hz) 
6 134.7 134.2 7.90 (dt, J=7.4, 1.8 Hz) 7.83(td, J=7.4, 1.4 Hz) 
7 133.5 133.8 7.80 (dt,  J=7.4, 1.8 Hz) 7.89 (td, J=7.5, 1.4 Hz) 
8 126.8 127.1 8.18 (d, J=7.4, 1.8 Hz) 8.15(dd, J=7.5, 1.4 Hz) 
8a 133.9 135.0 - - 
9 180.3 180.6 - - 
9a 118.1 118.34 - - 
10 182.8 183.1 - - 
10a 132.2 132.5 - - 
CH3 9.2 9.5 2.13s 2.16s 
OCH3 60.8 61.1 3.83s 3.79s 
 
 
 
  
* 
1
H NMR [400MHz, DMSO-d6],  
* 
13
C NMR [100MHz, DMSO-d6] 
Kohei et al, 2010 
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Figure 3.2.12.1: 
1
H NMR spectrum of Rubiadin-1-methylether 11 
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Figure 3.2.12.2:  
13
C NMR spectrum of Rubiadin-1-methylether 11 
 
 
 
 
  
Figure 3.2.12.3:  DEPT spectrum of Rubiadin-1-methylether 11 
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Figure 3.2.12.4:  HMQC spectrum of Rubiadin-1-methylether 11 
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3.2.13 Compound M:  Damnacanthol 
 
O
O
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4a
9a
8a
10a
2
3
5
6
7
8
1
4
9
10
 
72 
 
Damnacanthol 72 (compound M) was isolated as yellow amorphous powder. It 
produced pseudo-molecular ion peak [M-H]
 -
 at m/z 283.05991 with ESI-MS which is 
consistent with molecular formula C16H12O5. The UV spectrum recorded in MeOH 
exhibited maximum absorptions at 278, 239, 203 nm. The IR spectrum showed broad 
bands for OH groups (3300 cm
-1
), C-H aromatic signal (1647 cm
-1
) and a sharp signal at 
1672  cm
-1
 of C=O function (Silverstein et al., 1991). 
 
The  
1
H NMR spectrum (figure 3.2.13.1) showed an A2B2 aromatic spin system at δ8.10 
(dd,  J1=7.5 and J2=1.2 Hz, 1H, H-8), δ8.06 (dd, J1 =1.2 and J2=7.5 Hz, 1H, H-5), δ7.86 
(dt, J1=7.5 and J2=1.1 Hz, 1H, H-6) and δ7.77 (dt, J1 =7.5 and J2=1.2 Hz,1H, H-7) 
which could be assigned to be protons in the ring A (table 3.2.13).  It also showed an 
isolated aromatic proton at   δ7.48 (1H). Other signals include an overlapped  singlet of 
two hydrogens at δ4.54 and a singlet for three hydrogens at δ3.80 which indicated the 
presence of oxymethylene and methyl groups, respectively. Both signals protons were 
shifted down field due to the deshielding effect by the neighbouring oxygen.   
 
The 
13
C NMR spectrum (figure 3.2.13.2) together with the DEPT spectrum (figure 
3.2.13.3) confirmed the presence of sixteen carbons of which nine are quarternary 
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carbons, five methines, one methylene and one methyl group. Two quarternary chelated 
carbon at δ183.4 and δ180.8 were attributable to the carbonyl carbon of C-10 and C-9, 
respectively. Two oxygenated quarternary carbons resonated at δ163.0 and δ162.5 
attributed to C-3 and C-1 respectively. Another quarternary carbon resonated at δ136.2, 
δ135.4, δ133.9 and δ118.6 which was attributable to C-4a, C-8a, C-10a and C-9a 
respectively. The upfield shift of C-3 and downfield shift of C-9a can be attributed to 
the substituted OH-3 and its shielding effect on the para carbon, C-9a. The C-4 carbon 
was shifted to upper field (δ110.6)  compared to the other aromatic carbon C5-C8 due 
to the shielding effect of methoxy on C-1 on the para carbon, C-4. The methoxy group 
itself resonated at δ63.2 while the methylene carbon resonated at δ52.9. 
 
Finally, after thorough comparison of the empirical data with the literature values of the 
knowm compound (Kohei et. al, 2010) we concluded that compound M was 
damnacanthol 72. 
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Table 3.2.13: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 72 in 
DMSO-d6 
 
Position 
13
C* 
13
C 
*1
H(J,H) 
1
H(J,H) 
    - 
1 161.7 162.5 - - 
2 128.8 129.6 - - 
3 162.2 163.0 7.52s 7.48s 
4 109.8 110.6 - - 
4a 135.4 136.2 - - 
5 126.1 126.9 8.11 (dd, J=7.5, 1.5 Hz) 8.06 (dd, J=7.5, 1.2 Hz) 
6 133.4 134.2 7.83 (td, J=7.5, 1.4 Hz) 7.86 (dt, J=7.5, 1.1 Hz) 
7 134.6 135.4 7.89 (td, J=7.5, 1.5 Hz) 7.77 (dt, J=7.5, 1.2 Hz) 
8 126.6 126.9 8.16 (dd, J=7.5, 1.4 Hz) 8.10 (dd, J=7.5, 1.2 Hz) 
8a 134.6 135.3 -  
9 
9a 
178.0 
117.9 
180.8 
118.6 
- - 
10 182.6 183.4 - - 
10a 132.0 133.9 - - 
CH2O 52.2 52.9 4.57s 4.54s 
OCH3 62.4 63.2 3.87s 3.80s 
     
 
*
1
H NMR [400MHz] in DMSO-d6 
*
13
C NMR [100 MHz] in DMSO-d6     
(Kohei et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
134 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.13.1:  
1
H NMR spectrum of damnacanthol 72 
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Figure 3.2.13.2:  
13
C NMR spectrum of damnacanthol 72 
 
 
 
 
Figure 3.2.13.3:  DEPT spectrum of damnacanthol 72 
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3.2.14 Compond N: Rubiadin 
 
O
O
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10 
 
 
Rubiadin 10 (compound N) was isolated as yellowish orange crystals.  It produced 
pseudo-molecular ion peak [M - H]
 - 
 at m/z 253.04933 with ESI-MS which is consistent 
with molecular formula C15H10O4.  It showed maximum UV absorption at 409, 279, 245 
and 206 nm. The IR spectrum showed a broad band for OH groups (3391 cm
-1
) and a 
signal for C-H aromatic at 1621 cm
-1 
(Silverstein et al.,1991)
 
. It also showed a strong 
signal at 1660 cm
-1
 due to C=O function. 
 
The 
1
H NMR spectrum (figure 3.2.14.1) showed aromatic proton signal on A2B2 spin 
system for ring C at δ8.21 (dd, J1=7.0 and J2=1.7 Hz, 1H, H-8), δ8.13 (dd, J1=7.0 and   
J2= 1.7 Hz, H-5, 1H), δ7.90 (dt, J1 =7.0 and J2= 1.7 Hz, H-6, 7, 2H) (table 3.2.14).  It 
also showed a methyl proton signal at δ2.07 (s, 3H).   
 
Both the 
13
C NMR (figure 3.2.14.2) and DEPT spectrum (figure 3.2.14.3) were 
employed to analyze the carbon of this compound. Two quarternary carbon of carbonyl 
groups resonated at δ185.9 and δ182.2 attributable to C-10 and C-9 respectively. A 
quarternary carbon which resonated at δ162.6 could be assigned to C-4 which was 
deshielded to lower field by the hydroxyl group.  The other carbon signals (C-6, C-7, C-
5, C-8, C-9a, C-8a, C-10, C-9, C-4a, C-10a and C-4) are almost similar to the 
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previously discussed compound (K-M) except for additional peaks resonated at δ8.30.  
The later was sp
3
 carbon of methyl group.    
 
Analysis of all spectral data obtained and comparison with literature values of a known 
compound (Lee, 1968, Kohei et al., 2010) led to the conclusion that compound N was 
rubiadin 10.  
 
 
Table 3.2.14: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 10 in 
DMSO-d6 
 
 13C 
13
C* 
1
H(J,H) *
1
H(J,H) 
1 108.1 108.9 7.15s 7.19s 
2 162.6 162.4 - - 
3 108.5 107.4 - - 
4 162.6 162.9 13.15s 13.05 s 
4a 133.3 131.6 - - 
5 126.8 126.6 8.13 (dd, J=7.0, 1.7 Hz)      8.08 (dd, J=7.0, 2.1 Hz) 
6 134.7 134.3 7.90 (dt, J=7.0, 1.7 Hz) 7.84 (td, J=7.0, 1.7 Hz) 
7 134.5 134.4 7.90 (dt, J=7.0, 1.7 Hz) 7.87 (td, J=7.2, 2.1 Hz) 
8 126.5 126.3 8.21 (dd, J=7.0, 1.7 Hz) 8.14 (dd, J=7.2, 1.7Hz) 
8a 131.9 132.9 - - 
9 182.2 181.7 - - 
9a 117.3 117.3 - - 
10 185.9 186.1 - - 
10a 133.0 132.8 - - 
CH3 8.3 8.1 2.07s 2.03s 
 
*
1
H NMR [400 MHz] in DMSO-d6 
*
13
C NMR [100 MHz] in DMSO-d6 
(Kohei et al., 2010) 
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Figure 3.2.14.1:  
1
H NMR spectrum of rubiadin 10 
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Figure 3.2.14.2:  
13
C NMR spectrum of rubiadin 10 
 
 
 
Figure 3.2.14.3:  DEPT spectrum of rubiadin 10 
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Figure 3.2.14.4:  HMQC spectrum of rubiadin 10 
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3.2.15 Compound O: 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-anthraquinone  
 
O
O
HOH2C
9
10
9a 8a
4a 10a
8
4
1
6
OH
5
7
H3C  
(The position of substituents at C-2,C-3 and C-4 were not confirmed)  
73 
 
 
1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-anthraquinone 73 (compound O) was isolated 
as yellowish orange powder.  It produced pseudo-molecular ion peak [M - H]
 -
 at m/z 
283.26373 with ESI-MS which is consistent with molecular formula C16H12O5.  The UV 
spectrum showed maxima absorption at 277, 239 and 204 nm.  The IR spectrum 
indicated the presence of OH and C=O group with the broad signal at 3395 cm
-1 
and 
sharp signal at
 
1700 cm
-1
, respectively (Silverstein et al., 1991).  
 
Its 
1
H NMR spectrum (figure 3.2.15.1) showed aromatic proton signals at δ8.28 (dd, 
J=7.2, 1.2 Hz, 1H, H-8), δ8.17 (dd, J1=7.2 and J2=1.2 Hz, 1H, H-5) , δ7.82 (dt, J=7.5 
and J2=1.2 Hz, 1H, H-7) and δ7.76 (dt, J1=7.5 and J2=1.2 Hz, 1H, H-6) representing the 
insulated A2B2 spin system for ring C (table 3.2.15). A singlet peak resonated at δ4.66 
(2H) shifted downfield due to the deshielding effect of the neighbouring oxygen and 
anisotropic effect of the aromatic ring. A quartet corresponding to two protons of an 
ethyl groups was observed rather downfield at δ3.63. This may be due to the anisotropic 
effect caused by the adjacent carbonyl group. The respective methyl protons resonated 
as a triplet at δ1.20. 
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The 
13
C NMR (figure 3.2.15.2) and DEPT spectrum (figure 3.2.15.3) showed the 
presence of seventeen carbons; nine quarternary carbons, five methines, two methylenes 
and one methyl group. Four aromatic sp
2
 carbons resonated at δ135.4, δ134.9, δ127.9, 
δ127.5 which could be assigned to be methine carbons of C-6, C-7, C-8 and C-5 
respectively. Another sp
2
 carbon resonated at δ118.2 and δ111.1 attributable to the 
quarternary C-9a and C-4. The sp
3
 carbon of the methylene groups resonated at δ67.1, 
δ81.5 while of the methyl carbon at δ15.4. The former was shifted downfield due to the 
deshielding effect of the aromatic ring while the second was deshielded by the 
neighbouring oxygen atom.   
 
Complete assignments of 
1
H-
1
H and 
1
H-
13
C signals were established by COSY (figure 
3.2.15.4) and HMQC (figure 1.4.15.5) correlation spectra, respectively. The COSY 
spectrum showed the correlation between the methyl and methylene protons. 
 
Finally, by comparison of the empirical data with the literature values of a knowm 
compound brought to the conclusion that compound O was 1-ethyl-3-hydroxymethyl-4-
hydroxy-9,10-anthraquinone 73. 
 
 
 
 
 
 
 
 
 
  
143 
 
 
 
Table 3.2.15: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 73 in 
DMSO 
 
 13C 
1
H(J,H)  
1 ND -   
2 111.1 7.20s   
3 ND -   
4 180.0 -   
4a ND -   
5 127.5 8.17 (dd, J=7.2, 1.2 Hz) 
6 135.4 7.76 (dt, J=7.5, 1.2Hz) 
7 134.9 7.82 (dt, J=7.5, 1.2 Hz) 
8 127.9 8.28 (dd, J=7.2, 1.2Hz) 
8a ND -   
9 184.1 -   
9a 118.5 -   
10 187.1 -   
10a ND -   
CH3 15.4 1.20 (t, J=6.9 Hz)   
CH2O 81.5 4.66 s   
CH2 67.1 3.63 (q, J=6.9 Hz)   
 
 
 
ND=not detected
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Figure 3.2.15.1:  
1
H NMR spectrum of 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-
anthraquinone 73 
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Figure 3.2.15.2:  
13
C NMR spectrum of 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-
anthraquinone 73 
 
 
Figure 3.2.15.3:  DEPT spectrum of 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-
anthraquinone 73 
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Figure 3.2.15.4:  COSY spectrum of 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-
anthraquinone 73 
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Figure 3.2.15.5:  HMQC spectrum of 1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-
anthraquinone 73 
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3.2.16 Compound P:  2-methoxy-3-oxyhydroxymethyl-9,10-anthraquinone 
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Compound 2-methoxy-3-oxyhydroxymethyl-9,10-anthraquinone 74 (compound Q) was 
isolated as yellowish powder. It produced pseudo-molecular ion peak [M+Na]
+
 with 
ESI-MS 307.05450 which is consistent with molecular formula C16H12O5. The UV 
spectrum showed maximum absorption at 279, 239 and 203 nm. The IR spectrum 
showed sharp signal for C=O group at 1724 cm
-1
 , C-H aromatic at 1672 cm
-1
 and a 
strong broad band for the OH function at 3309 m
1 
(Silverstein et al., 1991
 
. 
 
The 
1
H NMR spectrum (figure 3.2.16.1) showed the aromatic protons resonated at 
δ9.03 (bd, J=6.7Hz, H-8), δ8.98 (bd, J=6.7Hz, H-5), δ8.73 (dt, J1=4.1 and J2= 7.3 Hz, 
H-6) and δ8.65 (dt, J1=7.4 and J2=4.1Hz, H-7), a typical signal for ring C protons (table 
3.2.17). Two isolated aromatic protons resonated at δ8.50 (d, J=3.2Hz) and δ8.30 (s) 
could be assigned to be H-1 and H-4 respectively. Another signal could be observable at 
δ5.43 (s, 2H) and δ4.66 (s, 3H) which belongs to hydroxyl methyl and methoxy protons 
respectively.   
 
The 
13
C NMR (figure 3.2.16.2) showed similar signals as those of damnacanthol 
(compound M) but with additional peak at δ168.6 and δ130.4. The former was sp2 
quarternary carbon C-2 which (figure 3.2.16.4) resonated downfield due to the 
deshielding effect of oxygen atom. The later was methine sp
2
 carbon of C-1. The DEPT 
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(figure 3.2.16.3) and HMQC (figure 3.2.16.4) spectra help to complete the structure 
assignment of compound Q.   
 
Finally by comparing the empirical data with the literature values of the known 
compounds brought to conclusion that compound P was 2-methoxy-3-
oxyhydroxymethyl-9,10-anthraquinone 74.   
 
Table 3.2.16: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 74 in 
DMSO-d6 
 
 13C 
1
H(J,H) 
1 130.5 8.50 (d, J=3.2 Hz) 
2 163.3 - 
3 168.7 - 
4 111.5 8.3 s 
4a 137.0 - 
5 136.2 8.98 (bd, J=6.7 Hz) 
6 128.4 8.73 (dt, J=7.4, 4.1 Hz) 
7 127.8 8.65 (dt, J=7.4, 4.1 Hz) 
8 136.3 9.03 (bd, J=6.7 Hz) 
8a 133.3 - 
9 181.6 - 
9a 120.0 - 
10 184.3 - 
10a 133.3 - 
CH2O 53.8 5.43s 
CH3O 64.1 4.66s 
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Figure 3.2.16.1:  
1
H NMR spectrum of 2-methoxy-3-oxyhydroxymethyl-9,10-
anthraquinone 74 
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Figure 3.2.16.2:  
13
C NMR spectrum of 2-methoxy-3-oxyhydroxymethyl-9,10-
anthraquinone 74 
 
 
 
 Figure 3.2.16.3:  DEPT spectrum of 2-methoxy-3-oxyhydroxymethyl-9,10-
anthraquinone 74 
 
10 
9 3 
2 4a 
10a,8a 
8,5 
1 
6,7 
9a 
4 CH2O 
  
 
 
50 100 150 200 
0 50 100 150 200 
O
O
H3CO
HOH2CO
A B C
9a
10a4a
8a
1
2
4
8
5
6
79
10
 
OCH3 
 
 
 
 
2 
CH2O 
 OCH3 
      
10     
9 
      
2 
3 
4 
9a 
10a,8a 
  4a 
  8,5 
6,7  1 
 OCH3 
CH2O 
4 
4 
6,
7 
  8,5 
  8,5 
6,7 
 152 
 
 
 
 
O
O
H3CO
HOH2CO
A B C
9a
10a4a
8a
1
2
4
8
5
6
79
10
 
 
 
 
 
Figure 3.2.16.4:  HMQC spectrum of 2-methoxy-3-oxyhydroxymethyl-9,10-
anthraquinone 74 
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3.2.17   Compound Q: Lucidin-ω-methyl ether 
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Lucidin-ω-methylether 21 (compound Q) was isolated as yellowish powder.  It 
produced pseudo-molecular ion peak [M - H]
- 
at m/z 283.05991 with ESI-MS which is 
consistent with molecular formula C16H12O5.   Its UV spectrum showed maximum 
absorption at 410, 280, 245, 205 nm.  The  IR spectrum indicate the presence of OH 
function with a broad band at 2929 cm
-1
 , C-H  (1623cm
-1
) and C=O function  with the 
strong signal at 1730 cm
-1
, 1674 cm
-1 
(Silverstein et al.,1991. 
 
The 
1H NMR spectrum (figure 3.2.17.1) showed a singlet signal δ13.32 assignable to be 
the chelated proton at C-1 (table 3.2.17). Another peak was broad singlet, assigned to be 
of the hydroxyl protons. The aromatic protons signal resonated at δ8.29 (dd, J1=1.8 and 
J2=7.2 Hz, H5),   δ7.82 (dt, J1=1.8 and J2=7.2 Hz, H-6), δ7.78 (dt, J1=1.8 and J2=7.2 
Hz, H-7), δ8.32 (dd, J1=1.8 and J2=7.2 Hz, H-8). A singlet at δ7.35 (1H) was the 
isolated aromatic proton of H-1. Another singlet signals appear at δ4.95 (s, 2H) and 
δ3.60 (s, 3H) attributable to oxygenated methylene and methoxy protons.  
 
The 
13
C NMR (figure 3.2.17.2) showed two quarternary carboxyl carbons of C-10 and 
C-9 resonated at δ186.9 and δ182.2,   respectively. Another quarternary sp2 carbon 
could be observed at δ164.0(C-4) and δ161.8 (C-2). Both of them were dishielded and 
shifted to the lower field by the electronegative oxygen neighbour   of the hydroxyl 
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group. The methylene and methoxy carbons both resonated at δ68.9 and δ59.5 
respectively.  
 
After the comparison of the empirical data together with the literature review (Kohei et 
al., 2010) of the known compound, it can be concluded that compound Q was lucidin- ω 
-methylether 21. 
 
 
Table 3.2.17: 
1H NMR [300 MHz, δH (J, Hz)] and 
13C NMR [75 MHz, δC] of 21 in 
DMSO-d6 
 
 13C 
13
C* 
1
H(J,H) *
1
H(J,H) 
1 109.7 109.8 7.35s 7.22s 
2 161.8 161.8 9.40bs 9.37s 
3 ND 134.1 -  
4 164.0 164.0 13.32s 13.22s 
4a ND 133.5 -  
5 134.1 134.1 8.29 (dd, J=7.2, 1.8 Hz) 8.08 (dd, J=7.1, 1.4 Hz) 
6 127.3 126.7 7.82 (dt, J=7.2, 1.8 Hz) 7.85 (dt, J=7.1, 1.4Hz) 
7 126.7 126.7 7.78 (dt, J=7.2, 1.8 Hz) 7.88 (dt, J=7.1, 1.4Hz) 
8 134.1 134.0 8.32 (dd, J=7.2, 1.8 Hz) 8.15 (dd, J=7.1, 1.4Hz) 
8a 127.3 127.3 - - 
9 182.2 182.2 - - 
9a 114.3 114.3 - - 
10 186.9 186.9 - - 
10a ND 133.5 - - 
CH2O 68.9 68.9 5.0s 4.40s 
OCH3 59.3 59.4 3.64s 3.25s 
*
1
H NMR [400.1 MHz] 
*
13C NMR [100.1 MHz, δC] in CDCl3 
ND= not detected 
(Kohei et al., 2010)
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Figure 3.2.17.1:  
1
HNMR spectrum of lucidin- ω -methyl ether 21 
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Figure 3.2.17.2:  
13
C NMR spectrum of lucidin-ω-methyl ether 21 
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Chapter 4:  
Synthesis 
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4.1    Introduction  
 
The compound ursolic acid 60 was identified as the most active compound on 
hyaluronidase activity inhibition (chapter 5.4.2). Based on Lipinski rules of five which 
mentioned that the orally administered drugs should have the molecular weight less than 
five hundred, not more than five hydrogen bond donor groups, ten or less hydrogen 
bond acceptor groups and calculated log P value less than five (Lipinski et al., 2001), 
ursolic acid 60 (456.707 g/mol) was found to follow the rules and thus has the 
‘druglike’ properties. Eventhough this compound has log P value of 7.317 (Maurya et 
al., 2012) which violating the Lipinski’s rule of five, but since the number of violating 
is no more than one, thus it is still acceptable.   
 
In order to study structure activity relationships of ursolic acid, the compound needs to 
be modified in order to obtain derivatives with various functionalities. Thus, the 
obtained derivatives together with ursolic acid 60 will be investigated with respect to 
their structure activity relationship quantitatively towards the hyaluronidase activity 
inhibition. The synthetic modifications were executed as described by Chao-Mei et al. 
(2005), with slight changes on the solvents and reagents used. 
 
Eight analogues were obtained (75-81) and they were tested for their inhibitory activity 
towards hyaluronidase. Scheme 4.1-4.3 outlined briefly the synthetic pathway of these 
analogues. Ursolic acid 60 was oxidized with pyridinium chlorochromate (PCC) in 
mixture of dichloromethane acetone to give the 3-oxo compound 75 (Scheme 4.1).  
Compound 75 was further treated with hydroxylamine hydrochloride in pyridine to give 
the hydroxyimino compound 76.       
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3-acetoxy ursolic acid 77 was obtained in a simple treatment with acetic anhydride in 
pyridine (Scheme 4.2). Compound 77 then was stirred with trimethylsilyl diazomethane 
(TMS) to give methyl ester compound 78.   
 
Treatment of ursolic acid 60 with trimethylsilyl diazomethane in methanol and toluene 
yielded methyl ester compound 79. It was oxidized with pyridinium chlorochromate to 
give the 3-oxo methyl ester compound 80. The compound 80 was further treated with 
hydroxylamine hydrochloride to obtaine 3-hydroxylamino methyl ester 81 (Scheme 
4.3). 
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HO
H3C CH3
H3C
CH3
H3C
CH3
COOH
3
(C5H6N {ClCrNO3}
-)/
CH2Cl2(CH3)2CO
O
H3C CH3
H3C
CH3
H3C
CH3
COOH
3
H2NOH HCl
Pyridine
HON
H3C CH3
H3C
CH3
H3C
CH3
COOH
3
56
74
75  
 
 
 
(C5H6N){ClCrNO3} = PCC;     CH2Cl2 = dichloromethane;    (CH3)2CO = acetone;    H2NOH HCl = hydroxylamine hydrochloride 
 
Scheme 4.1:  Synthesis of ursolic acid 60 derivatives 75-76 
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COOCH3
3
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(CH3CO)2 = acetic anhydride;   (CH3SiCH2N
+N) = trimethylsilyl diazomethane  (TMS) 
Scheme 4.2:  Synthesis of ursolic acid 60 derivatives 77-78 
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(CH3SiCH2N
+N) = TMS;  (C5H6N){ClCrNO3} = PCC;  H2NOH HCl = hydroxylamine hydrochloride 
Scheme 4.3:  Synthesis of ursolic acid 60 derivatives 79-81  
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4.1 Results and discussion  
 
The following paragraphs described briefly the structure elucidation of the analogues 
(75-81). The HRESIMS of compound 75 shows a pseudo-molecular ion peak [M-H] 
-
 at 
m/z 453.33524 corresponding to the molecular formula of C30H46O3. This observation 
was consistent with the removal of two hydrogen atoms from the compound 60, the H-3 
and C3-OH. This conclusion was supported by the absence of H-3 peak in the 
1
H NMR 
spectrum (figure 4.1). A peak at very low field (218.0 ppm) suggested the presence of 
ketone group in 75 (figure 4.2). The C-2 and C-4 chemical shift were observed at 28.5 
and 39.2 respectively, in 60. The corresponding value for the same carbon in 75 were 
33.5 and 47.5 demonstrated the high deshielding effect of CO at position C-3.  The 
value of same carbons, C-2 and C-4,   in 76 were 28.8 and 39.6 (figure 4.4) 
respectively, were almost similar to the initial compound 60.  Apart from that, the mass 
spectrum of 76 [ESI, M+H]
+  
at m/z 470.35516 corresponding to molecular formula of 
C30H47NO3  supported  the incorporation of the hydroxyimino functional group, NOH.   
 
The peak at 1.91 ppm in 
1
H NMR spectrum (figure 4.5) (3H, s) and 20.7 and 169.9 ppm 
in 
13
C NMR (figure 4.6) is consistence with the presence of acetyl group in 77. The 
large coupling constant of H-3 in the 
1
H NMR of 77 (4.68, 1H, dd, J= 5.1, 10.9) 
indicated that H-3 is α orientated (Ma et al., 2005). The mass spectrum of 77 showed 
value of m/z 497.36343 [M-H]
- 
corresponding to molecular formula C32H50O4. An 
additional peak could be observed in 
1
H NMR of compound 78 at 3.74 (3H, s) (figure 
4.7) and 51.6 in 
13
C NMR (figure 4.8) indicated the presence of methoxy group. The 
values for most of the carbons were almost similar to the compound 78. Apart from 
that, the mass spectrum [ESI, (M-K)
-
] showed value of m/z 473.28149 which is 
corresponding to the molecular formula C33H52O4. 
      
164 
 
 
The 
1
H NMR (figure 4.11) of compound 80 indicated the absence of H-3 signal. The 
methoxy signal, however, was present at 5.10 ppm in 
1
H NMR and 51.7 ppm in 
13
C 
NMR (figure 4.12).  The down field signal of C-3 at 216.3 ppm indicated the presence 
of ketone’s carbonyl group. As in compound 75, the C-4 chemical shifts were shifted 
downfield at 48.5 ppm, compared to ursolic acid 60, due to the deshielding effect of the 
electrophilic characteristic of the C-3 ketone functional group. The mass spectrum value 
m/z 491.34198 [ESI, (M+Na)
+
]  is consistent with the molecular formula C31H48O3 of 
compound 80.    
 
The presence of free hydroxyl group at the extreme downfield region of 12.36 ppm (1H, 
s) indicated the presence of hydroxyimino group, NOH, into the compound 81 (figure 
4.13). It was further supported by the signal for oximes (R2CNOH) at 164.3 ppm (figure 
4.14). The H-2 was shifted to 3.49 ppm (dd, J= 3.3, 5.2) due to the deshielding effect of 
the hydroxyimino group at C-3. The mass spectral data supported the molecular formula 
C31H49NO3 with m/z 506.35175 [ESI, (M + Na)
+
]. 
 
Table 4.1 and 4.2 summarised the value of 
1
H NMR and 
13
C NMR of each compound 
75-81. 
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Figure 4.1:  
1
H NMR spectrum of 3-oxo-urs-12-en-28-oic acid 75 
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Figure 4.2:  
13
C NMR spectrum of 3-oxo-urs-12-en-28-oic acid 75 
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Figure 4.3:  
1
H NMR spectrum of 3-hydroxyimino-urs-12-en-28-oic acid 76 
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Figure 4.4:  
13
C NMR spectrum of 3-hydroxyimino-urs-12-en-28-oic acid 76 
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Figure 4.5:  
1
H NMR spectrum of 3-acetyl-urs-12-en-28-oic acid 77 
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Figure 4.6:  
13
C NMR spectrum of 3-acetyl-urs-12-en-28-oic acid 77 
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Figure 4.7:  
1
H NMR spectrum of 3-acetyl-urs-12-en-28-oic acid methyl ester 78 
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Figure 4.8:  
13
C NMR spectrum of 3-acetyl-urs-12-en-28-oic acid methyl ester 78 
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Figure 4.9:  
1
H NMR spectrum of 3-hydroxy-urs-12-en-28-oic acid methyl ester 79 
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Figure 4.10:  
13
C NMR spectrum of 3-hydroxy-urs-12-en-28-oic acid methyl ester 79 
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Figure 4.11:  
1
H NMR spectrum of 3-oxo-urs-12-en-28-oic acid methyl ester 80 
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Figure 4.12:  
13
C NMR spectrum of 3-oxo-urs-12-en-28-oic acid methyl ester 80 
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Figure 4.13:  
1
H NMR
 
spectrum of 3-hydroxyimino-urs-12-en-28-oic acid methyl ester 
81 
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Figure 4.14:  
13
CNMR
 
spectrum of 3-hydroxyimino-urs-12-en-28-oic acid   methyl ester 
81 
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Table 4.1: 
13C NMR [70MHz, δC] of 75-81 in C5D5N
Position 60 75 76 77 78 79 80 81 
1 38.9 38.7 38.9 38.8 38.4 39.8 39.9 39.3 
2 28.4 28.0 28.8 28.0 28.5 28.8 28.5 24.7 
3 77.9 218.0 164.4 79.1 80.8 78.0 216.3 164.2 
4 39.3 47.5 40.1 41.8 39.3 39.0 48.4 38.9 
5 55.6 54.7 56.4 54.9 55.6 55.7 55.4 56.4 
6 18.5 19.2 19.5 17.9 18.5 18.7 21.3 19.4 
7 33.4 33.7 33.4 36.5 33.3 33.3 34.5 33.2 
8 39.7 39.2 40.3 38.9 38.0 39.6 42.5 39.4 
9 47.8 46.5 47.6 47.4 47.8 47.9 47.1 47.5 
10 37.2 36.8 37.6 36.8 38.0 37.3 37.1 37.1 
11 23.4 23.3 23.8 22.9 23.0 24.5 24.6 23.7 
12 125.4 126.0 125.7 124.8 125.8 125.9 125.8 126.0 
13 139.0 140.0 139.4 138.6 138.8 138.7 138.9 138.9 
14 42.3 41.9 42.7 41. 9 39.3 42.2 42.5 42.5 
15 27.8 30.4 - 32.7 28.5 28.7 26.8 28.5 
16 24.7 24.2 25.0 24.3 24.7 23.3 23.7 24.7 
17 47.8 46.1 48.2 47.2 51.6 51.4 47.5 48.4 
18 53.3 53.0 53.7 52.9 53.4 53.3 53.5 53.5 
19 39.1 38.9 37.4 37.8 42.4 39.3 39.4 40.0 
20 39.1 38.8 39.6 39.3 39.9 39.2 39.3 40.3 
21 30.8 32.3 31.2 30.5 30.9 30.7 32.8 30.9 
22 37.0 36.2 37.4 37.3 37.1 36.9 36.9 37.3 
23 28.6 26.1 28.2 27.6 28.3 28.1 30.9 28.1 
24 16.4 16.9 17.7 16.4 17.1 16.5 17.2 17.4 
25 15.4 14.5 15.2 15.0 15.6 15.6 15.3 15.2 
26 17.2 16.7 17.5 16.9 17.2 17.2 17.4 17.5 
27 23.7 23.3 23.9 23.3 24.0 22.9 23.9 23.9 
28 179.8 182.0 180.2 179.3 177.8 177.7 177.8 177.8 
29 17.3 20.8 21.6 16.8 17.4 17.3 19.9 17.3 
30 21.2 21.0 21.6 20.6 21.2 21.2 21.7 21.4 
COCH3 - - - 169.9 170.7 - - - 
COCH3 - - - 20.9 21.4 - - - 
         
COOCH3 - - - - 48.43 48.2 48.7 51.6 
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Table 4.2:  
1
 H NMR [300 MHz, δH (J,Hz)] of 75-81 in C5D5N  
Position 60 75 76 77 
1 - - - - 
2 - - 3.5bd, J=15.5 
2.6bd, 
J=11.25 
- 
     
3 β 3.39,btr NIL NIL α,4.68dd 
J=5.06, 10.9 
     
4 - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
8 - - - - 
9 - - - - 
10 - - - - 
11 - - - - 
12 5.40s 5.60bs 5.50bs 5.45bs 
13 - - - - 
14 - - - - 
15 - - - - 
16 2.17dt 2.15dt - 2.24m 
17     
18 2.65d J=11.8 2.75d J=11.8 2.30m 2.65d J=11.1 
     
19 - - - - 
20 - - - - 
21 - - - - 
22 - - - - 
23 1.07 1.04 1.08 1.06 
24 0.10 0.99 0.92 0.91 
25 0.94 0.90 0.91 0.88 
26 1.04 1.02 0.98 0.99 
27 1.06 1.16 1.20 1.08 
28 - - - - 
29 1.30 1.22 1.40 1.23 
30 1.08 1.00 0.96 0.95 
     
COCH3 - - - 2.09s 
     
COOCH3 - - - - 
NOH - - - - 
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Table 4.2:  
1
 H NMR [300 MHz, δH (J,Hz)] of 75-81 in C5D5N(continue)   
 
Position 78 79 80 81 
1 - - - - 
2 - - - 3.50d 
J=15.58  
2.25m 
     
3 α4.75dd 
J=5.4, 10.8 
3.51brt NIL NIL 
  - - - 
4 - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
8 - - - - 
9 - - - - 
10 - - - - 
11 - - - - 
12 5.41  5.42s 5.35s 
13 - - - - 
14 - - - - 
15 - - - - 
16 - - - 2.30m 
17     
18 2.49d 
J=11.1 
2.62 
J=13.11 
2.49d 
J=10.8 
2.42d 
J=10.8 
     
19 - - - - 
20 - - - - 
21 - - - - 
22 - - - - 
23 1.02 1.10 0.98 0.97 
24 0.98 0.99 0.97 0.90 
25 0.94 0.92 0.90 0.85 
26 1.00 0.98 1.13 1.12 
27 1.04 1.00 1.24 1.10 
28 - - - - 
29 1.20 1.30 1.26 1.41 
30 0.96 1.20 0.96 0.92 
     
COCH3 2.09s - - - 
 - - - - 
COOCH3 3.74s 3.75S 3.75s 3.68 
NOH - - - 12.36s 
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Chapter 5:  
Anti-inflammatory activity 
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5.1 Introduction  
 
Inflammation is a process by which the body’s white blood cells release chemicals to 
protect body from infection and foreign substances, such as bacteria and viruses. This 
process is often associated with the release of prostaglandins which, through 
chemotaxis, attract leucocytes at the point of invasion, create local pain and, after 
transport in the blood to the brain, raise the body temperature by displacing the balance 
of the centre of thermal regulation (Havsteen, 1983). It can be classified as either acute 
or chronic. The manifestations of an acute inflammation are redness, edema, heat, pain 
and disturbed tissue function. These manifestations are the results of complex 
pathophysiological processes that include increased blood flow and vascular 
permeability, activation of humoral and cellular defence mechanisms, sensibilisation 
and activation of nociceptors (Safayahi, 1997). These processes are mediated by a 
variety of signaling molecules produced by mast cells, macrophages, granulocytes, 
platelets, lymphocytes, nerve endings, endothelial cells, as well as by the activation of 
complement factors.  
 
In general, the inflammatory response involves three key processes 
(www.hcc.bcu.ac.uk/physiology/inflammation.htm): 
i.     Vasodilation resulting in increased blood flow to the damaged area 
ii. Increase vascular permeability-plasma leaks from blood vessels into the 
damaged area. 
iii. Emigration of neutrophils from blood into the damaged area 
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Prolonged inflammation, known as chronic inflammation, leads to a progressive shift 
in the type of cells present at the site of inflammation and is characterized by 
simultaneous destruction and healing of the tissue from the inflammatory process (en. 
wikipedia. org/ wiki /Inflammation). 
 
Figure 5.1 illustrates the general event during inflammation. When antigen exposure 
occurs repeatedly, inflammatory cells such as mast cells and eusinophils will 
participate to activate the immunological mechanism (Hiroichi, 2005). The activated 
mast cells will produce many mediators of different chemical classes such as amines 
(histamine, serotonin), proteins and peptides (hydrolytic enzymes, cytokines, growth 
factors, colony stimulating factors, complement factors, antibodies, kinines), activated 
oxygen species (superoxide anion, hydroperoxide, hydroxyl radicals) and lipids 
(platelet activating factor, prostanoids, leukotrienes) (Safayahi, 1997) which cause 
dilation of capillaries and changes in the endothelial cell membranes that increase 
microvascular permeability and enhance the trapping of circulating leukocytes such as 
neutrophils, at the site of injury (Robert, 1998). The matured neutrophils will 
phagocyte the microorganism or antigen such as bacteria 
(www.hcc.bcu.ac.uk/physiology/inflammation.htm).  
 
Therefore theoretically, anti-inflammatory compounds might be able to interfere with 
the pathophysiological processes by blocking the biosynthesis of pro-inflammatory 
mediators via direct interaction with a key enzyme, inhibiting the release of preformed 
and stored mediators, blocking mediator receptor interaction on target cells, or by 
acting as immune stimulation that could result in a less aggressive inflammatory 
response to allergen challenge.   
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5.2 Mediators of inflammation 
 
Inflammatory mediators are soluble and diffusible molecules that either act locally 
at the site of tissue damage and infection or at more distant sites. They can be 
divided into exogenous and endogenous mediator (John & Regina, 1987).    
 
 
Figure 5.1: Principal events in the inflammatory response 
(www.hcc.bcu.ac.uk/physiology/inflammation.htm) 
 
Bacterial products and toxins can act as exogenous mediators of inflammation whereas 
the endogenous mediators of inflammation are produced from within the innate and 
adaptive immune system itself.   
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Histamine, an amine mediator, is released from mast cells during antigen-antibody 
reactions (John & Regina, 1987). This mediator is involved in inflammatory response 
due to skin injury. It could also be found in the rheumatoid synovium and asthmatic 
lung (Holgate, 1986) but not a major player in arthritis and asthma (John & Regina, 
1987). 
 
Peptides such as bradykinin, tachykinins, endothelins (ETs) and complement are 
involved in the occurrence of asthma (Peter et al., 1998). Kinins reported to be present 
in rat pleural inflammatory exudates and nasal secretions.  They are vasoactive 
peptides that are formed from the high molecular weight (HMW) α-globulins and low 
molecular weight (LMW) kininogens via kininogenases (Bhoola, 1992). Bradykinin is 
metabolized by several peptidases known as kininases (Peter et al., 1998). It could be 
degraded by angiotensin converting enzyme (ACE) (Dusser et al., 1988), NEP (EC 
3.4.24.11) (Frossard et al., 1990) and carboxypeptidase-N. Small amounts of 
bradykinin will cause pain, vasodilation and edema, all contributing to inflammation 
(John & Regina, 1987).   
 
The structurally lipid mediators i.e. prostaglandins, thromboxane A2, prostacyclin and 
leukotrines are families of eucasanoids (http://en.wikipedia.org/wiki/Eicosanoid). 
Eucasanoids are signaling molecules made by oxidation of twenty-carbon essential 
fatty acids, (EFAs). They are synthesised from arachidonic acid (AA) that is released 
upon cell stimulation from membrane phospholipids via activation of lipid-cleaving 
enzymes, such as phosphoplipase A2 and three different pathways (Scheme 6.2) 
(Rowley et al., 1998).  The pathways are cyclooxygenase (COX) pathway, 
lipoxygenase (LOX) and cytochrome P-450.  In 1936, Euler discovered that 
prostaglandins (PGE) could cause contraction of smooth muscle cells in seminal fluid 
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and in prostate (Rowley et al., 1998). Moncada in 1976 discovered another 
prostaglandins, namely as prostacylin which could relaxes the blood vessels and 
inhibits aggregation of platelets (John a& Regina, 1987).  Thromboxane, however 
showed opposite activity. It could induce vasoconstriction, cell adhesion to the vessel 
wall and platelet aggregation. The leukotrienes (LTB4, LTC4 and LTD6) cause 
transient wheal and flare reactions in human skin (John & Regina, 1987). Morley in 
1986 reported that the phospholipids platelet-activating factor (PAF)-acether is 
released by the action of phospholipase A2 from most pro-inflammatory cells, as well 
as by vascular endothelial cells and platelets (John & Regina, 1987). It induces 
inflammatory reactions in human skin (Chung, 1987). It is particularly effective in 
producing hyper reactivity and accumulation of eusinophils in lung tissue.     
 
Interleukins-1 (IL-I) is a polypeptide produce by activated macrophages that mimics 
the symptoms of chronic inflammation (Dinarello, 1984). It has been detected in 
synovial fluids from patients with rheumatoids arthritis (Nouri et al., 1984.). Its action 
include activation of lymphocytes and production of fever that being mediated by 
release of PGE2.  
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Scheme 5.2: Arachidonic acid cascade 
 
5.3 Hyaluronidase vs hyaluronic acid 
 
Hyaluronic acid 82 (hyaluronan or hyaluronate, HA) is a linear high molar mass 
polysaccharide composed of  D-glucuronic acid-β(1,3)-N-acetyl-D-glucosamine 
disaccharide units linked together through β(1,4) glycosidic bonds (Jean-claude, 2009).  
It is a major constituent of the extracellular matrix (ECM) of vertebrates and is 
involved in many biological processes, such as cellular adhesion, mobility and 
differentiation processes (Catterall, 1995). The functions of HA 82 derived from its 
physicochemical properties. It acts as a lubricant responsible for the viscoelastic 
properties of tissue fluids.  It also acts as a stabilizing and hydrating component of soft 
connective tissue due to its water balance and osmotic pressure regulatory properties 
and besides acting as structure forming molecule in the vitreous humor of the eye, in 
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Wharton’s jelly and in joint fluids (Nermeen et al., 2010).  From its physicochemical 
properties as polymer, HA 82 also exerts biological effects via specific interactions 
with hyaluronan-binding proteins called hyaladherins (El Maradny et al., 1997).  
 
 The chemical structure of HA 82 of repeating disaccharide units linked by β-1,4 
glycosidic bonds has been elucidated in which each disaccharide unit consists of D-
glucuronic acid (GlcUAc) and N-acetyl-D-glucosamine (GlcNAc) connected by a  β-
1,3 glycosidic bond (Nermeen et al, 2010). This polymer usually consists of 2000-2500 
disaccharides to increase the molecular masses ranging from 10
6
 to 10
7
Da with 
extended lengths of 2-25 μm.   
 
Hyaluronidase, a glycosidase (Nermeen et al., 2010) is popularly known as “spreading 
factor” referring to its activity in degrading HA 82 (Deepa et al., 2006). These 
enzymes also degrade chondroitin and chondroitin sulphates with limited ability 
(Nermeen et al., 2010).  This inactive enzyme could be activated in vivo by metal ions 
such as calcium ions and HA 82 as the substrate (Yang et al., 2000). The interaction 
between hyaluronidase and HA 82 result a disruption of basement membrane integrity 
and followed by an angionic response (Takuya et al., 2003). This enzyme was reported 
to play a key role in the development of inflammatory diseases, since the destruction of 
the connective extracellular matrix promotes the spreading of chemotactic factors of 
inflammation (Facino et al., 1993). It is also involved in other fundamental biological 
phenomena such as fertilization and cancer (Stern, 2008) as well as tumor invasiveness 
and metastasis (Takuya et al., 2003).   
 
According to amino acid sequence homology, hyaluronidase could be grouped into 
two main families; from eukaryotes and prokaryotes (Csoka et al., 1997). First 
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classification   however is based on substrate specificity and on biochemical analysis 
of the hyaluronidase and their reaction products (Nermeen et al., 2010).    
 
The first group is hyaluronate-4-glycanohydrolases, mammalian hyaluronidase (EC 
3.2.1.35) (Nermeen et al., 2010). It degrades HA 82 by cleavage of the β-1,4-
glycosidic bond furnishing tetrasaccharide molecule as the main product. These 
enzymes are glycosidases with both hydrolytic and transglycosidase activity and 
degrade HA 82, chondroitin, chondroitin-4,6-sulphate to a small extent, dermatan 
sulphate. Examples from this class are testicular, lysosomal and bee venom 
hyaluronidase. The second group is hyaluronate 3-glycanohydrolases from leech (EC 
3.2.1.36). It degrades HA 82 by cleavage of the β-1,3-glycosidic bond to yield sugar 
fragments with glucuronic acid at the reducing end. This hyaluronidase generates tetra-
and hexasaccharide end products. The last group is microbial hyaluronidases (EC 
4.2.2.1) called hyaluronate lyases. They degrade HA 82 by a β-elimination reaction to 
yield unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-
enepyranosyluronic acid)-D-glucose as the main product.   
 
Hyaluronidase is present in substantial quantities in mast cells (Sasai & Tohoku., 
1975).  It demonstrated a variety of activity in different mamalian tissues (Bollet, 
Bonner & Nance, 1963) such as testes (Senn et al., 1992) and in various somatic 
tissues, e.g. liver, kidney, lymphatic system and skin as well as animal venom. It was 
also reported that hyaluronidase was expressed by metastatic human melanoma, colon 
carcinoma and glioblastoma cell lines (Liu et   al., 1996). 
 
Hyaluronic acid 82 existing as a polyanion as the carboxyl groups of the glucuronic 
acid causes the polymer highly negative charge (Nermeen et al., 2010). The 
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hydrophobic interactions and hydrogen bonds can be formed between HA 82 chains. It 
counteracted by electrostatic repulsion of the carboxyl groups (Scott et al, 1984). The 
positive charges of hyaluronidase interact with the negative charges of HA 82 to form 
non-specific electrostatic HA-Hyaluronidase complexes in which it is no more 
catalytically active (Jean-claude, 2009). This formation phenomenon is maximum at 
low ionic strength and pH 4 which is the optimal pH for hyaluronidase (Jean-claude, 
2009). It also exists at higher ionic strength including 150 mM and higher pH values 
including pH 7. The small fragments of HA 82 are highly angiogenic and potent 
inducers of inflammatory cytokines (Nermeen et al, 2010) while the high molecular 
weight HA 82 polymers prevent angiogenesis. For example, HA oligosaccharides (4-
25 disaccharides), the product of hyaluronidase in extracellular matrix, have an 
angiogenic action (Rooney et al., 1995, West et al., 1985, West et al., 1989) which 
favor the production of new blood vessels facilitating the development of cancer 
tumors. It also induced expression of inflammatory mediators in alveolar macrophages 
(Horton et al., 1999), inhibit tumor growth in vivo (Zeng et al., 1998). 
 
Since these enzymes have been implicated in many biological functions, such as 
allergy, inflammation, migration of cancer cells and permeability of the vascular 
system, the modulation of hyaluronidases by suitable inhibitors will be useful for 
normal homeostasis in the body. Hyaluronidase is related to histamine release from 
mast cells (Masateru et al., 2001) which related to type I allergy as well as as the 
degranulation of mast cells (Hisao et al., 1985). Therefore, potent hyaluronidase 
inhibitors are assumed to suppress the degranulation of mast cells and possess anti-
allergic activity (Toshihiro et al., 2010). The anti-allergic agents such as disodium 
cromoglycate (DSCG) and tranilast (N-3’,4’-dimethoxycinnamoyl anthranilic acid) is 
presumed to be involved in inhibition of the degranulation of mast cells caused by the 
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antigen IgE antibody reaction (Hisao et al., 1985). Anti-inflammatory drugs such as 
salicylates, dexamethasone and indomethacin have been reported to possess 
hyaluronidase inhibitory activity (Deepa et al., 2006). These drugs may exert a portion 
of their anti-inflammatory activity by preventing generation of small hyaluronic acid 
fragments. For example, compounds that have been used to treat snake bites or to 
promote wound healing have been subsequently demonstrated to possess anti 
hyaluronidase activity and thus delay / stop the diffusion of toxins after the 
envenomation (Deepa et al., 2006). Therefore, the search for new agents with potential 
regulating hyaluronidase activity is a possible approach for finding treatment for 
hyaluronidase mediated ailments or diseases.  
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5.4 Results and discussion 
 
A preliminary bioactivity screening programme for plants with potential therapeutic 
application in FRIM (Forest Research Institute Malaysia) has indicated that the crude 
extracts of Prismatomeris malayana exhibited strong anti-inflammatory properties 
(2004, not reported). In the study, it was found that the MeOH leaf extract inhibited 
TPA induced ear oedema at 96.03 ± 1.0 % at 2 mg/ear as compare with indomethacin 
(93.00 ± 0.20)% and platelet activating factor (PAF) receptor binding inhibitory 
activity at 76.9 ± 2.1 % at 18.2 µg/ml as compared to cedrol (74.4 ± 1.0 %) , 
respectively. In the light of the above finding, a bioassay guided study was performed 
on the most active extract (CHCl3) to find the compound(s) responsible for the anti 
inflammation. In addition, hyaluronidase inhibitory activity was also performed on 
other selected isolated PTCs and the synthesized analogues. 
 
5.4.1 Bioassay-guided study of the MeOH extracts of Prismatomeris malayana 
Ridley  
 
The dried leaves, roots and stems of Prismatomeris malayana Ridley were extracted 
with MeOH by soaking at room temperature repetitively and yielded 9.85%, 4.54% 
and 2.47% MeOH crude extract respectively. The extracts were then subjected to 
screening for hyaluronidase, lipoxygenase inhibitory and TPA induce mouse ear 
oedema activity.   
 
The leaf extract (PML) exhibited the highest inhibory activity of more than 70% in 
hyaluronidase (table 5.4.1.1) and TPA mouse ear oedema inhibitory assays (table 
5.4.1.2).  It was found to exhibit profound hyaluronidase activity (70.51 ± 4.34) % at 
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100 µg/ml as compare with that of positive control, apigenin  (88.97 ± 7.93) % and 
TPA mouse ear oedema (73.00 ± 31) % at 2 mg/ear as compare with indomethacin 
(92.80 ± 0.21)%.  These results suggest that the constituents in the leaf extract might 
be responsible for the inhibitory role in the hyaluronidase system (in vitro) and in vivo 
(TPA mouse ear oedema).  Therefore the methanol leaf extract was further fractionated 
into four fractions; petroleum ether, chloroform, ethyl acetate and water fractions. 
Table 5.4.1.3 showed the inhibitory activity of the fractions from the methanol leaf 
extract. 
 
Further bioassay guided fractionation and isolation based on the hyaluronidase 
inhibitory assays resulted in the isolation of  ursolic acid 60 (14.25 % yield of the 
chloroform fraction)  which gave the highest inhibition in hyaluronidase and TPA 
mouse ear oedema  inhibitory activity  at 79.67 ± 6.42  % and 73.00 ± 31% 
respectively (Table 5.4.1.3) (Please refer to scheme 8.1.6.1). By using the NMR 1D 
and 2D spectroscopic analysis method and by comparing the data with literature 
(Chien and Gow, 2001), compound 60 was identified as ursolic acid. 
 
Dose response study on ursolic acid 60 using hyaluronidase and TPA mouse ear 
oedema inhibitory assays gave the IC50 value of 103.18 µM and 0.42 mg/ear 
respectively, as compare with the positive controls; apigenin (214.74 µM) and 
indomethacin (0.38 mg/ear).  These findings showed that ursolic acid 60 exhibited 
strong inhibitory effects on hyaluronidase and ear oedema induced by TPA. 
 
Topical application of TPA offers a model of skin inflammation appropriate for 
evaluating anti inflammatory agents (Arulmozhi et al., 2005). TPA produces 
inflammation by activating phospholipase A2 (PLA2) which subsequently activates the 
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release and metabolism of AA. The COX and 5-LO inhibitors are very effective in 
suppressing TPA-induced ear inflammation indicating the role of prostaglandins and 
leukotrienes respectively (Recio et al., 2000). Thus topical application of 
Prismatomeris malayana extracts that mildly inhibited TPA-induced ear inflammation 
could be due to its combined inhibition towards lipoxygenase.   
 
 
 
 
Table 5.4.1.1: Hyaluronidase and lipoxygenase inhibitory activity of the methanol 
extracts from different parts of Prismatomeris malayana. 
 
 
 
 
 
 
 
 
a,b 
Data represent the mean + S.D of three independent experiments performed in  triplicates. 
     % inhibition at 100 µg/ml concentration. 
c,d  
Means for percentage inhibition were significantly different (one- way analysis  
         of variance, p < 0.05) 
 
 
 
 
 
 
 
 
Samples 
 
Hyaluronidase 
Percentage inhibition 
a
 
 
lipoxygenase 
percentage inhibition
b
 
 
Stem 
Leaf 
Root 
Apigenin 
NDGA 
 
64.31 ± 9.41
c 
70.51 ± 4.34
c 
59.40 ± 6.91
c 
88.97 ± 7.93 
 
 
61.04 ± 0.05
d
 
60.76 ± 0.16
d
 
55.53 ± 0.36
d
 
 
97.15 ± 0.01 
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Table 5.4.1.2: Inhibitory activity of the extracts of Prismatomeris malayana on TPA – 
induced inflammation in mice 
Samples Inhibition of inflammation, I.R,
a 
(%) 
Stem 
Leaves 
Root 
Indomethacin 
37.00  ±  11
b 
73.00
b 
± 31
b 
25.00
b 
± 10
b
 
72.00  ± 6 
 
a 
 I.R.: inhibitory ratio at 2.0 mg/ear for extracts and fractions, 0.5 mg for compound 97  (n=7) 
b  
Means for percentage inhibition were not significantly different (Duncan’s 
   multiple range test, p=0.05) 
 
 
 
 
 
Table 5.4.1.3: Hyaluronidase inhibitory activity of the fractions and sub-fractions from 
the leaves of Prismatomeris malayana. 
 
Samples 
 
Percentage inhibition
a
 
 
Petroleum ether 
Chloroform 
Ethyl acetate 
Aqueous 
*C1 
*C2 
*C3 
Ursolic acid 60 
 
Apigenin 
 
 
60.47 ±0.12
b
 
72.19 ± 1.25
b
 
48.19 ± 2.41
b
 
60.19 ± 1.85
b
 
61.26 ± 3.57
c
 
67.99 ± 10.23
c
 
74.26 ± 3.79
c
 
79.67 ±6.42
c
 
 
88.97 ± 7.93 
 
a     
Data represent the mean ± S.D of three independent experiments performed in triplicates. 
     % inhibition at 100 µg/ml concentration. 
b,c  
Means for percentage inhibition were significantly different (one- way analysisof variance, p < 0.05 
*C1,C2,C3-subfractions of chloroform fraction 
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5.4.2   Structure activity relationship (SAR) of ursolic acid 60 and its analogues. 
 
A total of thirty analogues of ursolic acid 60 were evaluated for their inhibitory activity 
on hyaluronidase. Three analogues were isolated from Prismatomeris malayana, i.e 
compound 60, 61 and 64.   Seven analogues were prepared from the modification on 
the functional groups at OH-3 and COOH-28 of ursolic acid 60 (Refer to chapter 4).  
These analogues were compounds 75, 76, 77, 78, 79, 80 and 81. The remaining 
nineteen analogues i.e., compound 83-104 were commercially available. They were 
purchased from CHROMADEX and SIGMA. Table 5.4.2 gives the IC50 value for each 
analogue. 
 
 
Basically, the analogues are under two basic pentacyclic triterpenes (PTC) skeleton; 
ursane (60, 61, 75, 76, 77, 78, 79, 80, 81, 84, 86, 91, 98, 99, 102) and oleanane (64, 85, 
87, 88, 89, 90, 92, 95, 96, 97, 101, 104). The result in table 5.4.2 showed that ursolic 
acid 60 (103.18±1.70 µM) is more active than oleanolic acid 92 (227.97±2.81 µM).  
However, comparison on the analogues or derivatives of both skeleton that are similar 
to each other such as 84 (227.00 ±5.99 µM) and 85 (206.21 ± 2.32 µM), 86 (211.00 ± 
3.16 µM) and 90 (215.00 ± 4.27 µM) does not revealed big difference in their activity. 
Thus it shows that the germinal or vicinal arrangement of methyl-29 and 30 would not 
give big effect on the activity but with some exceptional. The discussion will be 
divided into the ursane and oleanane skeleton. 
 
In the PTC oleanane skeleton, the activity was reduced slightly when the 
methylhydroxyl was introduced at C-23 (92 [227.97 ± 2.81 µM] vs. 96 [230.0 ± 2.17 
µM]).  The activity would however increased slightly when the methyl group was 
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introduced at C-17 (90 [215.66 ± 4.27 µM] vs 92 [227.97 ± 2.81 µM]). The 16-OH 
derivatives increased the activity (87 [140.91 ± 6.71 µM] vs. 92 [227.97 ± 2.81 µM]) 
or with introduction of carboxyl at C-23 (95 [1482.56± 0.7 µM]). The C-30 ester 
derivatives resulted in activity loss greatly (83 [1750.91 ± 2.38 µM] vs 93 [146.18 ± 
2.67 µM]). Carboxylation at the same carbon (C-30) increased the activity greatly (93 
[146.18 ± 2.67 µM]). Acetylation on 3-OH would decreased the inhibitory ability, 
greatly (64, [1466.5 ± 2.37 µM]).  Introduction of sugar moiety with glycosidic bond 
to 3-OH or 28-COOH could either reduced the acitivity drastically (89 [842.54 ± 0.11 
µM]) or become not active whereas additional oxo group at C-11 did not improve the 
activity or will reduce it slightly (92 [146.18 ± 2.67] µM vs. 94 [56.33 ± 0.01 µM] vs. 
83 [1750.91 ± 2.38 µM]). Too many methyl group (104) or hydroxyl group (101) also 
resulted in loss of activity. Significant improvement in the activity was observed when 
the functional group methylester was introduced at C-17 (88 [84.52 ± 0.01 µM] vs. 92 
[227.97 ± 2.81 µM], 90 [215.66 ± 4.27 µM]) or when carboxypropanoyloxy, S2 was 
introduced at C-3 (94 [56.33 ± 0.01 µM]).    
 
The inhibitory activity of PTC ursane skeleton will slightly decreased on the 3-oxo, 3-
hydroxyimino and 3-acetylate derivatives (75 [162.83 ± 6.37 µM], 76 [190.94 ± 0.01 
µM], 77 [136.92 ± 0.04 µM]) compared to ursolic acid 60.  The same phenomenon 
could also observable if the 28-OH substituted with methyl of (76 [190.94 ± 0.01 µM] 
vs 81 [275.68 ± 1.42 µM], 60 [103.18 ± 1.70] vs 79 [182.511 ± 0.84 µM], 77 [136.92 ± 
0.04] vs 78 [812.93 ± 10.29]). This situation suggested that the hydroxyl group of C-3 
and C-28 is essential for the hyaluronidase inhibitory activity. The substitution of 
methyl with the carboxyl group of C-23 would decrease the inhibitory activity (86 
[211.44 ± 3.16 µM] vs. 98, NA). The introduction of hydroxymethylene at C-23 and 
additional hydroxyl at C-1 did not affect the activity very much (91 [115.96 ± 0.47 
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µM] vs. 98, NA), however additional hydroxyl at C-19 decreased the activity more (61 
[286.95 ± 10.28 µM]). The position of hydroxyl group also affect the activity as it 
decreased the activity more in 61 (C-19)   compared to 91 (C-2), 115.96 ± 0.47 µM. 
The sugar moiety as usual, would be resulted in loss of activity (99, 102).   
 
It could be concluded that 3-OH is important for the activity in both ursane and 
oleanane skeleton. The methyl ester introduction at C-17 to replace the carboxylic 
functional group gives different effect on the hyaluronidase inhibition ability of both 
type of skeleton.  Replacement on 3-OH such as hydroxyimino, acetyl, methyl also 
would make the activity become lower. Additional hydroxyl at C-2, 1 and 19 or oxo at 
C-11 and 3, or methyl group, however, would either give no effect or decreased the 
activity. The introduction of sugar moiety at any position would result in loss of 
activity. This is probably due to the bulkiness of the structure that make the respected 
compound could not reach the active site in the target, which is in the hyaluronidase 
enzyme. However, carboxypropionylox, S2 that replace the 3-OH make the activity 
become very high. Figure 5.4.2 summarized the structure activity relationship on PTC 
compound from the observation on the activities of compound 60, 61, 64, 75-104. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 198 
 
 
 
 
 
 
 
 
 
 
 
 
HO
COOH
19
20
12
1
3
23 24
28
25 26
18
29
30
8
11
16
17
14
5 27
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.2: Structure activity relationship of pentacylic triterpenes 
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R1
H3C R2
CH3
R4
R5
R3
R9
R6
R7
R8
R10
1
3
5
9
11
12
13
15
17 28
29
30
19
20
7
102
 
Compound Substitutional pattern aIC50 
 R1 R3 R2 R4 R5 R6 R7 R8 R9 R10  
60 OH COOH CH3 CH3 H H H H H H 103.18 ±1.70** 
61 OH COOH CH2OH CH3 H H H H OH H 286.95 ± 10.28 
75 =O COOH CH3 CH3 H H H H H H 162.83 ± 6.37* 
76 NOH COOH CH3 CH3 H H H H H H 190.94±0.01* 
77 OAc COOH CH3 CH3 H H H H H H 136.92±0.04* 
80 =O COOCH3 CH3 CH3 H H H H H H 1184.15±6.63 
81 NOH COOCH3 CH3 CH3 H H H H H H 275.68±1.42 
79 OH COOCH3 CH3 CH3 H H H H H H 182.51±0.84* 
78 OAc COOCH3 CH3 CH3 H H H H H H 812.93±10.29 
84 OH CH3 CH2OH CH3 H H H H H H 227.97±5.99 
86 OH CH3 CH3 CH3 H H H H H H 211.44±3.16* 
91 OH COOH CH2OH CH3 H H OH H H H 115.96±0.47* 
98 OH CH3 COOH CH3 H H H H H H NA 
99 OH CH2OH S3 CH3 H H OH H H H NA 
102 OH COOS4 CH2OH CH3 H H OH H H OH NA 
Table 5.4.2: Hyaluronidase inhibitory activity of the ursolic acid 60 and analogues at the concentration of 100-2000 µM 
a 
NA-inhibitory activity ,20% at concentration up to 5000µM; positive control-Apigenin.  Values were presented as the mean ± S.D of three independent 
experiments performed in triplicates.                                                                                                                       
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R1
H3C R2
CH3
R3
R5
H
R8
R4
R6
R7
R9
R11
R12
1
3
5
9
11
12 18
19
20
28
17
29
30
15
CH3
103  
 
 R1 R2 R3 R4 R5 R6 R7 R8 R9 R11 R12  
64 OAc CH3 COOH H CH3 H H H H H H 1466.5±2.37 
83 OH CH3 CH3 H COOCH3 H H =O H H H 1750.91± 2.38 
95 OH COOH CH3 H CH3 H H H H H H 1482.56±0.70 
85 OH CH3 CH2OH H CH3 H H H H H H 206.21±2.32 
87 OH CH3 COOH H CH3 OH H H H H H 140.91±6.71 
88 OH CH3 COOCH3 H CH3 H H H H H H 84.52±0.01** 
89 S1 CH2OH COOH H CH3 H H H H H H 842.54±0.11 
90 OH CH3 CH3 H CH3 H H H H H H 215.66±4.27* 
92 OH CH3 COOH H CH3 H H H H H H 227.97±2.81 
93 OH CH3 CH3 H COOH H H =O H H H 146.18±2.67* 
94 S2 CH3 CH3 H COOH H H =O H H H 56.33±0.01** 
96 OH CH2OH COOH H CH3 H H H H H H 230.00±2.17 
97 
O-
glucoside 
CH3 COOH H CH3 OH H H 
H 
H H NA 
101 OH CH2OH CH2OH H CH3 OH H H H OH OH NA 
104            NA 
Apigenin            214.74 
a 
NA-inhibitory activity <20% at concentration up to 5000µM; positive control-Apigenin.  Values were presented as the mean. of three independent 
experiments performed in triplicates.                         
 * p <0.05, ** p<0.01 compared with apigenin (Student’s t-test). 
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Chapter 6:  
Quantitative structure 
activity relationship 
(QSAR)  
 
 
 
 
 
 
  
 
6.1  Introduction  
 
In search for a new drug, a number of strategies can be followed. Some research 
methodologies may be based on random synthesis of new compounds, utilizing 
combinatorial chemistry techniques, followed by a biological test to select active 
substances. Similarly, various natural materials such as plants, tissues or body fluids 
can be screened for biologically active substances. However, a systematic optimization 
of a lead structure is needed in order to develop it into a better drug.  
 
Structure activity relationship study (SAR) comes from the idea that biological 
response to a drug exposition depends on the drug’s molecular structure. Therefore, if 
the structure activity relationship is known, the effect of a molecule can, in principle, 
be predicted from its structure. The strategies involve was a change in functional 
groups or substituent such that the drug’s pharmacokinetics or binding site interactions 
will be improved. These strategies often involved the synthesis of analogues 
containing a range of substituents on aromatic or heteroaromatic rings or accessible 
functional groups. The problem is the number of possible analogues that could be 
made is infinite.   
  
A quantitative structure activity relationship (QSAR) was developed from several 
works, especially those by Hansch, Fujita, Free and Wilson (Rainer, 2003). QSAR 
development requires three basic elements;  
(1)   an activity or property data set, measured experimentally,  
(2) molecular descriptors / physicochemical properties, which are the 
quantitative descriptions of structural properties, and  
 
 
  
 
(3) statistical techniques to establish the relationship between molecular 
descriptors and activities (Jarai et al., 2006).   
 
QSAR describes the biological activity of the molecules mathematically in terms of 
molecular descriptors properties. This approach attempts to identify and quantify the 
physichochemical properties of a drug to see if any of these properties has the effect on 
the drug’s biological activity. By quantifying these properties, it is possible to estimate 
the properties of new chemical compound without the need to synthesize and test 
them. 
 
The first step in a QSAR study is the selection of a group of compounds for which 
experimental data are available. This group of compounds should cover the whole 
range of compounds whose activities or properties are to be modeled (Hall et al., 
2002b). The QSAR analysis is further based on the measurement or calculation of 
appropriate physichochemical properties. Many different physichochemical properties 
are available for QSAR analysis, but only a few of them might be used as independent 
variables in a QSAR model. Appropriate descriptors are selected from previous 
knowledge of interaction processes or by statistical techniques, i.e. by choosing 
descriptors that are highly correlated to the experimental parameters of interest.  
 
The most common physicochemical properties used in QSAR studies are hydrophobic 
(P or П), electronic (σ) and steric properties (Es). Other properties including dipole 
moments, hydrogen bonding, conformations and interatomic distances have also been 
used.   
 
 
  
 
6.2   Statistical concepts in QSAR 
 
Hansch equation relates biological activity to the most commonly used 
physichochemical properties (Graham, 2005). The basic assumption of Hansch 
analysis is that log BR (biological response) can be described by a weighted linear 
combination of the xi (molecule parameters or physichochemical properties (Rainer & 
Andreas, 2003); 
 
Log BR = ao + a1x1
n1
 + ….+arxi
ni
+...+airxn
nn                                                          
   (6.2) 
 
The exponents ni can be 1 (linear) or 2 (quadratic). The regression coefficients ai and 
are computed by multiple regression analysis. The reliability and significance of the 
regression equation could be determined by several statistical criteria: 
 
i. The correlation coefficient R, which is a relative measure of the quality of fit 
(R=0, no correlation; R=1, perfect correlation). Its squared value (R
2
) measures the 
percentage of variance of the dependent variable (log BR) explained by the equation 
i.e. how well the model fits the experimental data. The R value should be more than 
0.8 (R ≥ 0.8) for the regression model to be accepted.  R2 can be expressed as below 
(Kartisky et al., 2005): 
12R
Total
Error
SS
SS
 
 
Where SSError is the sum of squared residual values while  TotalSS  is the total sum of 
squared residual values of the dependant variables 
 
  
 
ii. The standard deviations, S, is an another measure for the quality of fit.  Its 
value should be as small as possible but never smaller than the error of the biological 
experiment (over prediction). It indicates how far the activity values are spread 
concerning their average.  S
2
 can be described as (Kartisky et al., 2005): 
1
2


kn
SS
S Error  
where n and k is the number of variables 
 
iii. Fisher’s F value ( F-test) , which is a measure of the statistical significance of 
the regression model (Kartisky et al., 2005). In other words, it can be interpreted as a 
ratio of the variance explained by the model. Thus larger values of the F-test mean 
better models, while values below 1 mean that the model is completely useless. The 
overall significance should be 95% for the regression model to be accepted. It depends 
on the number of parameters involved in the model. If an absolutely insignificant 
parameter is added to the models, then the coefficient of determination remain the 
same and the F-value becomes smaller. However, the highest F-values do not 
necessarily mean the best model, if the number of parameters in the model is 
increased. 
2
mod)1,(
ks
SS
knkF el                                                               
 
where k is the number of variables 
 
iv. Confidence intervals for the regression coefficients at a statistical level of 
significance of 95% (Kartisky et al., 2005). These intervals overlap the true 
values of the regression coefficients at a statistical probability of 95%. The 
confidence intervals should be smaller than the regression coefficient for the 
regression model to be accepted. 
 
  
 
In most of the QSAR work, the equations developed have been used for the prediction 
of property values for compounds not employed in the development of those equations 
(Kartisky et al., 2005). Several statistical criteria can be proposed to estimate the 
reliability of predictions made by a multiple regression equation. Cross validation is 
the most common method used. It is the most common way to solve problem of over-
fitting.   
 
The simplest and a commonly used method of cross validation in chemometrics is the 
“leave one out” method. In this technique, each compound is left out once from the 
analysis and the model is then derived from the remaining objects. The model is then 
used to predict the activity values of left out compounds.  
 
For evaluation, predicted values can be used for prediction error sum of squares 
(PRESS), root mean squares prediction error (RMSPE) and squared cross-validated 
correlation coefficient (R
2
cv).   
 
PRESS can be defined as (Kartisky et al., 2005): 
 2
,, 
i
ipie yyPRESS  
where  iey ,  are experimental values of the property and ipy ,  are predicted values s for 
external validation test. 
 
RMSPE can be defined as (Kartrisky et al., 2005): 
 
RMSPE
n
PRESS
 
 
It gives error on a per compound basis (Stone & Jonatahn, 1993) 
 
  
 
   
  can be computed by comparing the predicted and the observed activity values.  
The    
  is usually smaller than R
2
 and the value range from 1 to less than 0.  A value 
of 1 indicated a good prediction value and a value of 0 indicates no modeling power.   
The value of    
  should be over 0.6 for the regression model to be accepted.  
 
   
 
  can be defined as: 
SD
PRESSSDRcv 
2
 
Where SD is the Sum-of-Squares deviation for each activity from the mean. 
 
The dataset could also divide into two parts by means of series design method (Jorgen, 
2004).  One part is taken as a training series to derive the QSAR model while the other 
as test set which biological potencies are calculated from the QSAR derived from the 
training set.  Good correlation between the predicted and observed value indicated the 
high predictive power of the developed QSAR.  However, this approach is only 
applicable into a big data set probably more than thirty compounds or activity. 
 
6.3    Quantum chemical method 
 
The development of QSAR model requires several physicochemical properties to be 
measured or calculated, in addition to the activity measurements. However these 
physicochemical properties are intrinsically related to the molecular structural 
properties. Hence a quantitative description of the structural and electronic properties 
of the molecules will provide the information similar to the physicochemical properties 
required for QSAR model. 
 
  
 
The use of quantum chemical and molecular properties descriptors has been widely 
accepted to account for the various types of activities of the molecule and they were 
found useful in predicting the activities of other derivatives hitherto unknown (Hansch 
& Leo, 1979). Quantum chemistry can provide more accurate and detailed description 
of electronic distribution than empirical methods (Karelson, 2000). This method 
represents an attractive source of new molecular descriptors which can express almost 
any electronic and geometric property of molecules and the characteristics of 
intermolecular interactions. It enables the definition of a large number of molecular 
and local quantities characterizing reactivity, shape and binding properties of the 
whole molecule or its fragments (Karelson, 2000). Unlike the empirical molecular 
descriptors, there is no experimental error in quantum chemically derived descriptors.  
Its molecular wave function could calculate the electrical moments of a molecule. 
 
Quantum chemical descriptors are related to atomic charges, the highest occupied 
molecular orbital (HOMO), the lowest unoccupied molecular orbital (LUMO), orbital 
electron density and molecular polarizability (Kartizky et al., 1994, Hu et al., 2009).  
Therefore, the descriptors can be classified into three main categories: (i) charge 
distribution-related descriptors; (ii) valency related descriptors; (iii) quantum 
mechanical energy-related descriptors.   
 
Compared to other ab initio methods that are extremely time consuming and require 
large storage memories, finally, the semiemprical quantum chemical methods are 
relatively inexpensive and can be used for the calculation of molecular descriptors for 
very large sets of molecules within very short computational time. There are a variety 
of semiempirical quantum chemical methods including Austin model (AM1) 
(Karelson, 2000) and Recife model (RM1).   
  
 
6.4   Recife model (RM1) 
 
Semi empirical quantum chemical method supplies realistic quantum chemical 
molecular quantities in a reasonable computational time frame (Karelson et al.,1996).  
The Austin model 1 (AM1) was developed 20 years ago. This semi empirical method 
was introduced for the quantum calculations of molecular electronic structure.  AM1 
provides good descriptions even for anions and hydrogen bonded system. Re-
optimization of AM1 parameters both in quality and quantity (Rocha et al., 2006) and 
better numerical methods resulted in more precise method of Recife model 1 (RM1).  
RM1 is expected to be very competitive.  Theoretically it is identical with AM1 as well 
as the methodology, but with much newer and better parameters.  It is capable of 
modeling most molecular systems in biological system. 
 
6.5 Results and discussion 
 
In order to ensure the validity of the predictive power of the QSAR model which will 
be developed from the set of chemical structure and their bioactivity, the structure of 
the molecule must be validated first. The experimentally obtained values for the 
chemical structures such as bond length, bond angle and dihedral angle should not be 
much different from the values calculated using the optimized structure.  The dihedral 
angles of the optimized structure of the compound 80 are compared with the data 
obtained from the crystal structure of the same compound.  The selected dihedral angle 
data was summarized in table 6.5. The data of both structures showed not much 
different between each other and thus could be concluded that the geometry 
optimization did not affect the configuration of the compound. 
  
 
Figure 6.5.1 showed the optimized structure while the figure 6.5.2 showed the 
experimental structure of compound 80. 
 
 
Figure 6.5.1: The optimized geometry of compound 80 
 
Figure 6.5.2: The absolute geometry of compound 80 from the crystallography 
experiment 
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Table 6.5: The selected dihedral angle value of the optimized and the experimental 
geometry of compound 80. 
 
Dihedral angle Optimised Experimental Dihedral angle Optimised Experimental 
O1-C4-C5-C12 158.133 159.651 H63-C20-C26-
C28 
-51.865 -52.723 
C4-C5-C12-C10 165.266 163.996 H63-C20-C21-
C23 
-68.444 -69.088 
C6-C5-C17-H57 51.312 52.542 C21-C20-C26-C25 -54.152 -53.181 
C12-C5-C17-C16 -61.854 -62.666 C21-C20-C26-C27 72.059 72.714 
C5-C6-C7-H40 -64.323 -64.482 C14-C21-C23-C24 -166.691 -166.283 
H38-C6-C7-H40 173.237 174.3 C14-C21-C23-
H67 
71.165 72.307 
C6-C7-C8-C10 -59.123 -58.801 C14-C21-C23-
H68 
-43.545 -44.762 
C7-C8-C10-C11 177.631 178.355 C20-C21-C23-C24 -48.469 -47.66 
C15-C14-C21-C23 58.132 58.443 C20-C21-C23-
H67 
-170.616 -169.07 
C16-C14-C21-C20 -179 -179.684 C20-C21-C23-
H68 
74.674 73.863 
C16-C14-C21-C23 -59.992 -59.955 C22-C21-C23-C24 74.479 73.611 
H55-C16-C17-
H58 
169.111 169.459 C22-C21-C23-
H67 
-47.667 -47.798 
C18-C19-C20-C26 -
167.325 
167.109 C21-C23-C24-C25 58.014 57.866 
C19-C20-C21-C14 -63.618 -62.185 C21-C23-C24-
H70 
179.292 178.481 
C19-C20-C21-C22 56.367 57.78 C23-C24-C25-C26 -64.5 -65.061 
H63-C20-C21-C14 51.517 50.47 C24-C25-C26-C20 60.587 60.73 
H63-C20-C21-C22 171.506 170.436 C24-C25-C26-C27 -64.313 -65.596 
C21-C20-C26-C28 -
169.345 
-168.684 C24-C25-C26-C28 176.517 175.412 
H63-C20-C26-C25 63.332 62.781 H76-C28-C29-
C30 
65.098 66.904 
H63-C20-C26-C27 -
170.457 
-168.684 H78-C29-C30-
C31 
172.613 173.715 
 
  
 
6.6 Quantum chemical QSAR models to predict hyaluronidase inhibitory 
activity of ursolic acid 60 and its analogues 
 
In this study, thirty compounds were evaluated for their IC50 values on the 
hyaluronidase inhibitory activity. The structures are shown in table 5.4.2. In this assay, 
the inhibitory effects of the thirty compounds on the activation of bovine testis 
hyaluronidase were examined using a spectrophotometric assay, which measure the 
turbidity of the complex formed between the undigested hyaluronic acid and albumin 
at 600nm (Ling et al., 2003). The percentage inhibition for each compound was 
determined with respect to the reference values in control experiments, which was run 
simultaneously. The results were expressed in terms of IC50 values. Compounds 
showing inhibitory activities of less than 20% at 50 x 10
2
 µM are considered as not 
active. Therefore, only 24 compounds were considered to be into the data set. The IC50 
value was converted into molar log IC50. The experimental data was summarized in 
Table 5.4.2.  
 
6.7 Heuristic method 
 
The heuristic method was carried out in this study. The first set which consists of 
twenty four analogues gives seventeen correlations with three, four and five 
descriptors (Table 6.7.1). Correlation 1 was selected as it gives highest R
2
 value of 
0.6347.  Figure 6.7 showed several outliers.  To improve the correlation, the outliers 
such as compound 88, 93 and 64 were eliminated either alone of in combination with 
each other.  However, the R
2
 values did not reach the 0.9 values.  The result for 
compound 88 elimination was shown in table 6.7.2.    
  
 
Even though several outliers were eliminated from the data set, the R
2
 values did not 
improve very much by using this method. Therefore, another method was applied to 
generate better correlation.  
 
 
 
Table 6.7.1:  The best three to five descriptor correlation using Heuristic method for 24 
PTC analogues 
 
Correlation 
no. 
Number of 
descriptors  
Correlation 
coefficient (R
2
) 
Fisher criteria 
(F) 
Standard 
deviation (s
2
) 
1 3 0.4855 6.2906 0.1039 
2 4 0.5568 5.967 0.0942 
3 4 0.5575 5.9843 0.094 
4 4 0.5634 6.1288 0.0928 
5 4 0.5644 6.1553 0.0926 
6 4 0.5656 6.1834 0.0923 
7 4 0.5781 6.5098 0.0896 
8 4 0.5957 6.9992 0.0859 
9 5 0.6006 5.4139 0.0896 
10 5 0.6008 5.419 0.0895 
11 5 0.6012 5.4262 0.0895 
12 5 0.6039 5.4888 0.0888 
13 5 0.6086 5.5982 0.0878 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 6.7:  Calculated versus experimental activity according to Heuristic method for 
24 PTC analogues (R
2
=0.6347, F=6.25, s
2
=0.0819; 5 descriptors) 
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Table 6.7.2:  The best two to five descriptor correlation using Heuristic method after 
elimination of compound 88. 
 
Correlation 
no. 
Descriptor 
number 
Correlation 
coefficient (R
2
) 
Fisher criteria 
(F) 
Standard 
deviation (s
2
) 
1 2 0.433 7.6358 0.1069 
2 3 0.5409 7.4605 0.0911 
3 3 0.541 7.4652 0.0911 
4 3 0.5446 7.5725 0.0904 
5 3 0.5497 7.7312 0.0894 
6 3 0.5633 8.1687 0.0867 
7 4 0.6201 7.3439 0.0796 
8 4 0.6299 7.6582 0.0776 
9 4 0.6345 7.8112 0.0766 
10 4 0.6351 7.8312 0.0765 
11 5 0.6783 7.1678 0.0714 
12 5 0.6627 6.6796 0.0748 
13 5 0.6632 6.696 0.0747 
 
 
6.8   Multi linear method 
 
Another method applied in this study was the best multi linear regression algorithm 
(BMLR). Calculation using BMLR method on the first data set which consists of 24 
compounds (60, 61,64,75,76,77,78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 
92, 93, 94, 95) was carried out to give best QSAR equation. Table 6.8.1 showed the 
number of descriptor and statistical parameters. The R
2
 value given is very low 
(0.3620). The correlation plots are shown in figure 6.8.1. Compound labeled as 95 
(boswellic alpha) and 88 (oleanolic acid methyl ester) were found as outliers and 
therefore were eliminated in order to improve the regression model. The two 
compounds display largest different between experimental and predicted log IC50 
values. Compound 88 presents the second lowest value of log IC50 and among the most 
the active compound in the whole series of hyaluronidase inhibitors. Compound 95 
however represent the lowest activity in hyaluronidase inhibition with high log IC50 
value. Therefore from the second data set which consists of twenty two compounds, 
  
 
eleven models obtained which consist of two to thirteen descriptors as listed in table 
6.8.2. The R
2
 values also improved (close to 1) as well as the other statistical values.   
 
This method managed to avoid over fitting of the regression equations by monitoring 
the increase of R
2
 in the equations with successive number of descriptors involved.  
The procedure is called the break point technique as illustrated in figure 6.8.2 that 
shows the change in slope in the plot of R
2
 versus the number of descriptors added 
(Kartrizky et al., 2006).  It could select the optimum multi regression model as shown 
in figure 6.8.2.  The procedure was stopped when the difference between R
2
 of the two 
consequent regression equations was less than or equal 0.02 (Kartrizky et al., 2006).  
From the second data set, this procedure showed that the optimum descriptors number 
was seven. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 6.8.1:  The best two descriptor correlation using BML method for 24 PTC 
analogues 
 
Number of 
descriptor  
Correlation 
coefficient  (R
2
) 
Fisher criteria (F) Standard 
deviation (s
2
) 
    
2 0.3620 5.9569 0.1227 
 
 
 
 
 
Table 6.8.2:  The best two to thirteen descriptor correlation using BML method after 
elimination of compound 88 and 95 of PTC analogues 
 
 
 
 
 
 
 
 
 
 
 
 
Descriptor 
number 
Correlation 
coefficient (R
2
) 
Fisher criteria 
(F) 
Standard 
deviation (s
2
) 
2 0.6285 16.07 0.0633 
3 0.7926 22.9313 0.0373 
4 0.8635 26.8767 0.026 
5 0.9177 35.7046 0.0167 
6 0.9431 41.41 0.0123 
7 0.9717 68.77 0.0065 
8 0.9851 107.4421 0.0037 
9 0.9922 169.5916 0.0021 
10 0.9965 310.7043 0.001 
11 0.9984 579.3852 0.0005 
12 0.9996 1723.6849 0.0002 
13 0.9998 2904.9854 0.0001 
  
 
 
Figure 6.8.1: Calculated versus experimental activity according to BML method for 24 
PTC analogues (R
2
=0.3620,F= 5.96, s
2
=0.1227; 2 descriptors) 
 
 
 
 
 
Figure 6.8.2:  Correlation coefficient R
2
 versus number of descriptors from BML 
method. 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 2 4 6 8 10 12 14 
C
o
rr
e
la
ti
o
n
 c
o
e
ff
ic
ie
n
t 
R
2
 
Number of descriptors 
 
95 
88 
  
 
6.9 QSAR equation 
 
A total of thirty analogues were evaluated for their IC50 towards hyaluronidase 
inhibitory activity (table 5.4.1). Six compounds were found to be inactive and thus 
could not contribute into the model development study. After making a comparison 
between the two methods on the data set, the QSAR model from the BML method are 
more effective than the Heuristic method. This is because the improvement in R
2
 is 
more than 0.02. Thus, the best QSAR model was develop using the statistical data 
from table 6.8.2 which corresponding to seven descriptors. These descriptors were 
selected due to the break even point showed by figure 6.8.2. The multilinear equation, 
regression coefficients, their errors and t-test values is given in table 6.9.1. The 
geometry optimization and the values obtained from the semi empirical calculations 
are shown in table 6.9.2. If all the predicted parameters were taken for the generation 
of the model, the following equation was obtained using the BML method for the data 
set: 
 
Log(1/IC50) = 4.72 x 10
2    + 6.55 x 10
-1     + 4.84 x 10
-3      + 1.00 x 10-1    - 
4.20   + 1.95x 10
2   – 8.77 x 10
-1    -1.722 x 10
2
      
              
 
 (6.9) 
F = 68.77     s
2
=0.0065     R
2
= 0.971         R
2
cv = 0.9506 
                                                                         
From the equation 6.9, the descriptors involved in the model was of charge 
distribution-related or electronic descriptor (  ,     ), quantum chemical descriptor 
(   ,    ,   ,   ) and geometrical descriptor (  ). From the t-test value which show 
the statistical significance of the selected descriptors in the QSAR model, the order of 
significance of the descriptors are:     >    >       >     >  >  >   . The plotted 
  
 
graph from the model is shown in figure 9.5. The calculated predicted logIC50 value 
from equation 6.9, experimental value and the difference were listed in table 6.9.2.  
The geometrical descriptor YZ Shadow YZS (  ) is the area of the shadows of the 
molecule as projected on the YZ planes by the orientation of the molecule in the space 
along the axes of inertia (Liu et al., 2003). It could be define as (Karelson, 2000): 
 
)(
)(
2
1
c
K pdvvdpS  
Where  
C – contour of the projection of the molecule on the plane defined by two principle 
axes  of the molecule ( ORYZXZXYk ,, ) 
v – x or y 
p - y or z 
 
The normalized shadow areas are calculated as the ratios S2 / (YmaxZmax), where 
Ymax and Zmax are the maximum dimensions of the molecule along the YZ axes 
(Karelson, 2000). The shadow area are calculated by applying 2D square grid on the 
molecular projection and by summation of the areas of the squares overlapped with a 
projection. Those indices thus reflect the size (natural shadow indices), and 
geometrical shape (normalized shadow indices) of the molecule. The higher values of 
the YZ shadow thus increase the inhibitory activity.     
 
It is known that the local electron densities or charges determine the mechanism and 
rate of most chemical reactions and physico-chemical properties of compounds. The 
valence electrons in molecules are not fixed to any particular atom but can move 
around the molecule. The electrons will be more at electronegative atoms compared to 
  
 
electropositive one, thus results in the molecules partially negative and the others 
positive (Graham, 2005). In the equation 6.9, two electronic descriptors involved.   
 
First descriptor was the partial positive surface area (PPSA1) is defined as the sum of 
the positively charged solvent-accessible atomic surface areas, SA, in the molecule 
(Karelson, 2000):  
 

A
ASPPSA1   A Є {δA > 0} 
Where AS  is the respective atomic solvent-accessible surface area.   
Positive regression coefficient of PPSA1 shows that the surface area of positive charge 
is a good physical-chemical parameter for hyaluronidase inhibitory activity. PPSA1 
indicate that the positive charge and the atomic surface area can increase the inhibition 
towards the hyaluronidase activity.    
 
Another electronic descriptor was min partial charge for a C atom (Zelfirov’s PC) (  ).    
It could be defined as (Zefirov et al., 1987):  
 XifQi   
Where Xi - atomic electronegativities 
)1/(1
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Where 0iX - electronegativities of isolated atoms 
   n  - atoms in the first coordination sphere of a given atom i.e C  
 
Partial charges are important for the ionic interactions between the drugs and its 
binding site on the receptors. The positive regression in the model in the equation 6.9 
  
 
showed that the bigger the partial charges in the molecule, the bigger the inhibition on 
hyaluronidase activity.   
 
Four chemical descriptors involved in the selected model. First descriptor was min 
electron-nuclear attraction for a H atom (   ). The definition of the descriptor is 
(Karelson, 2000): 
 

v
R
Z
PABE
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Where  
A- given atomic species (in this case, H) 
B- other atoms 
Pµv - density matrix elements over atomic basis {µv} 
ZB   - charge of atomic nucleus B 
RiB – distance between the electron and atomic nucleus, B 
 v
R
Z
iB
B  - electron-nuclear attraction integrals on atomic basis {µv} 
 
The first summation is performed over all atomic nuclei in the molecule (B) whereas 
the second summation is carried out over all atomic orbitals at a given atom (A). The 
terms  v
R
Z
iB
B  denote the nuclear-electron attraction integrals on the given atomic 
basis. This energy describes the nuclear-electron attraction-driven processes in the 
molecule and could be related to the conformational (rotational, inversional) changes 
or atomic reactivity of the H atom. Thus the positive regression in the equation 6.9 
indicated that the stronger the H electron-nuclear attraction, the higher the inhibition 
towards the hyaluronidase activity.  
 
  
 
The second quantum chemical descriptor is min nuclear-nuclear repulsion for a C-O 
bond (   ) which can be calculated as (Clementi, 1980); 
AB
BA
nn
R
ZZ
ABE )(  
 Where  
A-given atomic species 
B-another atomic species 
ZA – charge of atomic nucleus, A 
ZB – charge of atomic nucleus, B 
RiB – distance between the atomic nuclei, A and B  
 
This energy describes the strength of the nuclear repulsion at particular atom (C,O) and 
it might related to the conformational changes or atomic reactivity in the molecule 
(Karelson, 2000). This energy is considered as the global characteristics of a 
compound. Positive regression in the equation 6.9 showed that this energy contributed 
to increase the inhibition towards the hyluronidase activity. Thus, the lower the 
strength of C-O nuclear repulsion, the lower the inhibition will be.    
 
The third quantum chemical descriptor is max valency of a H atom (  ); VA where A is 
the given atom. The atomic valence states energies for the given atomic (H) species in 
the molecule and its fragments (Karelson, 2000). It characterized the magnitude of the 
perturbation experienced by an atom in the molecular environment as compared to the 
isolated atom. 
 
The final quantum chemical descriptor is max electron-electron repulsion for a C-H 
bond (   ). It could be defined as (Clementi, 1980):   
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Where:-  
, P - density matrix elements over atomic basis }{ v  
v      - electron repulsion integrals on atomic basis }{ v  
 
The energy characterize the electrostatic interactions between the chemical bond of 
C,H in a molecule (Karelson, 2000). Thus, the negative regression in the equation 6.9 
indicated that high repulsion energy between C-H contributed to decrease the 
inhibition towards the hyaluronidase activity.   
 
Table 6.9.2 showed the pIC50 values from the experimental and converted to logarithm 
of molar units and the predicted log IC50 values for all the twenty four compounds 
which were obtained from QSAR model; the equation 6.9. From the values of 
predicted log IC50, it is clear that the QSAR equation generated through quantum 
chemical method predicted the pIC50 values very close to experimental values. Table 
6.9.3 summarized the seven descriptors values for each compounds.     
 
 
 
 
 
 
 
 
vP
  
 
 
 
 
 
Table 6.9.1:  The best nonlinear seven descriptors selected using BML method for 22 
PTC analogues set 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Descriptor symbol t-test X ΔX 
 
Min partial charge for a C   
atom (Zelfirov's PC) 
   
  
12.6150 
 
4.7198E+02 
 
3.7414E+01 
Min e-n attraction for a H atom     14.9564 6.5471E-01 4.3775E-02 
PPSA-1 partial positive surface 
area (Zelfirov's PC) 
      11.1724 4.8406E-03 4.3326E-04 
Min n-n repulsion for a C-O 
bond 
    7.9805 1.0042E-01 1.2583E-02 
YZ shadow    
 
-6.0610 -4.2035E+00 6.9354E-01 
Max valency of a H atom 
 
    
5.2010 
 
1.9541E+02 
3.7572E+01 
Max e-e repulsion for a C-H 
bond 
    -4.0086 -8.7670E-01 2.1871E-01 
Intercept  
 
-4.4921 -1.7229E+02 3.8353+01 
     
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.9.2:  The calculated and experimental values of the best correlation for 22 PTC 
analogues set (second set). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Experimental 
log IC50 
Predicted 
log IC50 
Differences 
60 2.0100 1.9792 0.0308 
61 2.4600 2.5909 0.1309 
64 3.1700 3.1793 0.0093 
75 2.2100 2.1746 -0.0354 
76 2.2800 2.2988 0.0188 
77 2.1400 2.1573 0.0173 
80 3.0700 3.0697 -0.0003 
81 2.4400 2.4073 -0.0327 
79 2.2600 2.2502 -0.0098 
78 2.9100 2.9120 0.0020 
83 3.2400 3.1135 -0.1265 
95 3.1700 3.1793 0.0093 
84 2.3600 2.4008 0.0408 
85 2.3100 2.2383 0.0717 
86 2.3300 2.3264 -0.0036 
87 2.1500 2.0864 -0.0636 
88 1.9300 2.9307 1.0007 
89 2.9200 2.9247 0.0047 
90 2.3300 2.3264 -0.0036 
91 2.0600 2.2502 -0.0098 
92 2.3600 2.2832 -0.0768 
93 2.1600 2.2143 0.0543 
94 1.7500 1.7862 0.0362 
96 2.4100 2.3959 -0.0141 
  
 
 
 
 
 
 
 
 
 
 
 
Table 6.9.3:  Quantum chemical descriptor for each PTC analogues 
 
 
 
 
 
 
 
 
 
 
 
                             
        
60 36.6742 0.9975 56.2409 204.3285 555.0946 9.3014 -0.0301 
61 36.6227 0.9979 58.461 203.1068 614.576 9.6601 -0.0302 
64 36.4354 0.9967 58.961 203.0384 608.9415 10.6594 -0.0315 
75 36.7109 0.9972 59.021 202.7228 648.3613 10.6196 -0.0315 
76 36.5866 0.9987 51.3408 203.8475 612.1571 9.6232 -0.0317 
77 36.5799 0.9977 61.681 204.213 571.1239 9.1528 -0.0315 
78 36.7072 0.9975 58.781 204.1242 597.2751 9.5378 -0.0312 
79 36.5468 0.998 51.3008 204.2344 618.3597 9.6505 -0.0318 
80 36.7038 0.9974 63.161 204.1346 575.3271 9.1104 -0.0309 
81 36.7489 0.9981 62.9211 203.1493 653.3146 9.6533 -0.0311 
82 36.4912 0.9967 84.9215 202.9983 765.997 9.1568 -0.031 
83 36.5851 0.9977 59.641 204.1928 603.0916 9.6231 -0.0313 
84 36.3918 0.9971 56.6809 204.2373 543.0753 9.2816 -0.0315 
86 36.5456 0.9976 58.341 203.1455 643.8741 9.6211 -0.0315 
87 36.5788 0.9971 52.1808 209.0011 545.268 9.2768 -0.15 
89 36.6251 0.9968 63.1011 203.1738 618.0181 9.7915 -0.0315 
90 36.5435 0.9976 56.8809 204.2068 594.6963 9.1587 -0.031 
91 36.6216 0.9968 57.7809 209.5274 561.1042 9.169 -0.0315 
95 36.5903 0.9982 69.7412 204.3086 649.1003 9.6347 -0.031 
88 36.4572 0.9969 60.861 202.0786 633.923 9.1607 -0.0315 
94 36.6651 0.9973 54.4609 204.1924 555.4807 9.1298 -0.0302 
96 36.4739 0.997 57.8409 202.0863 649.9969 9.0889 -0.0324 
60 36.5033 0.996 54.5209 204.1782 594.6964 9.1252 -0.0313 
61 36.419 0.9981 56.6409 204.2075 559.7748 9.2979 -0.031 
  
 
 
 
Figure 6.9:  Calculated versus experimental activity according to BML method after 
elimination of compounds 95, 88 for PTC analogues set (second set) (R
2
=0.9717, 
F=68.77, s
2
=0.0065). 
 
 
 
 
 
 
 
 
 
 
 
  
 
6.10 Method validation [leave-one-out method] 
 
The most important test of the model is its ability to correctly predict the properties of 
other or new compounds that were not included in the QSAR model. The leave-one-out 
method technique is based on the difference between the squared cross-validated 
correlation coefficient (R
2
cv) and correlation coefficient (R
2
). The corresponding R
2
cv 
for all selected models will be calculated automatically by the validation module which 
implemented in CODESSA 2.6 package. From the calculation, the value of R
2
cv   
(0.9506) is very close to the R
2
 (0.9717) since the difference is very small (0.9717-
0.9506 = 0.0211). This finding suggests a good predictive ability of the selected best 
multi linear model.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 7:  
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
  
 
CONCLUSIONS 
 
The first part of the study was aimed at an investigation of the alkaloid contents of a 
plant species from the Rubiaceae family namely as Prismatomeris malayana Ridley. 
From the bioassay guided isolation on the methanol extracts of roots, stems and leaves 
of Prismatomeris malayana Ridley (FRI 50080) based on the hyaluronidase inhibitory 
activity, a pentacylic triterpenoid, ursolic acid 60, was isolated and identified as the 
most active component. Apart from that, another sixteen compounds were isolated from 
the three parts and the structures were confirmed from the spectroscopic data of the 
NMR, IR, UV and Mass spectrum. Five of them are pentacyclic triterpenoids (61, 62, 
63, 64, 65), seven are anthraquinones (71, 11, 72, 10, 73, 74, 21) and four of them are 
iridoids (66, 68, 69, 70).   
 
The second part involved the modification on the functional group 3-OH and 28-COOH 
of ursolic acid 60 either by oxidation, acetylation, methylation or substituted with 
hydroxyimino group. A total of seven derivatives or analogues were successfully 
synthesized and strucutures were identified from the NMR and mass spectroscopic data.  
The compounds are 3-oxo-urs-12-en-28-oic acid 75, 3-hydroxyimino-urs-12-en-28-oic 
acid 76, 3-acetyl-urs-12-en-28-oic acid 77, 3-acetyl-urs-12-en-28-oic acid methyl ester 
78, 3-hydroxy-urs-12-en-28-oic acid methyl ester 79, 3-oxo-urs-12-en-28-oic acid 
methyl ester 80 and 3-hydroxyimino-urs-12-en-28-oic acid methyl ester 81.  
 
The study on the inflammation properties of P. malayana was also involved in this part.  
Three bioassays were applied on the investigation of the methanol extracts of different 
parts i.e. hyaluronidase and lipoxygenase inhibitory assay and TPA induced mouse ear 
oedema assay. The methanol extract of the leaves showed highest inhibitory on all three 
  
 
assays, thus was selected for further bioassay guided fractionation and isolation study 
base on the the hyaluronidase inhibitory assay. Although the TPA induced mouse ear 
oedema assay showed good inhibition result of the methanol leaves extract, it was not 
applied for further study due to large quantity of sample required, specifically at the 
compound level. The structure activity relationship study on thirty analogues of 
pentacylic triterpenes towards the hyaluronidase inhibition showed that compound (3β)-
3-[(3-carboxypropanoyl)oxy]-11-oxolean-12-en-30-oic acid 94 and oleanolic acid 
methyl ester 88 showed higher inhibition compared to ursolic acid 60 and positive 
control, apigenin (Table 5.5). It could be concluded that 3-OH and 28-COOH might 
play an important role in the activity and the presence of sugar moiety could make the 
compound lost their activity. However, note that glycosides would be lower in activity 
than aglycones, but in vivo they may well be converted into the aglycone and thus exert 
activity. 
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The computational approach was carried out successfully to quantitatively correlate the 
three dimensional structures of bioactive pentacyclic triterpenes and the hyaluronidase 
inhibitory activity. A data set which consisted of twenty four pentacylic triterpenoids 
derivatives with hyaluronidase inhibitory properties was investigated to relate their log 
IC50 values to the molecular structure. Two compounds labeled as 95 and 88 were 
eliminated and registered as outliers as they display large difference between 
experimental and predicted logIC50 values. Compound 88 presents the lowest value of 
logIC50 and is the most active compound in the data set. A QSAR modeling was carried 
out using CODESSA V 2.6 software.    
 
The QSAR model was developed by using the BMLR method.  Seven descriptors in the 
model were the descriptors involved in the model was of charge distribution-related or 
electronic descriptor (  ,     ), quantum chemical descriptor (   ,    ,   ,   ) and 
geometrical descriptor (  ). The two electrostatic descriptors playing role in 
determining the chemical properties of compounds involved in the QSAR model. The 
multi linear regression equation is good in terms of stability and predictive ability with a 
lower difference in R
2
-R
2
cv.  
 
To the author’s knowledge, until present, no QSAR works have been previously 
published for the inhibition of hyaluronidase activity for pentacylic triterpenoids.  
Therefore, the present work contributes towards hyaluronidase inhibitory activity 
prediction with the developed QSAR model and could be very useful in future research 
on anti-inflammatory drug development of such type of compounds. In the future, 
mechanistic studies on the active anti-inflammatory compounds can be pursued and 
further studies on anti-inflammatory drug development of pentacylic triterpenes (PTC) 
can be further investigated.  
  
 
 
 
 
 
 
 
 
 
Chapter 8:  
Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
8.1    Phytochemical study 
 
 
An intensive phytochemical investigation on Prismatomeris malayana Ridley was 
carried out starting from plant identification, phytochemical analysis, extraction, 
isolation and structure identification of the isolated chemical entities from this species. 
 
8.1.1 Plant material   
 
 
P. malayana in this study was collected from Setiu, Terengganu on 29
th
 January 2006 
and deposited in the herbarium of Forest Research Institute Malaysia (FRIM) with 
herbarium specimen number FRI 50080. The plant sample was identified by FRIM 
botanist. The plant sample was dried in an oven at 40
o 
C, divided into different parts and 
ground.   
 
8.1.2   Instrumentation 
 
Melting points were measured on Biocote SMP10 melting point apparatus. The infrared 
spectra were obtained on Spectrum 100 Fourier transform Infrared (FT-IR) 
spectrometer Perkin Elmer equipped with a mid-infrared deuterated triglycine sulphate 
(DTGS) detector. NMR analysis were carried out on a Bruker DRX 300 NMR 
spectrometer (300 MHz for 
1
H NMR and 75 MHz for 
13
C NMR) system with deuterated 
solvents such as chloroform (CDCl3), demethyl sulphoxide (DMSO), methanol (MeOD) 
and phyridine (C5D5N). The mass spectra were obtained on LTQ Orbitrap mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with an 
electrospray ionisation probe by employing either negative or positive ion mode, which 
ever could afforded the best limits of detection for the compounds.  
 
 
  
 
8.1.3  Chromatography 
 
Chromatography separation and isolation was performed using various techniques such 
as column chromatography (CC) and thin layer chromatography (TLC). 
 
Several packing materials were used for column chromatography i.e MCI gel CHP 20P, 
Sephadex LH-20, Chromatorex ODS, silica gel 60 (70-230 Mesh ASTM or equivalent 
to silica gel of size 0.063-0.200 mm). The ratio of silica gel to sample is approximately 
30:1 while for the other packing material is 10:1. The gel was made into slurry with a 
suitable solvent before packing into the glass column with various dimension and height 
depending on the quantity of the sample. 
  
Aluminium supported silica gel F254 plates were used for thin layer chromatography 
(tlc). TLC spots were visualized under ultra-violet light (254 nm and 365 nm). The 
plates were then sprayed with 10% sulphuric acid followed by heating using heating 
mantel to detect the presence of phenolics and terpenes which indicated by the presence 
of colourful spots. The iodine vapour was also used for the detection purpose. 
 
8.1.4 Visualising reagents 
a) Iodine vapour 
The TLC plate was placed in a container or tank containing iodine/iodine vapour.  
Brown spots on a yellow background indicated the presence of unsaturated compounds. 
 
b) 10% sulphuric acid solution 
The 10% acid sulphuric solution was sprayed on the TLC plate. The plate was then 
heated at 100
o
C-150
o
C until full development of colours had occurred. The occurrence 
  
 
of pink, red, brown, purple, grey, dark green and black colours indicated the presence of 
phenyl propenes and simple terpenes.   
 
8.1.5  Extraction, fractionation and isolation  
8.1.5.1      Bioassay-Guided Fractionation Process 
 
The crude methanol extracts were evaluated for anti inflammatory activity using three 
assays; lipoxygenase inhibitory hyaluronidase inhibitory and 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced mouse ear oedema assays (refer chapter 
5.2.1, 5.2.2). The results for the extracts, fractions from the active extracts followed by 
the sub fractions and active component were listed in table 5.2.3. Scheme 8.1.5.1 
outlines the bioassay guided fractionation and isolation of the bioactive compound from 
Prismatomeris malayana Ridley. Table 8.1.5.1 showed the percentage yield of each 
fraction, while table 8.1.5.2 – 8.1.5.4 showed the percentage yield of pure compounds. 
 
8.1.5.2  Isolation of chemical constituents  
 
Leaves: Oven-dried leaves (2.041 kg) were ground and extracted with MeOH by 
soaking for three times at room temperature. The concentrated extract (20.1g) was 
suspended in H2O and partitioned with petroleum ether, followed by CHCl3 and finally 
with EtOAc (Table 8.1.5.1). The CHCl3 layer obtained was concentrated and 
chromatographed over Diaion HP-20SS column using 100% MeOH to afford three 
fractions. Fraction 1 and 2 was purified by using silica gel column eluting with CHCl3-
MeOH (CM) system, to afford four pentacylic triterpenoids; 60, 61,  62 and 65. The 
EtOAc and H2O layer was chromatographed over Sephadex LH-20 column eluted with 
100% MeOH while the H2O layer was chromatographed over MCI gel CHP20P column 
  
 
using H2O with increasing proportion of MeOH. The resulting fraction obtained were 
further purified by a combination of column chromatography employing silica gel with 
CM system, MCI gel with water- methanol (WM) system and MCI gel CHP20P. The  
EtOAc layer afforded one saponins,  63 and one iridoids 66 while the H2O layer gave 
two iridoids; 68 and 70. Table 8.1.5.2 listed all the isolated compounds from the leaves 
while scheme 8.1.5.2 summarized the isolation and purification procedures taken in a 
flow diagram. 
 
Roots:  Cut and oven-dried roots (2.2 kg) were ground and extracted with MeOH 
by soaking for three times at room temperature. The concentrated extract (100g) was 
suspended in H2O and successively partitioned with EtOAc. The EtOAc layer after 
drying under reduced pressure (15.6 g) was chromatographed over silica gel and eluted 
using petroleum ether with increasing amounts of acetone to give 8 fractions. Each of 
these fractions was further fractionated and purified by a silica gel column and eluted 
with hexane-CHCl3 systems to afforded six anthraquinones; 11, 72, 10, 73, 74 and 21) 
and one triterpenoid 64. The H2O layer was fractionated and purified using MCI gel 
CHP20P column to give one iridoids 68  (Table 8.1.5.3 Scheme 8.1.5.3). 
 
Stems:  Oven-dried and ground stems (4.2 kg) was extracted with MeOH at room 
temperature for three times. The extract was concentrated under reduced pressure 
(103.68 g) and was partitioned between H2O and CHCl3. The resulting CHCl3 layer 
(13.5 g) was chromatographed over Sephadex LH-20. The resulting fractions were 
further purified using silica gel column with petroleum ether-acetone followed by 100% 
hexane to afforded one anthraquinone 21. The H2O layer was chromatographed over 
MCI gel CHP20P to give one iridoids 68 (Table 8.1.5.4, Scheme 8.1.5.4). 
 
  
 
 
 
 
 
 
 
 
 
 
Table 8.1.5.1:  Percentage yield of extracts and fractions from leaves (PML), roots 
(PMR) and stem (PMS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code 
Dry 
sample 
Weight 
(Kg) 
Percentage yield (w/w %) 
MeOH 
extract 
Petroleum 
ether 
fraction 
CHCl3 
fraction 
EtOAC 
fraction 
H2O 
fraction 
PML 2.04 9.85 11.14 17.46 5.81 24.58 
PMS 4.20 2.47 - 13.02 - 35.50 
PMR 2.20 4.55 - - 15.60 35.0 
  
 
Prismatomeris 
malayana 
Ridley
Roots
(PMR)
LOX=55.53%
HYA = 59.40±6.91
TPA=22% 
XO=34.2%
Leaves
(PML)
LOX=60.76%
HYA=70.51±4.34
TPA= 73 %  ±31%
XO=17.8%
Stems
(PMS)
LOX=61.04%
HYA = 64.31± 9.41
TPA=37 ±11%
XO=34.2%
Ethyl acetate
(PMLEA)
LOX=59.68% 
HYA=48.19±2.41 
TPA=7% 
XO=NA      
Chloroform
(PMLC)
LOX=51.37%  
HYA=72.19±1.25
 TPA= 90 % ± 8 %
 XO=11.3%     
Water
(PMLW)
LOX=58.75%    
HYA=60.19±1.85  
TPA=14 %
XO=20.3%
Three different parts.
Extraction method: soak at room temperature, concentrated by 
using rotary evaporator at 40 C.
Petroleum ether
(PMLPE)
LOX=61.96%
HYA=60.47±0.12
TPA=14 %
Solvent-solvent partitioning by using petroleum ether, chloroform, and ethyl acetate.
PMLC1
HYA=61.26 
± 3.57
PMLC2
HYA=67.99 
± 10.23
PMLC3
HYA=74.26 
± 3.79
PMLC4
HYA=45.84 
±2.46
Fractionation with Diaion eluted with 100% MeOH 
PMLC31
HYA=NA
PMLC32
HYA=26.28 
±3.61
PMLC33
HYA=27.29 
± 3.12
PMLC34
HYA=41.96 
±2.79
PMLC35, 
HYA=58.69 
±8.34
PMLC36, 60
HYA=79.67± 
6.42
PMLC37
HYA=33.33 
±1.44
Fractionation with silica gel eluted with chloroform and MeOH
 
 
 
Scheme 8.1.5.1:  Bioassay guided isolation and purification of active anti inflammatory 
compound from Prismatomeris malayana 
 
 
 
 
 
  
 
Table 8.1.5.2:  Isolated compounds from the leaves of Prismatomeris malayana Ridley 
 
Crude extract Name of compound 
% Yield of 
compounds 
from crude 
extract 
Petroleum ether - - 
 
 
CHCl3 
 
 
 
3β-urs-12-en-28-oic acid (urolic acid), 60 4.5900 
3β,19,23-trihydroxyurs-12-en-28-oic acid, 61 0.0087 
3β,23-dihydroxyurs-12-en-28-oic acid, 62 0.0020 
3β-hydroxyurs-11,12-epoxy-ursane-            
28, 13-olide, 65 
0.0015 
 
EtOAC 
 
28-O-glucopyranosyl-3α,19α,24-
trihydroxyurs-12-en-28 oic acid, 62 
0.0110 
Prismalayanoside, 66 0.0054 
 
H2O 
 
Asperulosidic acid, 68 0.1116 
Scandoside, 70 0.4975 
 
 
 
 
 
Table 8.1.5.3: Isolated compounds from the roots of Prismatomeris malayana Ridley. 
 
Crude extract Name of compound 
% Yield of 
compounds 
from crude 
extract 
 
 
 
 
 
 
EtOAC 
 
 
 
1-hydroxy-2-hydroxymethyl-3-methoxy-9,10-
anthraquinone, 74 
0.500 
Rubiadin-1-methyl ether, 11 0.1300,  
0.0110 
Damnacanthol, 72 0.0923,  
0.0058 
Rubiadin, 10 0.200 
2-ethyl-3-hydroxymethyl-4-hydroxy-9,10-
anthraquinone, 73 
0.0030 
Lucidin-ω-methyl ether, 21 0.0580 
1-hydroxy-2-hydroxymethyl-3-methoxy-9,10-
anthraquinone, 74 
0.005 
3β-acetylolean-12-en-28-oic acid, 64 0.0220 
H2O Asperulosidic acid, 68 
 
1.40 
 
 
 
 
 
 
  
 
Table 8.1.5.4:   Isolated compounds from the stem of Prismatomeris malayana Ridley. 
Crude extract Name of compound 
% Yield of 
compounds 
from crude 
extract 
CHCl3 Lucidin-3-methyl ether, 71 0.0230 
H2O Asperuloside, 69 0.3300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    CC, D  100% (MeOH) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC-Column chromatography; S-Silica gel: C:M-Chloroform methanol; W:M- Water methanol; M-MCI gel CHP 20P; L-Sephadex 
LH-20; D-Diaio 
 
Scheme 8.1.5.2   Isolation of leaf components of Prismatomeris malayana 
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CC-Column chromatography; S-Silica gel: C:M-Chloroform methanol; W:M- Water methanol; M-MCI gel CHP 20P; L-Sephadex 
LH-20; D-Diaion; PE-Petroleum ether 
 
Scheme 8.1.5.3:  Isolation of root components of Prismatomeris malayana 
 
 
 
 
 
 
 
 
Root 
(2.2 kg dry wt) 
MeOH extract 
(100.0 g) 
Solvent-solvent partitioning 
EtOAc Layer 
(15.6 g) 
Fr3 
(0.1g)  
Fr7 
(2.5 g) 
Fr8 
(1.7 g) 
Fr5 
(0.6 g) 
64 
(20 mg) 
74 (402.20 mg) 
11 (179.20 mg) 
11 (11.40 mg) 
72 (93.20 mg) 
73 (3.00 mg) 
21(6 mg) 
74 (5 mg) 
10 
(0.2 g) 
CC, S  9:1-35:65 (PE:Acetone) 
Crystallisation 
CC, S 100-0 (Hex;C) 
CC,S 100-50 (Hex;C) 
 
 
CC,S 100-2:8 (Hex;C) 
CC,S 100-50 (Hex;C) 
 
 
CC, M 0-100 
(W:M) 
H2O Layer 
(12.7 g) 
Fr7 
(1.4 g) 
68 
(1.4 g) 
CC, M 6:4 
(W;M) Crystallisation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC-Column chromatography; S-Silica gel: C:M-Chloroform methanol; W:M- Water methanol; M-MCI gel CHP 20P; L-Sephadex 
LH-20; D-Diaion; PE-Petroleum ether 
 
Scheme 8.1.5.4:  Isolation of stem components of Prismatomeris malayana 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stem 
(4.2 kg dry wt) 
MeOH extract 
(103.7 g) 
Solvent-solvent partitioning 
CHCl3 Layer 
(13.5 g) 
71 0.02 mg) 
CC, L  100% MeOH 
CC,S 7:3 (PE:Acetone) 
CC,S  100%  Hexane 
H2O Layer 
(36.8 g) 
69 
(0.79 g) 
CC,M  88:12 (W;M) 
 
 
  
 
8.1.6      Physical and spectral data of isolated compounds 60-66 and 68-74 
 
3β - urs-12-en-28-oic acid (Ursolic acid) 60 
: white amorphous powder 
: C30H48O3 
UV λmax (MeOH), nm     : Not tested 
IR νmax (CHCl3), cm
-1
                                      :1686cm
-1,  
3866 – 3188 cm-1,  2860 cm-1 
Mass (M+Na)
+
 m/z                      : 479.35059 
1
H NMR (300MHz, C5d5N) δ   : See Table 3.2.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 3.2.1 
 
3α, 19α, 24-trihydroxyurs-12-en-28-oic acid 61 
: white amorphous powder 
: C30H48O5 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                     : 1688cm
-1,  
3691 -3208 cm
-1
,  2937 cm
-1
  
Mass (M+Na)
+
 m/z                       : 511.34012 
1
H NMR (300MHz, C5d5N) δ   : See Table 3.2.2 
13
C NMR (75MHz, C5D5N) δ   : See Table 3.2.2 
 
3β, 23-dihydroxyurs-12-en-28-oic acid 62 
: white amorphous powder 
: C30H48O4 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                     : 1689cm
-1
, 
 
3736 - 3066 cm
-1
,  2933 cm
-1
  
Mass (M+Na)
+
 m/z                       : 495.34546 
1
H NMR (300MHz, C5d5N) δ   : See Table 3.2.3 
13
C NMR (75MHz, C5D5N) δ   : See Table 3.2.3 
 
28-O-glucopyranosyl-3α,19α,24-trihydroxyurs-12-en-28 oic acid 63. 
: brown solid 
: C36H58O10 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                     : 1724 cm
-1
, 
 
3716 and 3018 cm
-1
  
Mass (M+Na)
+
 m/z                       : 673.39362 
1
H NMR (300MHz, C5d5N) δ   : See Table 3.2.4 
13
C NMR (75MHz, C5D5N) δ   : See Table 3.2.4 
 
3β-acetylolean-12-en-28-oic acid 64 
: colorless crystal 
: C32H50O4. 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                     : 1722  cm
-1
,
  
2947cm
-1
 , 1694 
Mass (M+Na)
+
 m/z                       : 497.36142 
1
H NMR (300MHz, C5d5N) δ   : See Table 3.2.5 
13
C NMR (75MHz, C5D5N) δ   : See Table 3.2.5 
 
 
 
3β-hydroxyurs-11-en-ursane-13,28-olide 65 
: white amorphous powder 
: C30H46O3. 
  
 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                      : 2884 cm
-1
 ,
 
1687 cm
-1
 
Mass (M+Na)
+
 m/z                       : 477.33621 
1
H NMR (300MHz, C5d5N) δ   : See Table 3.2.6 
13
C NMR (75MHz, C5D5N) δ   : See Table 3.2.6 
 
prismalayanoside 66 
: yellowish amorphous solid 
: C31H36O17 
:  [α]D -0.31 (c=0.22, MeOH) 
UV λmax (MeOH)  nm     : 234, 292 and 314 nm 
IR νmax (CHCl3)  cm
-1
                                      : 2929 cm
-1
,
 
1686 cm
-1  
Mass (M-H)
-
 m/z                      : 679.41669 
1
H NMR (300MHz, CD3OD) δ   : See Table 3.2.10 
13
C NMR (75MHz, CD3OD) δ  : See Table 3.2.10 
 
asperulosidic acid 68 
: brown amorphous powder 
: C18H24O12 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                      : 3365 cm
-1
,
 
1688 cm
-1
 and 1636 cm
-1
 
Mass (M-H)
-
 m/z                       : 431.11816    
1
H NMR (300MHz, CD3OD) δ   : See Table 3.2.8 
13
C NMR (75MHz, CD3OD) δ  : See Table 3.2.8 
 
asperuloside 69.   
: white amorphous powder 
: C18H22O11 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                      : 3360cm
-1
,
 
1689 cm
-1
 and 1635cm
-1 
Mass (M+ K)
+
 m/z                 : 453.11 
1
H NMR (300MHz, CD3OD) δ   : See Table 3.2.9 
13
C NMR (75MHz, CD3OD) δ  : See Table 3.2.9 
 
 
scandoside 70 
: brown amorphous powder 
: C16H22O11. 
UV λmax (MeOH)  nm     : Not tested 
IR νmax (CHCl3)  cm
-1
                                      : 3369 cm
-1
,
 
1635 cm
-1
  
Mass (M-H)
-
 m/z                       : 389.10745 
1
H NMR (300MHz, CD3OD) δ   : See Table 3.2.7 
13
C NMR (75MHz, CD3OD) δ  : See Table 3.2.7 
 
 
 
 
 
 
 
 
  
 
Lucidin-3-methyl ether 71 
: yellow amorphous powder 
: C16H12O5 
UV λmax (MeOH)  nm     : 283, 247, 203 nm  
IR νmax (CHCl3)  cm
-1
                                      : 3306 cm
1
,
 
1647 cm
-1 
Mass (M-H)
-
 m/z                             : 283.05963   
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.11 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.11 
 
 
Rubiadin-1-methyl ether 11 
: yellow amorphous powder 
: C16H12O4 
UV λmax (MeOH)  nm     : 280, 238 and 204 nm 
IR νmax (CHCl3)  cm
-1
                                      :3306 cm
-1 
 cm
1
,
 
1650 cm
-1 
Mass (M-H)
-
 m/z                             : 267.06534   
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.12 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.12 
 
Damnacanthol 72 
: yellow amorphous powder 
: C16H12O5 
UV λmax (MeOH)  nm     : 278, 239, 203 nm 
IR νmax (CHCl3)  cm
-1
                                      : 3300 cm
-1
,
 
1647 cm
-1
,
 
1672 cm
-1 
Mass (M-H)
-
 m/z                             : 283.05991 
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.13 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.13 
 
Rubiadin 10 
: yellowish orange crystal 
: C15H10O4 
UV λmax (MeOH)  nm     : 409, 279, 245 and 206 nm  
IR νmax (CHCl3)  cm
-1
                                       : 3391 cm
-1
,
 
1621 cm
-1 
Mass (M-H)
-
 m/z                             : 253.04933  
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.14 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.14 
 
 
1-ethyl-3-hydroxymethyl-4-hydroxy-9,10-anthraquinone 73. 
: yellowish orange powder 
: C16H12O5 
UV λmax (MeOH)  nm     : 277, 239 and 204 nm 
IR νmax (CHCl3)  cm
-1
                                       : 3395 cm
-1
,
 
1700 cm
-1 
Mass (M-H)
-
 m/z                             : 283.26373 
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.15 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.15 
 
 
 
 
 
 
  
 
2-oxyhydroxymethyl-3-methoxy-9,10-anthraquinone 74.      
      : yellowish powder 
: C16H12O5 
UV λmax (MeOH)  nm     : 279, 239 and 203 nm 
IR νmax (CHCl3)  cm
-1
                                      :1724 cm
-1
,
 
1672 cm
-1
, 3309 m
1 
Mass (M+Na)
+
 m/z                             : 307.05450  
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.17 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.17 
 
lucidin-ω-methyl ether 21        
      : yellowish powder 
: C16H12O5 
UV λmax (MeOH)  nm     : 410, 280, 245, 205 nm 
IR νmax (CHCl3)  cm
-1
                                       :2929 cm
-1
,
 
1623cm
-1
, 1730 cm
-1
,1674 cm
1 
Mass (M-H)
-
 m/z                             : 283.05991 
1
H NMR (300MHz, DMSO-d6) δ   : See Table 3.2.18 
13
C NMR (75MHz, DMSO-d6) δ  : See Table 3.2.18 
 
 
 
8.1.7  Physical and spectral data of compounds 83-99 
 
3β-hydroxy-11-oxoolean-18α-12-en-28-methyl-29-oate  
(18-α-glycyrrethinic acid methyl ester) 83 
      :White amorphous powder 
: C31H48O4   
Mass (M+H)
+ 
 m/z    : 485.54 
 
1
H NMR (300MHz, C5D5N) δ: 5.72(1H,s,H-12), 3.68(3H,s,OCH3), 3.54(1H, dd, 
J=4.74, 10.26, H-3), 3.11(1H,d,J=13.2), 2.4(1H, S,H-9), 2.28(1H,d,J=12.0, H-18 α), 
1.40(3H,s,H-28), 1.27(3H,s,H-23), 1.21(3H,s,H-26), 1.13(3H,s,H-29), 1.09(3H,s,H-24), 
0.64 (3H,s,H-25). 
 
13
C NMR (75MHz, C5D5N) δ: 37.6 (C-1), 27.05(C-2), 78.06(C-3), 52.06(C-4), 61.2(C-
5) 18.2(C-6), 32.3 (C-7) ,37.7(C-8), 55.5(C-9), 40.5(C-10), 199.4(C-11), 124.5(C-12), 
165.5(C-13), 43.01(C-14), 28.3(C-15), 27.05 (C-16), 45.3(C-17), 44.2 (C-18), 39.9(C-
19), 36.1(C-20 ), 35.7(C-21), 34.2(C-22), 20.9(C-23), 16.8(C-24), 16.1(C-25), 17.2(C-
26), 20.7(C-27 ), 20.7(C-28), 28.9(C-29), 179 (C-30):  
 
3β-urs-12-en-3-28-diol  
(uvaol) 84: 
      :White amorphous powder 
: C30H50O2  
Mass (M-H)
-
 m/z    : 441.34 
 
1
H NMR (300MHz, C5D5N) δ:5.27(1H,bt,H-12), 3.93(1H,dd,J=5.4,10.47) 
3.48(1H,dd,J=5.34,10.5,H-28), 1.24(3H,s,H-27), 1.2(3H,s,H-23), 1.04(3H,s,H-29), 
1.0(3H,s,H-26), 0.9(3H,s,H-30), 0.88(3H,s,H-24), 0.86(3H,s,H-24). 
 
13
C NMR (75MHz, C5D5N) δ: 38.7(C-1), 8.1(C-2), 78.0(C-3), 39.7(C-4), 55.7(C-5), 
18.7(C-6), 33.2(C-7), 40.3(C-8), 48.0(C-9), 37.1(C-10), 23.8(C-11), 25.01(C-12),  
 
  
 
139.6(C-13), 42.3 (C-14), 28.8(C-15), 25.5(C-16), 39.2(C-17), 54.6(C-18), 39.8(C-19), 
39.4(C-20), 31.2(C-21), 36.2(C-22), 28.8(C-23), 16.6(C-24), 15.9(C-25), 16.9 (C-26), 
23.6(C-27), 69.1(C-28),17.8(C-29), 21.6(C-30): 
 
 
3β-olean-12-en-3,28-diol  
(erithrodiol) 85 
      :White amorphous powder 
 C30H50O2  
Mass (M-H)
-
 m/z    : 441.33 
 
1
H NMR (300MHz, C5D5N):5.5(1H, bs, H-12), 3.91(1H, d, J=10, H-28a), 3.38(2H, m, 
H-3, H-28b), 1.34(3H, s, H-27), 1.15(3H, s, H-24), 1.09(3H,s,H-30), 1.09(3H, s, H-26), 
1.0(3H,s,H-25), 0.98(3H, s, H-29). 
 
13
C NMR (75MHz, C5D5N) δ: 39.3(C-1),26.5 (C-2),81.3 (C-3),43.8 (C-4), 47.9(C-5), 
18.4(C-6),33.2 (C-7), 40(C-8),48.5 (C-9),37.2 (C-10), 24(C-11), 122(C-12),145.5 (C-
13), 42.4(C-14), 28.7(C-15), 24(C-16), 46.9(C-17), 42.4(C-18), 47(C-19), 31.2(C-20), 
34.6(C-21), 33.6(C-22), 27.9(C-23), 14.4(C-24), 16.4(C-25), 17.9(C-26), 26.4(C-27), 
64.4(C-28), 33.1(C-29), 23.9(C-30): 
 
3β-hydroxyurs-12-en-28-methyl  
(amyrin alpha) 86 
      
:White amorphous powder
  
 
: C30H50O  
Mass (M-H)
-
 m/z    : 425.34 
 
1
H NMR (300MHz, C5D5N) δ: 5.27(1H,t,J=3.12,H-12), 3.56(1H,dd,J=5.55, 10.86, H-
3), 1.31(3H,s,H-28), 1.2(3H,s,H-23), 1.12(3H,s, H-26), 1.09(3H, s, H-27), 1.02(3H, s, 
H-24), 0.97(3H, s, H-30), 0.96(3H, s,H-29), 0.94(3H,s,H-25).  
 
13
C NMR  (75MHz, C5D5N) δ: 39.2(C-1), 28.2(C-2), 78.1(C-3), 41.7(C-4), 55.7(C-5), 
18.8(C-6), 33.26(C-7), 39.9(C-8), 48.1(C-9), 37.1(C-10), 23.6(C-11), 124.9(C-12), 
139.9(C-13), 48.1(C-14), 28.2(C-15), 26.9(C-16), 33.9(C-17), 59.2(C-18), 39.8(C-19), 
39.4(C-20), 31.4(C-21), 41.7(C-22), 28.8(C-23), 15.9(C-24), 16.6(C-25), 17.08(C-26), 
23.5(C-27), 28.9(C-28), 17.8(C-29), 21.5(C-30): 
 
 
Echinocystic acid 87 
      :White amorphous powder 
: C30H48O4  
Mass (M-H)
-
 m/z    : 471.35 
 
1
H NMR (300MHz, C5D5N) δ: 5.63 (1H, bs, H-12), 5.23 (1H,bs,H-16), 3.65 (1H, bd, 
J=11.91, H-18), 3.41(1H, bd, J=7.68), 2.87(1H, t, J=13.17, H-19), 2.87(1H, m, H-15), 
1.85(3H, s, H-27), 1.36(3H, s, H-23), 1.16(3H, s, H-30), 1.04(3H, s, H-29), 
1.00(3H,s,H-26), 0.97(3H,s, H-24), 0.82(3H,s,H-25). 
 
13
C NMR (75MHz, C5D5N) δ: 39.0 (C-1), 74.7(C-2), 78.05(C-3), 39.4(C-4), 55.8 (C-5), 
18.8(C-6), 33.3(C-7), 38.9 (C-8), 47.2(C-9), 39.4(C-10), 23.8(C-11), 41.4(C-14), 
36.1(C-15), 23.8(C-16), 47.2(C-17), 42.1(C-18), 49.8(C-19), 31.04(C-20), 37.4(C-21),  
 
  
 
32.9(C-22), 28.7(C-23), 16.6(C-24), 15.6 (C-25), 18.8(C-26), 27.2(C-27), 33.5(C-29), 
24.6(C-30): 
 
 
Oleanolic acid methyl ester 88 
      :White amorphous powder   
: C31H50O3  
Mass (M-H)
-
 m/z    : 469.50 
 
1
H NMR (300MHz, C5D5N) δ: 5.44 (1H,bt,H-12), 3.75(3H,s,OCH3), 3.52(1H,dd,J= 
5.1,10.5), 3.16(1H,bd,J=10.5), 1.35(3H,s,H-27), 1.25(3H,s,H-23), 1.08(3H,s,H-26), 
1.02(3H,s,H-24,30), 0.97(3H,s,H-29), 0.9(3H,s,H-25) .   
 
13
C NMR (75MHz, C5D5N) δ: 43.3(C-1), 32.3(C-2), 79.5(C-3), 41.1(C-4), 57.2(C-5), 
26.2(C-6), 38.8(C-7), 43.3(C-8), 53.1(C-9), 39.9(C-10), 24.9(C-11), 132.1(C-13), 
47.4(C-14), 32.3(C-15), 25.1(C-16), 49.5(C-17), 43.4(C-18), 48.4(C-19), 29.6(C-20), 
34.6(C-21), 21.1(C-22), 18.05(C-24), 17.04(C-25), 18.7(C-26), 17.04(C-27), 21.1(C-
28), 21.1(C-29), 21.1(C-30), 11.7 (CH3CO):
 
 
3β-(2-O-(6-deoxy-alpha-L-mannopyranosyl)-alpha-L-arabinopyranosyl) oxy)-23-
hydroxyolean-12-en-28-oic acid  
(hederin alpha) 89 
      :White amorphous powder  
: C41H66O12  
Mass (M-H)
-
 m/z    : 749.45 
 
1
H NMR (300MHz, C5D5N) δ:  6.42(1H,s,H-1”), 5.69(1H,s,H-12), 5.17(1H,d, 6.3,H-
1’), 4.77-4.56(3H,m,H-2”, 2’, 3”), 4.38-4.15(5H,m,H-3’, 4’,5a’, 4”, 23a, 3), 3.80(2H, 
m, H-5b’, 23b), 3.35(1H, bd, J=10.38, H18), 1.69(1H, d, J=6.03, H-6”),  1.26(3H,s,H-
27), 1.12(3H, s, H-24), 1.06(3H,s,H-26), 1.04(3H,s, H-30), 0.97(3H X 2, s, H-25, 29).   
 
13
C NMR (75MHz, C5D5N) δ: 38.0(C-1), 26.0(C-2), 80.9 (C-3), 41.9(C-4), 48.1(C-5), 
18(C-6), 33.2(C-7), 39.7(C-8), 47.7(C-9), 36.8(C-10), 23.6(C-11), 122.8(C-12), 
144.8(C-13), 43.5(C-14), 28.3(C-15), 23.6(C-16), 46.3(C-17), 42.1(C-18), 46.6(C-19), 
30.9(C-20), 34.0(C-21), 32.8(C-22), 26.1(C-23), 16.02(C-24), 14.0(C-25), 17.4(C-26), 
23.7(C-27), 180.0(C-28), 33.2(C-29), 18.5(C-30), 104.5(C-1’), 101.7(C-1”), 75.7(C-2’), 
72.5(C-2”), 74.1(C-3’), 72.4(C-3”), 69.5(C-4’),74.9(C-4”), 63.4(C-5’), 69.7(C-5”): 
 
3β-olean-12-en-28-methyl  
(amyrin beta) 90 
      : White amorphous powder 
: C30H50O  
Mass (M-H)
-
 m/z    : 425.45 
 
1
H NMR (300MHz, C5D5N) δ:5.29(1H, bs,H-12), 3.53(3H,dd, J=5.46, 10.71), 
1.30(3H,s,H-28), 1.26(3H,s,H-27), 1.16(3H,s,H-26), 1.05(3H,s,H-30), 1.01(3H,s,H-25), 
0.97(1H,bd, H-23,24,29). 
 
13
C NMR (75MHz, C5D5N) δ: 39.1 (C-1), 28.1 (C-2), 78.03 (C-3), 40.1 (C-4), 55.1 (C-
5), 18.7(C-6), 39.1 (C-7), 48.0 (C-8), 37.4 (C-9), (C-10), 23.3 (C-11), 122.3(c-12), 
145.2 (C-13), 41.3 (C-14), 26.4 (C-15), 27.1 (C-16), 33.4 (C-17), 47.5 (C-18), 47.03  
 
  
 
 
(C-19), 33.44 (C-20), 34.3 (C-21), 37.2 (C-22), 28.6 (C-23), 15.7 (C-24), 16.6 (C-25), 
17.01 (C-26), 26.1 (C-27) 28.7 (C-28), 32.7 (C-29), 23.8 (C-30):  
 
2α,3β,23-Trihydroxyurs-12-en-28-oic acid 
(asiatic acid) 91 
      :White amorphous powder 
: C30H48O5  
Mass (M-H)
-
 m/z    : 487.34 
 
1
H NMR (300MHz, C5D5N) δ: 5.51(1H,s,H-12), 4.35-4.22(3H,m,H-3,H-23a,H-3), 
3.76(1H,d,J=10.5,H-23b), 2.68(1H,d,J=11.4,H-18), 1.186 (3H,s,H-27), 1.11(3H,s,H-
26,H-29), 1.01(3H,s,H-30), 0.99(3H,s,H-25), 0.97(3H,s,H-24).  
 
13
C NMR (75MHz, C5D5N) δ: 47.8 (C-1), 68.6 (C-2), 77.9 (C-3), 43.4 (C-4), 44.8 (C-
5), 21.1 (C-6), 27.9 (C-7), 39.8 (C-8), 47.8 (C-9), 38.05 (C-10), 23.5 (C-11), (C-12), (C-
13), 42.3 (C-14), 28.4 (C-15), 24.6 (C-16), 47.6 (C-17), 53.3 (C-18), 39.8 (C-19), 39.1 
(C-20), 30.8 (C-21), 37.2 (C-22), 14.2 (C-23), 17.2 (C-24), 17.2(C-25), 17.2 (C-26), 
23.6 (C-27), (C-28), 17.3 (C-29), 21.1 (C-30): 
 
3 β-hydroxy-olean-12-en-28-oic acid  
(oleanolic acid) 92 
      :White amorphous powder 
: C30H48O3  
Mass (M+Na)
 +
 m/z    : 479.35 
 
1
H NMR (300MHz, C5D5N) δ: 5.88(1H,bs,H-12), 3.54(1H,t,J=6.33, 15.66), 
3.41(1H,dd,J=4.08, 9.78,H-18), 1.35(3H,s,H-27), 1.31,s,H-23), 1.097(3H, s,H-24,30), 
1.07(3H,s,H-26). 1.02(3H,s,H-29), 0.96(3H,s,H-25).   
 
13
C NMR (75MHz, C5D5N) δ: 38.7(C-1), 28.05 (C-2), 77.8 (C-3), 39.1 (C-4), 55.5 (C-
5), 18.5 (C-6), 33.9 (C-7), 39.5 (C-8), 46.4 (C-9), 37.1 (C-10), 23.6 (C-11),122.5(C-12), 
144.6 (C-13), 41.7 (C-14), 27.8 (C-15), 23.4 (C-16), 47.8 (C-17), 41.9 (C-18), 46.2 (C-
19), 30.7 (C-20), 32.9 (C-21), 33 (C-22), 28.5 (C-23), 16.3 (C-24), 15.3 (C-25), 18.5 
(C-26), 25.9 (C-27), 179.9 (C-28), 33 (C-29), 23.5 (C-30): 
 
 
3α-hydroxy-11-oxo-12-en-30-noroleane-20β-oic acid  
(18α-glycyrrhetinic acid) 93 
       :White amorphous powder 
: C31H48O4  
Mass (M-H)
-
 m/z     : 469.33 
 
1
H NMR (300MHz, C5D5N) δ: 5.88 (1H,s,H-12), 3.58(1H,bd, J=7.32,H-3), 3.17(1H, 
bd,J=13.2, H-8), 2.46(1H,s, H-9), 1.52(3H,s,H-28), 1.46(3H,s,H-30), 1.32(3Hx 2,s,H-
23, 26), 1.19 (3H,s,H-29), 1.15(3H,s,H-24), 0.77(3H,s,H-25). 
 
13
C NMR (75MHz, C5D5N) δ: 37.6 (C-1), 27.1(C-2), 78.1(C-3), 52.1(C-4), 61.2(C-5) 
18.2(C-6), 32.3 (C-7) ,37.7(C-8), 55.5 (C-9), 40.5(C-10), 199.4(C-11), 124.5(C-12), 
165.5(C-13), 43.01(C-14), 28.3(C-15), 27.05 (C-16), 45.3(C-17), 44.2(C-18), 39.9(C-
19), 36.1(C-20 ), 35.7(C-21), 34.2(C-22), 20.9(C-23), 16.8 (C-24), 16.1 (C-25), 17.2(C-
26), 20.7(C-27 ), 20.7(C-28), 28.9(C-29), 179 (C-30).  
  
 
 
3β-3-[(3-carboxypropanoyl) oxy]-11-oxoolean-12-en-30-oic acid 
 (carbenoxolone) 94 
       :White amorphous powder 
: C34H50O7 
Mass (M-H)
-
 m/z     : 569.54 
 
1
H NMR (300MHz, C5D5N) δ: 5.58(1H,s,H-12), 4.38(1H,dd, J=4.65, 11.61, H-3), 
2.64(1H, bd,J=13.56, H-18), 1.29 (3H,s,H-28), 1.03 (3H,s,H-27), 1.01 (3H,s,H-26), 
0.89 (3H,s,H30), 0.78 (3H X 2, d, J=3.3, H-23, 24), 0.57 (3H,s,H-25).   
 
13
C NMR (75MHz, C5D5N) δ: 39.8(C-1), 32.4 (C-2), 81.9 (C-3), 46.7 (C-4), 62.9 (C-5), 
18.4 (C-6), 33.7 (C-7), 38.2 (C-8), 56.2 (C-9), 39.1 (C-10), 202.6 (C-11), 128.8 (C-12), 
174.02 (C-13), 46.4 (C-14), 27.7 (C-15), 27.6 (C-16), 44.6 (C-17), 46.4 (C-18), 43.8 (C-
19), 33.05 (C-20), 33.0 (C-21), 39.8 (C-22), 29.6 (C-23), 18.4 (C-24), 16.9 (C-25), 19.3 
(C-26), 28.6 (C-27), 29.4 (C-28), 184.8 (C-29), 23.8 (C-30), COOH(180.4), COO 
(175.1): 
 
 
3α-hydroxy-olean-12-en-24-oic-acid 
(boswellic alpha) 95 
      :White amorphous powder  
: C30H48O3  
Mass (M-H)
-
 m/z    : 455.45 
 
1
H NMR (300MHz, C5D5N) δ:5.33(1H, bs, H-12), 4.79(1H,bs,H-3), 1.86(3H,s,H-30), 
1.33(3H,s,H-26), 1.21(3H,s,H-25), 1.17(3H, s,H-29), 0.93(3H, s,H-28), 0.93(3H,s,H-
27). 
 
13
C NMR (75MHz, C5D5N) δ: 36.1 (C-1), 27.7 (C-2), 72.5 (C-3), 49.6 (C-4), 50.8 (C-
5), 22.02 (C-6), 34.7 (C-7), 41.6 (C-8), 48.6 (C-9), 38.7 (C-10), 25.1 (C-11), 123.9 (C-
12), 146.4 (C-13), 43.4 (C-14), 28.5 (C-15), 28.9 (C-16), 32.5 (C-17), 48.9 (C-18), 48.3 
(C-19), 34.1 (C-20), 34.7 (C-21), 38.7 (C-22), 25.1 (C-23), 181.3 (C-24), 15.2 (C-25), 
18.4 (C-26), 27.1 (C-27), 26.7 (C-28), 29.9 (C-29), 25.1 (C-30): 
 
 
3β, 23-dihydroxy-olean-12-en-28-oic acid  
(hederagenin) 96 
      :White amorphous powder 
: C30H48O4  
Mass (M-H)
-
 m/z    : 471.34299 
 
1
H NMR (300MHz, C5D5N) δ: 5.52(1H,s,H-12), 4.26-4.2(2H, m, H-23a, H-3), 
3.76(1H,d,J=10.29, H-23b), 3.35(1H,bd, J=10.38, H-18), 1.25(3H,s,H-27), 
1.07(3H,s,H-24), 1.05 (3H,s,H-26), 1.02(3H,s,H-30), 0.98(3H,s,H-25), 0.94(3H,s,H-
29). 
 
13
C NMR (75MHz, C5D5N) δ:
 
38.9 (C-1), 33.4 (C-2), 73.4 (C-3), 39.05 (C-4), 48.6 (C-
5), 18.7 (C-6), 33.4 (C-7), 37.3 (C-8), 42.1 (C-9), 39.05 (C-10), 23.6 (C-11), 128 (C-
12), 146 (C-13), 42.3 (C-14), 27.8 (C-15), 23.6 (C-16), 43.01 (C-17), 48.3 (C-18), 46 
(C-19), 31.06 (C-20), 28.4 (C-21), 35.0 (C-22), 67.9 (C-24), 13.3 (C-25), 18.6 (C-26), 
26.2 (C-27), 16.07 (C-28), 23.8 (C-30): 
  
 
 
3α-hydroxy-urs-12-en-24-oic-acid  
(Boswellic beta) 98 
      :White amorphous powder  
: C30H48O3  
Mass (M-H)
-
 m/z    : 455.53 
 
1
H NMR (300MHz, C5D5N) δ:5.33(1H,bs,H-12), 4.78(1H,bs,H-3), 1.82(3H,s,H-23), 
1.22(3H,s,H-27), 0.85(3H,s,H-29,30). 
 
13
C NMR (75MHz, C5D5N) δ:
 13
C-NMR (75MHz, C5D5N) δ: 36.7 (C-1), 28.5 (C-2), 
72.2 (C-3), 49.9 (C-4), 51.1 (C-5), 22.4 (C-6), 35.7 (C-7), 39.8 (C-8), 49.05 (C-9), 42.1 
(C-10), 25.5 (C-11), 126.8 (C-12), 141.5 (C-13), 44.5 (C-14), 29.9 (C-15), 29.3 (C-16), 
35.7 (C-17), 61.05 (C-18), 41.6 (C-19), 41.5 (C-20), 33.1 (C-21), 43.4 (C-22), 25.5 (C-
23), 182.4 (C-24), 15.8 (C-25), 18.9 (C-26), 23.2 (C-27), 27.06 (C-28), 19.4 (C-29), 30. 
7 (C-30): 
 
Friedelin 99 
      :White amorphous powder   
: C30H50O  
Mass (M-H)
-
 m/z    :425.56 
 
1
H NMR (300MHz, C5D5N) δ:2,51(1H, m,H-2a), 2.42(1H, m, H-2b), 2.28 (1H,q,H-4), 
1.89 (1H, m, H-1a), 1.22(3H, s, H-1.22), 1.11(3H, s, H-27), 1.08(3H, s, H-26), 1.05 
(3H, s, H-29), 1.03(3H,d, J=6.69,H-23),0.98(3H,s,H-25), 0.73(3H,s,H-24).  
 
13
C NMR (75MHz, C5D5N) δ: 2.6 (C-1), 41.7 (C-2), 212 (C-3), 58.1 (C-4), 42.2 (C-5), 
41.3 (C-6), 18.6 (C-7), 53.2 (C-8), 36.4(C-9), 59.3 (C-10), 35.8 (C-11), 30.8 (C-12), 
40.02 (C-13), 38.5 (C-14), 32.7 (C-15), 36.4 (C-16), 30.3 (C-17), 43.2 (C-18), 35.7 (C-
19), 28.5 (C-20), 33.2(C-21), 39.6 (C-22), 7.4 (C-23), 14.8 (C-24), 18.1 (C-25), 20.5 
(C-26), 19 (C-27), 32.7 (C-28), 32.1 (C-29), 35.2 (C-30): 
 
 
 
8.2 Preparation of ursolic acid derivatives 
  
 
8.2.1 3-Oxo-urs-12-en-28-oic acid (75) 
To a solution of ursolic acid 60 (112.3 mg, 0.25 mmol) in acetone-dicholoromethane 
(10 ml) was added pyridinium chlochromate (PCC) (161.3 mg, 0.75 mmol).  After 
being stirred at room temperature until the reaction almost complete (TLC monitoring), 
the mixture was concentrated and partitioned with H2O and CH2Cl2.  The CH2Cl2 was 
concentrated and purified by silica gel column chromatography eluted with hexane 
acetone (95:5) to give 75. Yield 79.34%, white amorphous powder. 
 
  
 
8.2.2 3-hydroxyimino-urs-12-en-28-oic acid (76) 
 
A solution of 75 (26.2 mg, 0.34 mmol) and hydroxylamine hydrocholoride (27.6 mg, 
0.40 mmol) in pyridine (5 ml) was  heated  for  four  hour  at  50 
o
C.   After coolling to 
room temperature, the reaction mixture was concentrated under vacuum to dryness. It 
was then purified using silica gel and eluted with petroleum ether CHCl3 to obtain 76. 
Yield 90%: colorless crystal. 
 
8.2.3 3-acetyl-urs-12-en-28-oic acid (77) 
 
Ursolic acid 60 (120.0 mg, 0.26 mmol) was treated with acetic anhydride (534.0 mg, 
5.32 mmol) and pyridine at room temperature overnight and worked up with 10% HCl, 
NaHCO3, followed by separation using separating funnel to get the dicholoromethane 
layer.  MgSO4 was added to absorb water from it and rinse using dichloromethane.  It 
was purified using silica gel and eluted using chloroform petroleum ether (90:10) to 
give 76. Yield 50%, white amorphous powder. 
 
8.2.4 3-Oxo-urs-12-en-28-oic acid methyl ester (80) 
 
Methyl ursolate 79 was treated with PCC same fashion as in 75 to get compound 80. It 
was purified using silica gel column chromatography and eluted   using chloroform 
petroleum ether (90:10). Yield 90%, colorless crystal. 
 
 
 
 
  
 
8.2.5 3-hydroxyimino-urs-12-en-28-oic acid methyl ester (81) 
 
A solution of 80   (80.0 mg, 0.17 mmol) and hydroxylamine hydrochloride   (108.0 mg, 
1.56 mmol) in pyridine was heated for 2hrs at 50 
o 
C.  It was then cooled to room 
temperature and diluted after that with CH2Cl2 followed by washing with 10% HCl for 
three times.  It was then dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. It was purified with silica gel column chromatography using CHCl3 hexane 
(40:60) to give 81 Yield 95%. 
 
8.2.6 3-hydroxy-urs-12-en-28-oic acid methyl ester (79) 
 
To a stirred solution of ursolic acid 60 (10.0 mg, 0.02 mmol) in approximately 10 ml of 
toluene: MeOH (3:2) and solution of TMSCHN2 (trimethylsilane diazomethane) in 
hexane was added drop wise until the yellow color persisted.  The mixture was stirred at 
room temperature and concentrated.  It was purified using silica gel column 
chromatography with hexane CHCl3 (70:30) to give 79. Yield 95 %, white amorphous 
powder. 
 
8.2.7  3-acetyl-urs-12-en-28-oic acid methyl ester (78) 
 
Compound 77 was treated with TMSCHN2 in the fashion as in preparation of 79 to give 
78.  Yield   95%, colorless crystal. 
 
 
 
 
  
 
8.2.8 Physical and spectral data of compounds 75-81 
 
3-oxo-urs-12-en-28-oic acid (75) 
: white amorphous powder 
: C30H46O3. 
UV λmax (MeOH), nm     : Not tested 
Mass (M-H)
-
 m/z                      : 453.33524 
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
3-hydroxyimino-urs-12-en-28-oic acid (76) 
: white amorphous powder 
: C30H47NO3. 
UV λmax (MeOH), nm     : Not tested 
Mass (M+H)
+
 m/z                      : 470.35516 
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
 
 
3-acetyl-urs-12-en-28-oic acid (77) 
: white amorphous powder 
: C32H50O4 
UV λmax (MeOH), nm     : Not tested 
Mass (M-H)
-
 m/z                      : 497.36343  
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
3-acetyl-urs-12-en-28-oic acid methyl ester (78) 
: white amorphous powder 
: C32H50O4 
UV λmax (MeOH), nm     : Not tested 
Mass (M-K)
-
 m/z                      : 473.28149  
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
3-hydroxy-urs-12-en-28-oic acid methyl ester (79) 
: white amorphous powder 
: C31H50O3 
UV λmax (MeOH), nm     : Not tested 
Mass (M-K)
-
 m/z                      : 493.35556 
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
  
 
3-oxo-urs-12-en-28-oic acid methyl ester (80)  
: white amorphous powder 
: C31H48O3 
UV λmax (MeOH), nm     : Not tested 
Mass (M+Na)
+
 m/z                      : 491.34198 
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
 
3-hydroxyimino-urs-12-en-28-oic acid methyl ester (81)  
: white amorphous powder 
: C31H49NO3 
UV λmax (MeOH), nm     : Not tested 
Mass (M+Na)
+
 m/z                     : 506.35175 
1
H NMR (300MHz, C5d5N) δ   : See Table 4.1 
13
C NMR (75MHz, C5D5N) δ   : See Table 4.2 
 
8.3 Biological assays 
 
The biological evaluations were performed on inflammatory related bioassays. The 
assays were hyaluronidase and lipoxygenase inhibitory and TPA induced mouse ear 
oedema.  
 
8.3.1 Hyaluronidase inhibitory assay 
 
The assay was performed according to the Sigma protocol with slight modifications 
(Ling et al., 2003). The assay medium consisting of 1.00-1.67 U hyaluronidase in 100 
µl 20 mM sodium phosphate buffer pH 7.0 with 77 mM sodium chloride and 0.01% 
Bovine Serum Albumin (BSA)  was preincubated with 5 µl of the test compound in 
DMSO (dimethyl sulphoxide) for 10 min at 37
o
C. Then the assay was commenced by 
adding 100 µl hyaluronic acid 82 (0.03% in 300 mM sodium phosphate, pH 5.35) to the 
incubation mixture and incubated for a further 45 min at 37 
o
C. The undigested 
  
 
hyaluronic acid 82 was precipitated with 1 ml acid albumin solution made up of 0.1% 
bovine serum albumin in 24 mM sodium acetate and 79 mM acetic acid, pH 3.75. After 
standing at room temperature for 10 min, the absorbance of the reaction mixture was 
measured at 600 nm. The absorbance in the absence of enzyme was used as the 
reference value for maximum inhibition. The inhibitory activity of test compound was 
calculated as the percentage ratio of the absorbance in the presence of test compound 
vs. absorbance in the absence of enzyme.  
 
% Inhibition =   At   x   100% 
                          Ac 
 
Where:      At = absorbance in the presence of test compound; and 
       Ac = absorbance in the absence of enzyme 
 
The enzyme activity was determine by control experiment that run simultaneously, in 
which the enzyme was pre incubated with 5µl DMSO, followed by the assay procedures 
described above. In this case, the percentage ratio of the absorbance in the presence of 
enzyme vs. that in the absence of enzyme was in the range of 15-20%. The performance 
of the assay was verified using apigenin as a reference under exactly the same 
experimental conditions. The extract was tested at concentration of 100 µg/ml in the 
final reaction mixture. The compounds however were tested at several concentration 
from 100-2000 uM in the final reaction mixture. The results were expressed as mean of 
the inhibitory values ± S.D of three separate experiments measured in triplicates. 
 
 
 
 
  
 
8.3.2  TPA induced mouse ear oedema assay 
  
The assay was performed according to Hirota (1990). The 12-O-tetradecanoylphorbol-
13-acetate, TPA (1 µg) dissolved in acetone (20 µl) was applied to the ear of male strain 
albino mice (25-30g) by means of a micropipette. The plant extracts were applied 
topically to the inner surface of the right ear at 2 mg/ear about 30 min before each TPA 
treatment. The other ear which acted as a control was applied with sample vehicle. After 
eight hours of TPA treatment, the mouse was sacrified and the ears were cut off.  The 
ears were weight to investigate the resulting oedema. The results were expressed as 
percentage inhibition (IE%), taken to mean the complete suppression of erythema in the 
test animals. Each value used was the mean of individual determinations from seven 
mice. Indomethacin, a known inflammatory inhibitor was used as a positive control for 
this study.    
 
The inhibitory effects (IE%) of each extract was calculated as the ratio of the weight 
increase of the ear sections, according to the following formula: 
 
Inhibitory effect (IE%) = [(L-R)/(L-C*)] x 100 
          = [(L-R)/(L-(L/2.41))]x 100 
 
Where:    L = weight of leaf ear which treated with TPA only 
               R = weight of right ear which is treated with TPA plus tested extract 
             *C = weight of normal ear (untreated ear) 
*C is calculated weight. It has been found that treating a normal ear with 1 µg TPA 
resulted in a 2.41 times increase in weight.  
 
  
 
8.3.3 Lipoxygenase inhibitory assay 
 
Lipoxygenase inhibiting activity was measured using a spectrophotometric method    
(Riaz et al., 2004). The reaction mixture consisted of Sodium phosphate buffer 160 µl, 
10 µl of test sample solution and 20 µl of soybean lipoxygenase solution was initiated 
by the addition of 10 µl of the substrate in the form of sodium linoleic acid solution. 
The enzymatic conversion of linoleic acid was measured at 234 nm over a period of 6 
min. Test compounds and reference standards were dissolved in MeOH. All reactions 
were performed in triplicates in a 96-well microplate.    
 
 
                             Inhibition %=   E-S   x 100 
                                      E 
 
        Where:   E= Optical density of control 
            S= Optical density of sample (test compounds) 
 
8.3.4    Statistical analysis 
 
Data obtained were expressed as mean standard error (± S.D.). The data were analyzed 
for statistical significance using Student’s t-test (for hyaluronidase and lipoxygenase) 
and Duncan’s multiple range tests for TPA mouse ear oedema inhibitory activity. P-
values less than 0.05 were considered to be significant [*p<0.05; **p<0.01; 
***p<0.001]. The IC50 value was calculated using Probit analysis program version 
1987. 
 
 
  
 
8.4    QSAR model preparation using quantum chemical method  
 
The self consistent field (SCF) calculation and frequency calculation using RM1 semi 
empirical quantum chemical method were performed followed by QSAR analysis using 
CODESSA 2.6 to come out with QSAR model.  
 
8.4.1   Data collection from the biological and chemical aspect 
 
A number of ursolic acid 60 derivatives or analogues were prepared either from the 
structure modification process 75-81, isolated from Prismatomeris malayana; 60, 61, 
64 together with the commercially available compounds 83-103 which were purchased 
from Chromadex. The structure of each compound 60, 61, 64, 75-81, 83-103 was 
confirmed from the spectroscopic data of NMR and LCMS/MS and compared with the 
literature values. The spectral properties of compounds 60, 61, 64 and 75-81 were 
discussed in chapter 3 and 4 respectively while for compounds 83-103 were listed in 
8.1.8 section. 
 
Two compounds 78 and 80 were isolated as crystal and the crystal data were collected 
using Bruker SMART APEX diffractometer. The crystallographic data allowed to 
determines the absolute configuration of the two compounds. The crystal structure file 
was converted into molecular structure files using Chem3D Ultra 7.0 software package. 
All the analogues are listed in the table 5.4.2 (Please refer to chapter 5).  
  
All analogues were evaluated for their inflammatory activity on the hyaluronidase 
enzyme and the data was calculated as IC50 values. The data however were converted 
into log IC50 value units which were used instead of IC50 to improve the normal 
  
 
distribution of the experimental data points (Kartizky, 2006). The data were presented 
in table 6.9.2. 
 
8.4.2 Conversion into 3D structure and mopac file 
 
The crystal structure of compound 80 was used to determine the relative configuration 
of the other analogues. Starting from this structure, other structures were drawn using 
Chem 3D Ultra software. These structures were optimized using the MOPAC software 
package available in the Chem3D Ultra 7.0.     
 
8.4.3   Structure optimization using quantum chemical method 
 
The optimized 3D structures then are used for self consistent field (SCF) calculation. 
The SCF method was also known as the Hartree-FOCK method. The SCF calculation 
will provide quantum chemical molecular properties. The main idea of SCF theory is to 
replace all interactions to any one body with an effective interaction and thus reduce 
any multi-body problem into an effective one-body problem. The geometry 
optimization was done at RM1 semi empirical quantum chemical level which 
implemented in the MOPAC 6.0. The output files from scf calculation provide 
structural information on the basis of wave function of the molecular system.   
 
8.4.4 Force calculation using quantum chemical method 
 
The optimized 3D structures were subjected to frequency calculation using RM1 semi 
empirical quantum chemical method. The force constants are first calculated from the 
second derivatives of the energy with respect to displacements of all pairs of atoms.  
The force constants and the isotopic masses are then used to calculate the vibrational 
  
 
frequencies. The force calculation will also give the thermodynamic characteristics of 
compounds. The output file provided the structural information on the basis of the 
potential energy surface of the molecular system. 
 
8.4.5 QSAR analysis using CODESSA  
 
 
An input file was prepared which contained the data obtained from scf, 
thermodynamics, force and molecular structure calculations for each structure together 
with the activity value (log IC50). All the data files were loaded into the CODESSA 2.6 
(Kartizky et al., 1994) for further calculation.  
  
8.4.5.1    Calculation of descriptors 
 
The first step in developing a QSAR model is the descriptors calculation. Descriptors 
are defined as numerical characteristics associated with chemical structures (Kartisky, 
2005). They are derived on the basis of the structures chemical constitution, topology, 
geometry, and inherent wave function and potential energy surface. The molecular 
descriptors calculated in CODESSA are divided into six groups; constitutional, 
topological, geometrical, electrostatic, quantum chemical and thermodynamic. In the 
CODESSA program, over 450 descriptors could be calculated on the basis of the 
geometrical or electronic structures of the molecules. New descriptors also could be 
constructed using descriptors already calculated and standard mathematical operations. 
 
 
 
 
 
  
 
8.4.5.2   Developing a QSAR model 
 
The exceedingly large number of descriptors creates difficulties in the generation of the 
best multi linear model for a given property. The consequences are: 
 
i. The number of all possible multi-parameter correlation is enormous to 
calculate all of them.   
ii. Many of the theoretical descriptor scales are statistically interrelated 
which results in a critical loss of information if applied simultaneously in 
the same correlation. 
 
This phenomenon is called overfitting and it could be avoided by selecting only several 
descriptors (Jurgen, 2004). Thus, for the optimal number of descriptors in a QSAR 
model, the rule-of-thumb should be applied which describe that the number of 
descriptors should be equal one-sixth or one-third the number of molecules in the data 
set.   
 
Therefore, the good statistical methods that could select appropriate descriptors and best 
quality correlation are essential in developing QSAR/QSPR models. The two most 
advanced procedures for systematic development of the multi-linear QSAR/QSPR 
equations are the Heuristic method and the Best Multi-Linear Regression method.   
 
In QSAR models, the correlation represents the results of the (multi)linear regression 
between the property (a set of experimental values of a physical or chemical property, 
biological activity or performance under the study), y 
y =ao + ∑aixi 
  
 
and selected descriptors xi. This object is therefore composed of regression coefficients 
ai, correlation coefficient R
2
, standard error s
2
, and Fisher criterion F value for the set of 
structures used to derive the correlation. By default each correlation is characterised by 
its correlation coefficient, R
2
, and Fisher criterion F value. These values could be used 
to determine the quality of the derived model (section test of methods). 
 
a.   Heuristic method 
 
The Heuristic method could demonstrate which descriptors are insignificant from the 
standpoint of a single-parameter correlation and highly inter-correlated. All descriptors 
are checked to ensure that values of each descriptor are available for each structure and 
there is a variation in these values. Descriptors for which values are not available for 
every structure in the data in question are discarded. Descriptors having a constant value 
for all structure in the dataset are also discarded. This information will be helpful in 
reducing the number of descriptors involved in the search for the best QSAR model.   
 
In Heuristic method, a descriptor is eliminated if: 
i. the F-test’s value for the one-parameter correlation with the descriptor is 
below 1.0. 
ii. the squared correlation coefficient of the one parameter equation is less 
than  R
2
min = 0.1. 
iii. The parameter’s t-value is less than t1 = 1.5  
iv. The descriptor is highly inter-correlated which is above rfull =  0.99 
 
 
 
  
 
b. Best multi linear method 
 
The Best Multi-Linear Regression (BMLR) method is a more thorough procedure as it 
builds a single correlation using all selected descriptors in order to find the best 
regression model. Therefore, it will take longer time to complete compared to the 
Heuristic method. This method could processes 300 descriptors and 150 structures 
simultaneously. To achieve the maximum effectiveness, this method should fulfill the 
following criteria: 
 
i. The upper limit of the square of the linear correlation coefficient 
R
2
min for two descriptors scales to be considered orthogonal.  Is set 
to R
2
min = 0.1. 
ii. The lower limit of the square of the linear correlation coefficient for 
two descriptor scales to be considered non-collinear. Default value 
R
2
nc = 0.65 
iii. The maximum number of best correlations to be considered in the 
search of the best correlations with one descriptor scale added, is set 
to Nc= 400.   
iv. The probability level for the Fisher criterion F is taken as 95%. 
 
8.4.6 Method validation 
 
The good, robust and predictive QSAR model is its capability of making accurate and 
reliable predictions of the modeled response of new analogues. Validation is the process 
that established the reliability and relevance of a procedure for a specific purpose. The 
model could either validated using internal or external method. The internal method are 
  
 
such as least square fit (R
2
), cross-validation (Rcv
2
), chi (χ), root-mean-squared error 
(RMSE) and scrambling (Jorgen, 2004). External validation will use compounds test set 
that not included in the model development or so called training set.   
 
The internal validation was applied in this study due to considerably small data set. In 
least square method, linear regression, R
2 
shows the comparison between the 
experimental and predicted values. Thus, any outlier s from the data set will be removed 
in order to optimize the QSAR model. Leave-one-out-cross validation was also applied 
in this study again to measure the model predictive ability and any possibility if the 
model has been over fitted. The R
2
 should be larger than the Rcv
2
. The model will be 
suspected to be over fitting if the R
2
 value significantly larger (25%) than the Rcv
2 
(Jorgen, 2004).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
REFERENCES 
 
 
Abe, I., Rohmer, M. & Prestwich, G.C. (1993). Enzymatic cyclization of squalene and    
oxidosqualene to sterols and triterpenes.  Chem. Rev., 93, 2189-2206. 
 
Andersson, L.& Rova, J. H. (1999). The rps16 intron and the phylogeny of the 
Rubioideae (Rubiaceae).  Plant Syst. Evol., 214, 161-186. 
 
Arulmozhi, D.K., Veeranjaneyulu, A., Bodhankar S.L. & Arora S.K. (2005).   
Pharmacological investigations of Sapindus trifoliatus in various in vitro and in vivo 
models of inflammation.  Indian J. Pharmaco.l, 37 (2), 96-102. 
 
Atsuko, I., Takao, T., Naotaka, N. & Toyoyuki, N. (2003). Two triterpenoid saponins 
from Neonauclea sessilifolia. Chem. Pharm. Bull., 51 (11), 1335-1337. 
 
Bauch, H.J.& Leistner, E. (1978). Aromatic metabolites in cell suspension cultures of 
Galium mollugo.  Planta Med., 33,105-123. 
 
Bhoola, K,D., Figueroa, C.D. & Worthy, K. (1992). Bioregulation of kinins: kallikreins, 
kininogens, and kininases. Pharmacol. Rev., 44 (1),1-80. 
 
Biswanath, D., Sudhan, D. & Yoshihiro, H. (2007). Natural occurring iridoids. A 
review, part 1.  Chem. Pharm. Bull., 55 (2), 159-222.   
 
Bollet, A.J., Bonner, W.M. & Nance, J.L. (1963). The present of hyaluronidase in 
various mammalian tissues.   J. Biol. Chem., 238, 3522-3572. 
 
Bremer, B. & Manen, J.F. (2000). Phylogeny and classification of the subfamily 
Rubioideae (Rubiaceae). Plant Syst. Evol., 225, 43-72. 
 
Briggs, L.H., Cain, B.F., Le Quesne, P.W. & Shoolery, J.N. (1963). The structure of 
asperuloside.  Tett. Lett., 69-74.  
 
Burkill, I.H. (1966). A dictionary of the economic products of the Malay Peninsula. 
Kuala Lumpur, Malaysia: Ministry of Agriculture and co-operatives. 
 
Catterall, J.B. (1995). Hyaluronic acid, cell adhesion and metastasis. Cancer J., 8, 320-
324. 
 
Chan, K.Y., Zhang, J., Chang, C.W. (2011). Mode of action investigation for the anti-
bacterial cationic anthraquinones analogs. Bioorg. Med. Chem. Lett., 21, 6353-6356. 
 
Chao-Mei, M., Shao-Qing, C., Jing-Rong, C., Rui-Qing, W., Peng-Fei, T., Masao &, H., 
Mohsen, D. (2005). The cytotoxic activity of ursolic acid derivatives. Eur. J. Med. 
Chem., 40, 582–589. 
 
Chen, G., Xue, J., Xu, S.–X, & Zhang, R.–Q. (2007). Chemical constituents of the 
leaves of Diospyros kaki and their cytotoxic effects. Journal of Asian Natural Products 
Research, 9(4) 347-353. 
 
 
  
 
Chung, K.F., Dent, G., McCusker, M., Guinot, P., Page, C.P. & Barnes, P.J. (1987).  
Effect of ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to 
platelet activating factor in man. Lancet, 1, 248-251. 
 
Clementi, E. (1980). Computational aspects of large chemical systems, New York: 
Springer Verlag. 
 
CODESSA PRO User’s manual (2005). Florida: University of Florida. 
Retrieved from 
http://www.codessa-pro.com. 
 
Corner, E.J.H. (1940). Wayside trees of Malaya, vol. 2. Singapore: Government printing 
office.  
 
Csoka, A.B., Frost, G.I., Wong, T. & Stern, R. (1997). Purification and 
microsequencing of hyaluronidase isozymes from human urine. FEBS Lett., 417, 307-
310. 
 
De las Heras, B., Rodriguez, B., Bosca, L. & Villar, A.M. (2003). Terpenoids: sources, 
structure elucidation and therapeutic potential in inflammation. Curr. Top. Med. Chem., 
3, 171-185. 
 
De Padua, L.S., Bunyapraphatsara, N. & Lemmens, R.H.M.J. (1999). Plants resources 
of South-East Asia, Medicinal and poisonous plants 1. Bogor: Prosea foundation, 12 
(1), 24.  
 
Deepa, K.M., Girish, K.S. & Veerabasappa, G. T. (2006). A glycoprotein from a folk 
medicinal plant, Withania somnifera, inhibits hyaluronidase activity of snake venom. 
Comp. Biochem. Physicol.-C., 143, 158-161. 
 
Derek, V.B. & John, J.W. (1995). Novel anthraquinones from undifferentiated cell 
cultures of Galium verum.  Phytochem., 38 (1), 107-111.   
 
Dey, S. K., Islam, S., Mostafa, M., Nahar, N. & Mosihuzzaman, M. (2003). Some 
secondary metabolites from cytotoxic extract of Prismatomeris tetrandra. J. 
Bangladesh Chem. Soc., 6, 22-27. 
 
Dinarello, C.A. (1984).  Interleukin-1. Rev.  Infect. Dis., 6, .51-95. 
 
Dong-Hyun, K., Kyung-Min, H., In-Sik, C., Dae-Keun, K., Sung-Hoon, K., Byoung-
Mog, K., Tae-Sook, J., Mi-Hyun, P., Eun-Mi, A. & Nam-In, B. (2005). Triterpenoids 
from the flower of Campsis grandifolia K. Schum.  as human acyl-CoA: Cholesterol 
acyltransferase inhibitors. Arch Pharm Res, 5, 550-556. 
 
Dudley, H.W. & Ian, F. (1989). Spectroscopic methods in organic chemistry 4
th
 ed.  
England. McGraw-Hill Book company Europe. 
 
Dusser, D.J., Nadel, J.A., Sekizawa, K., Graf, P.D.& Borson, D.B. (1988). Neutral 
endopeptidase and angiotensin converting enzyme inhibitors potentiate kinin-induced 
contraction of ferret trachea.  J. Pharmacol. Exp. Ther., 244, 531-536. 
 
  
 
El Maradny, E., Kanayama, N., Kobayasi, H., Hossain, B., Khatun, S. & She, L.P. 
(1997). The role of hyaluronic acid as a mediator and regulator of cervical ripening.  
Human Reproduction, 12, 1080-1088.  
 
 
en.wikipedia.org/wiki/Inflammation  
Retrieved on 14 April 2014. 
 
 
Facino, R.M., Carini, M., Aldini, G., Marnelio, C., Arlandini, E., Franzoi, L., Colombo, 
M., Pietta & P., Mauri, P. (1993). Direct characterization of caffeol esters with 
antihyaluronidase activity in crude extracts from Echinacea augustifolia roots by fast 
atom bombardment tandem mass spectrometry  II.  Farmaco., 48, 1447-1461.   
 
Floss, H.G. (1979). Biochemistry of plant phenolics, recent advances in phytochemistry. 
Proceedings of the joint symposium of the phytochemical society of Europe and the 
Phytochemical Society of North America, 12, 59-89.   
 
Frossard, N., Stretton, C.D. &Barnes, P.J. (1990). Modulation of bradykinin responses 
in airway smooth muscle by epithelial enzymes. Agents Actions, 31(3-4), 204-209. 
 
Goh, S.H. (1995). Malaysian medicinal plants for the treatment of cardiovascular 
diseases, Kuala Lumpur: Pelanduk Publication (M) Sdn. Bhd. 
 
Graham, L.P. (2005). An introduction to medicinal chemistry (3
rd
 ed.). Oxford:  Oxford 
university press.  
 
Grisehach, H. (1965). Biosynthetic pathways in higher plants. London: Academic Press, 
London.  
 
Hall, L.H., Kellog, G.E, Haney, D.N. & Molconn-Z. (2002a). 4.00 user’s guide. 
Edusoft.Ic, Inc, Ashland , VA.  
  
Hall, L.H., Kier, L.B. & Hall, L.M. (2002b). The guide for development of QSAR with 
MDL  QSAR.  San Leandro: MDL information system. 
Retrieved on 20 December 2012 from  
http://www.edosoft-lc.com/molcomm/manuals/400/chaptwo.html 
 
Hansch, C. & Leo, P. (1979). Substituent constants for correlation analysis in chemistry 
and biology. New York: Wiley and sons.  
 
Haralampidis, K., Trojanowska, M. & Osbourn, A., E. (2002). Biosynthesis of 
triterpenoid saponins in plants. Adv. Biochem. Eng., 75, .31-49. 
 
Harborne, J.B. & Simmons, N.W. (1964). Biochemistry of phenolic compounds. New 
York: Academic Press. 
 
Havsteen, B. (1983). Flavonoids, a class of natural products of high pharmacological 
potency,  Biochem Pharmacol., 32 (7), 1141-1148. 
 
Hiroichi, N. (2005). Immunopharmacological approach to elucidating the mechanism of 
allergic inflammation.  Allergology International., 54, 251-261. 
  
 
 
Hirota, M., Mori, T., Yoshida, M. & Iriye, R. (1990). Suppression of tumor promoter-
induced inflammation of mouse ear by ursolic acid and 4,4-dimethylcholestane 
derivatives. Agric. Biol. Chem., 54 (4), 1073-1075.  
 
Hisao, K., Hitoshi, M. & Toshio, S. (1985). Activation of hyaluronidase by metallic 
salts and compound 48/80, and inhibitory effect of anti-allergic agents on 
hyaluronidase.  Chem Pharm. Bull., 32 (2), 642-646.  
 
Holgate, S.T. (1986). The pathophysiology of bronchial asthma and targets for its drug 
treatment.  Agents action, 18, 281-287. 
 
Holstein, S.A. & Hohl, R.J. (2004). Isoprenoids: remarkable diversity of form and 
function. Lipids, 39,  293-309. 
 
Horton, M.R., Shapiro, S., Bao, C., Lowenstein, C.I. & Noble, P.W. (1999). Induction 
and regulation of macrophage metalloelastase by hyaluronan fragments in mouse 
macrophages.  J.  Immunol., 162, 4171-4176. 
 
http://en.wikipedia.org/wiki/Eicosanoid  Retrieved on 28 July 2012 
 
http://iphy10.org/~rpage/theplantlist/A/rubiaceae/Prismatomeris Retrieved on 15 
January 2012 
 
http://www.edosoft-lc.com/molcomm/manuals/400/chaptwo.html Retrieved on 2 
August 2012 
 
Hu, R., Jean-Pierre, D., Michel, D. & Ruisheng, Z. (2009). QSAR models for 2-amino-
6-arylsulfonylbenzonitriles and congeners HIV-1 reverse transcriptase inhibitors based 
on linear and nonlinear regression methods. Eur. J. Med. Chem., 44, 2158-2171.   
 
Imbimbo, B.P. (2009). An update on the efficacy of non-steroidal anti-inflammatory 
drugs in Alzheimer’s disease.  Expert Opin. Investig. Drugs, 18, 1147-1168. 
 
In-Ah, L., Jin, H.L., Nam-In, B. & Dong-Hyun, K. (2005). Antihyperlipidemic effect of 
crocin isolated from the fructus of Gardenia jasminoides and its metabolite crocetin. 
Bio. Pharm. Bull., 28 (11), 2106-2110. 
 
Inger, L.M., Mart, A.F.J. & van de laar Harald, E.V.(2010). Non-steroidal anti-
inflammatory drugs:  an overview of cardiovascular risks, Pharmaceuticals, 3, 2146-
2162. 
 
Inoue, K., Shiobara, Y., Nayeshiro, H., Inouye, H., Wilson, G. & Zenk, M.H. (1984). 
Biosynthesis of anthraquinones and related compounds in Gallium mollugo cell 
suspension cultures. Phytochemistry, 23, 307–311. 
 
Inouye, H., Inouye, S., Shimokawa, N. &  Okigawa, M. (1968). Die iridoid glucoside 
aus Paederia scandens (lour.) merrill var. mairei (léveillé) hara. Tet. Let., 9(6), 683-
688.   
 
  
 
Inouye, H., Inouye, S., Shimokawa, N. & Okigawa, M. (1969). Studies on monoterpene 
glucosides. VII. Iridoid glucosides of Paederia scandens. Chem Pharm Bull., 17, 1942 
– 1948 
 
Inouye, H., Yoshida ,T., Tobita, S. & Okigawa, M. (1970). Studies on monoterpene 
glucosides–IX: Chemical correlation between asperuloside and loganin. Tetrahedron, 
26(16), 3905-3915. 
 
Jarai, M., Markus, F. & James, H. (2006). A quantitative structure-activity relationship 
(QSAR) analysis of triarylmethane dye tracers.  Jounal of Hydrology, 316, 84-97. 
 
Jean, B. (1995). Pharmacognosy, phytochemistry, medicinal plants. Lavoisier: 
Technique and Documentation-Lavoisier. 
 
Jean-claude, V. (2009). How hyaluronan-protein complexes modulate the hyaluronidase 
activity: The model. Biophysical Chemistry, 145, 126-134. 
 
Jiang, J.s, Feng, Z.M. & Zhang, P.C. (2005). Chemical constituents from the root of 
Prismatomeris tetrandra. Zhongguo Zhong Yao Za Zi,  30(22), 1751-1753. 
 
Jie-Ping, F. & Chao-Hong, H. (2006). Single step preparative separation of barbinervic 
acid and its epimer (rotungenic acid), along with two other pentacyclic triterpene acids 
from the leaves of Diospyros kaki using HSCCC.  Journal of Liquid Chromatography 
and Related Technologies, (29), 1-13. 
 
John, V. & Regina, B. (1987). Inflammation and the mechanism of action of anti-
inflammatory drugs. The FASEB journal, 11, 89-86. 
 
Jurge, B. (2004). Chemoinformatics: Concepts, methods and tools for Drug Discovery.  
United State: Springer International publisher science, technology, medicine.  
 
Kanchanapoom, T., Kasai, R., Yamasaki, K. (2002). Iridoid and phenolic glycosides 
from Morinda corei. Phytochemistry, 59, 551-556. 
 
Karelson M. & Lobanov, V. S. (1996). Quantum chemical descriptors in QSAR/QSPR 
studies.  Chem. Rev., 96, 141-354. 
 
Karelson, M. (2000). Molecular descriptors in QSAR/QSPR. New York: John Wiley 
and sons, Inc., Publication.  
 
Kartisky, A.R., Svetoslav, H.S., Dimitar, A.D. & Karelson, M. (2008). QSAR modeling 
of the antifungal activity against Candida albicans for a diverse set of organic 
compounds.  Bioorg. Med. Chem.,  16, 7055-7069. 
 
Kartizky, A.R., Liliana, M.P., Svetoslav, S., Dimitar, A.B. & Karelson, M. (2006).  
QSAR study of antiplatelet agents.  Bioorg. Med. Chem, 14, 7490-7500. 
  
Kartizky, A.R., Lobanov, V.S. & Karelson M. (1994). Comprehensive descriptors for 
structural and statistical analysis.  Reference Manual, Version 2.0.,  
 
  
 
Kartizky, A.R., Ruslan, P., Subbu, P., Karelson, M., Indra, P. & Nitin, D. (2002). A 
QSPR study of sweetness potency using the CODESSA program.  Croatia Chemical 
Acta, 75, 475-502.   
 
Kartsen, K., Dietmar, G., Sujit, K.D., Nilufar, N., Mohammad, M., Nasim, S. M., 
Hossain, S, Philip, J.S. & Jian-Jung, P.F.S. (2007). Prismatomerin, a new iridoid from 
Prismatomeris terandra. Structure elucidation, determination of absolute configuration 
and cytotoxicity.  J. Nat. Prod., 70 (8), 1339-1343. 
 
Keng, H. (1969). Orders and families of Malayan seed plants. Kuala Lumpur: 
Singapore University of Malaya Press.   
 
Kim, I.H., Uchiyama, N., Kawahara, N., Goda, Y. (2006). Iridoid glycosides and 
cucurbitacin glycoside from Neopicrorhiza scrophulariiflora. Phytochemistry, 67, 
2691-2696. 
 
Kittisak, L., Sukanya, D.A., Vichien, J. & Jerapan, K. (1999). Anti-malarials from 
Stephania venosa, Prismatomeris sessiliflora, Diospyros Montana and Murraya 
siamensis.  Planta Medica, 65, 754-756. 
 
Klaus, M. H. (1995). The shikimate pathway as an entry to aromatic secondary 
metabolism.  Plant Physiology, 107), 7-12. 
 
Kohei, K., Wakako, H., Shogo, T., Ken, H., Toshiko, S., Yuko, K., Hiromi, Y. & 
Yoshiyuki, M. (2010).  Inhibitory effect of anthraquinones isolated from the Noni 
(Morinda citrifolia) root on animal A-, B- and Y-families of DNA polymerases and 
human cancer cell proliferation.  Food Chem., 118, 725-730.   
 
Kohej, K., Yohei, T., Hanani, E., Mansur, U. & Toshiko, S. (2005).  New anthraquinone 
and iridoid from the fruits of Morinda citrifolia. Chem. Pharm. Bull., 53 (12),1597-
1599. 
 
Kotaro, T.  & Masako T. (1978). Studies on the const. of the medicinal plants. XXL. 
Const. of the leaves of Clethra barbinervis Sieb. Et Zucc and the 
13
C-Nuclear Magnetic 
Resonance spectra of 19α-hydroxyurs-12-en-28-oic acid type of triterpenoids.  Chem. 
Pharm Bull, 26 (9), 689-2693. 
 
Koyama, J., Nisino, Y. (2008). Correlation between reduction potentials and inhibitorns 
of Epstein-Barr virus activation by anthraquinone derivatives. Bioorg. Med. Che. Lett., 
18, 4106-4109. 
 
Krohn, K., Gehle, D., Dey, S.K., Nahar, N., Mosihuzzaman, M., Sultana, N., Sohrab, 
M.H., Stephens, P.J., Pan, J.J., Sasse, F. (2007). Prismatomerin a new iridoid from 
Prismatomeris tetrandra.  Structure elucidation, determination of absolute configuration 
and cytotoxicity.  J. Nat. Prod., 70, 1339-1343. 
 
Kuigoua, G.M., Kouam, S.F., Ngadjui, B. t., Schulz, B., Green, I.R., Choudhary, M.I., 
Krohn, K. (2010). Secondary metabolic products from the stem bark of Plumeria rubra 
Linn. displaying anti-microbial activities.  Planta Med, 76, 620-625. 
 
  
 
Kwanjai, K., Somdej, K. & Ruchanee, P. (2005). Biological activity of anthraquinones 
and triterpenoids from Prismatomeris fragrans.  Journal of Ethnopharmacology, 100, 
284-288. 
 
Lee, H.H. (1968).  Colouring matters from Prismatomeris malayana.  Phytochem., 8, 
501-503. 
 
Leistener, E. (1981). Biosynthesis of plant quinones. In: Conn, E.E.(Ed), The 
biochemistry of plants (pp. 403-423). vol 7. London: Academic  Press. 
 
Leistener, E. (1985).  Biosynthesis of chorismate-derives quinones in plant cell cultures. 
In: Primary and secondary metabolism of plant cell cultures (pp.215-224). Berlin: 
Springer Berlin,. 
 
Leistner, E. (1967). Incorporation of shikimic acid into 1,2-dihydroxy-anthraquinone 
(alizarin) by Rubia tinctorum L.,  Tet. Lett., 475-476. 
 
Lemmens, R.H.M.J. & Bunyapraphatsara, N. (2003). Plant resources of South-East 
Asia, Medicinal and poisonous plants 3 12 (3). Bogor, Indonesia:  Prosea Foundation. 
 
Ling, S.K. (2003). Chemical and biological studies of four selected medicinal plants of 
Malaysia, PhD Thesis. Nagasaki: Nagasaki University, Japan. 
 
Ling, S.K., Takashi, T. & Isao, K. (2003). Effects of iridoids on lipoxygenase and 
hyaluronidase activities and their activation by β-glucosidase in the presence of amino 
acids.  Biol. Pharm. Bull. 26, 352-356. 
 
Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. (2001).  Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development sttings.  Adv. Drug Deliv. Rev., 46, 3-26. 
 
Liu, D., Pearlman, E., Diaconu, E., Guo, K., Mori, H. T. & Markowitz, S., (1996).    
Expression of hyaluronidase by tumor cells induces angiogenesis in vivo.  Proc. Natl. 
Acad. Sci. U.S.A., 93, 7832-7837.   
 
Liu, H.X., Zhang, R.S., Yao, X.J., Liu, M.C., Hu, Z.D. & Fan, B.T. (2003).  QSAR 
study of ethyl 2-[(3-methyl-2.5-dioxy(3-pyrrolinyl) amino-4-(trifluoromethyl) 
pyrimidine-5-carboxylate: An inhibitor of AP-1 and NF-кB mediated gene expression 
based on support vector machines.  J. Chem. Inf. Comput. Sci.. 43, 1288-1296.   
 
Maria, A.A., Antonietta B., Anita, G. & Luisa, M. (2010). Non-steroidal anti-
inflammatory drugs and brain inflammation: Effects on microglial functions.  
Pharmaceuticals, 3, 1949-1964. 
 
Masaaki, K., Tadamasa, T & Haruo, M. (1983). Triterpenoid,s of the bark of  Jieris 
japonica   D.Don II.,  
13
C nuclear Magnetic Resonance of the Ƴ-lactones of ursane- and 
oleanane-type triterpenes.  Chem. Pharm. Bull., 31 (5), 1567-1571.   
 
Mariko, K., Ute, F., Mio, N., Mika, O., Masahiro, U. (1998). Anthraquinones from 
Ophiorriza pumila tissue and cell culture. Phytochemistry, 48, 107-111. 
 
  
 
Masateru, O., Chikako, M., Takemi, T., Yasuyuki, I. & Toshihiro, N. (2001). Anti- 
oxidantive and anti-hyaluronidase activities of some constituents from the aerial part of 
Daucus carota. Food sci. technol. Res., 7 (4), 307-310. 
 
Maurya, A., Feroz, K., Bawankule, D.U. & Yadav, D.K. (2012).  QSAR, docking and in 
vivo studies for immunomodulatory activity of isolated triterpenoids from Eucalyptus 
tereticornis and Gentiana kurroo.  European Journal of Pharmaceutical Sciences, 47, 
152-161. 
 
Miyako, Y., Masahiro, F., Tsuneatsu, N., Hikaru, O., Kazuhisamat S., Jiro T., 
Yoshiharu, K., Ryota, T, Junei K., Kunihide, M. & Tushihiro, F. (2005). Anti-
proliferative constituents from Umbeliferae plants VII.  Active triterpenes and 
rosmarinic acid from Centella asiatica.  Biol. Pharm. Bull., 28 (1), 173-175. 
 
Milkyas, E., Annabel, E., John, P.A., Hoseah, M.A., Albert, N. (2013).  Anthraquinones 
of the roots of Pentas micrantha.  Molecules, 18, 311-321. 
 
Moncada, S., Gryglewski, R., Bunting, S. & Vane, J.R. (1976). An enzyme isolated 
from arteries transforms prostaglandind endoperoxides to an unstable substance that 
inhibits platelet aggregation.  Nature (London) (263), 663-665.  
 
Morley, J. (1986). Platelet activating factor and asthma. Agents Actions, 19, 100-108. 
 
Mulholland, D.A., Mohammed, A.M., Coombes, P.H, Haque, S., Pohjala, L.L., 
Tammela, P.S. &  Crouch, N.R. (2011). Triterpenoid acids and lactones from the leaves 
of Fadogia tetraquetra var. tetraquetra (Rubiaceae). Nat. Prod. Commun., 6(11), 1573-
6. 
 
Nakanishi, K., Goto, T., Itồ, S., Natori, S. & Nozoe, S. (1974). Natural Products 
Chemistry, 1, 1-10. 
 
Nermeen, S. El-Safory, Ahmed E. F. & Cheng-Kang, L. (2010).  Hyaluronidases, a 
group of glycosidases:  Current and future perspectives. Carbohydrate polymers, 81, 
165-181.   
 
Newman, D. J., Gordon M. C. & Kenneth M. S. (2003). Natural Products as Sources of 
New Drugs over the Period 1981-2002. J. Nat. Prod., 66, 1022-1037. 
Ng, F.S.P.(1940).  Tree flora of Malaya, vol.4. Kuala Lumpur: Longman Malaysia. 
 
Nouri, A.M. E., Panayi, G.S. & Goodman, S.M. (1984). Cytokines and the chronic 
inflammation of rheumatic disease.1. The presence of interleukin-1 in synovial fluids.  
Clin. Exp. Immunol. , 55, 295-302. 
 
O’Neil, M.J. & Lewis, J.A. (1993). The renaissance of plant research in the 
pharmaceutical industry. Washington: American Chemical Society. 
 
Ogihara, K., Iraha, R., Higa, M.E. & Yogi, S. (1997).  Studies on const. from the twigs 
of Messerschmidia argentea 2. Bulletin of the college of Science University of the 
Ryukyus, 64, 53-59. 
 
  
 
Peter, J.B., Chung, K.F. & Clive, P.P. (1988). Inflammatory mediators of asthma: An 
update, Pharmacological Reviews, 50(4), 517-572. 
 
Pimm, S.L., Russell, G.j., Gittleman, J.L. & Brooks, T.M. (1995). The future of 
biodiversity.  Science, 269, 347-350. 
 
Pittaya, T., Yuttapon, B., Piyanut, S., Uma, P. & Walter, C. T. (2008).  Anthraquinones 
from the roots of Prismatomeris malayana.  Nat. Prod. Res., 22 (11), 962-968. 
 
Rainer, F. & Andreas, G. (2003). General introduction to QSAR Chapter 1. In: 
Quantitative strucuture activity relationship (QSAR) models of mutagens and 
carcinogens. New York: CRC Press.   
 
Recio, M.C., Giner, R.M., Uriburu, L., Manez, S., Cerda, M. & De La Fuenta J.R. 
(2000). In vivo activity of pseudoguaianolide sesquiterpene lactones in acute and 
chronic inflammation.  Life Sci, 66, 2509-18. 
 
Riaz, N,. Malik, M., Rehman, A., Ahmed Z., Muhammad, P., Nawaz, S.A., Siddiqui, J. 
& Choudhary, M.I. (2004). Lipoxygenase inhibiting and antioxidant oligostilbene and 
monoterpene galactoside from Paeonia emodi.  Phytochemistry, 65, 1129-1135.   
 
Ridley, H. N. (1967). The Flora of the Malay Peninsula.  Kuala Lumpur: L. Reeve & 
Co., LTD. 
 
Rocha, G.B., Freire, R.O., Simas, A.M. & Stewart, J.J.P. (2006). RM1: A 
reparameterisation of AM1 for H,C,N,O,P,S,F,Cl, Br and I. J. Computational 
Chemistry, 27, 1101-1111. 
 
Rohmer, M. (1999). The discovery of a mevalonate-independent pathway for isoprenoid 
biosynthesis in bacteria, algae and higher plants.  Nat. Prod. Rep., 16, 565-574. 
 
Rooney, P., Kumar, S., Ponting, J. & Wang, M. (1995). The role of hyaluronan in 
tumour neovascularisation. Int J. Cancer, 60, 632-636. 
 
Rowley A.F., Kuhn H. & Schewe T. (1998). Eicosanoids and related compounds in 
plants and animals. Portland: Portland Press. 
 
Ruzicka, L, (1953). The isoprene rule and the biogenesis of terpenic compounds. 
Experientia, 9, 357. 
 
Ruzicka, L. & Trebler, H. (1921). Zur Kenntnis des Pinens III Konstitution des 
Nitrosopinens und seiner Umwandlungsprodukte. Helv. Chim. Acta, 4, 505. 
 
Safayahi, H. (1997). Anti-inflammatory actions of pentacyclic triterpenes. Planta Med, 
63, 487-493. 
 
Sasai, Y. & Ishibashi, M. (1975). Histochemical demonstration of hyaluronic acid in 
human dermal mast cells. Tohoku J. Exp. Med., 116, 285-293. 
 
Scott, J.E, Heatley, F. & Hull, W.E. (1984). Secondary structure of hyaluronate in 
solution. A 
1
H NMR investigation at 300 and 500 MHz in dimethyl sulphoxide solution. 
Biochemical Journal, 220, 197-205.   
  
 
 
Senn, A., Germond, M. &  De Grandi, P. (1992).  Immunofluorescence study of actin, 
acrosin, dynein, tubulin and hyaluronidase and their impact on in-vitro fertilization. 
Human Reproduction, 6, 841-849. 
 
Silverstein, R.M., Bassler, G.C., Morrill, T.C. (1991). Spectrometric identification of 
organic compounds.  Singapore: John Wiley and Sons, Inc. 
 
Simone, C.B.G, Alexandra, D-K, Sophie, Da N., Philippe, G., Karim, B., Grace, G., 
Pascal, S. & Safa, M. (2008). Evaluation of ursolic acid isolated from Ilex 
paraguariensis and derivatives on aromatase inhibition. Eur. J. Med. Chem., 43, 1865-
1877.  
 
Simpson, H. (1998). Biotechnology and the economics of discovery in the 
pharmaceutical industry. London: BSC Print Ltd.  
 
Singh, D.N., Verma, N., Raghuwanshi, S. (2006). Anti-fungal anthraquinones from 
Saprosma fragrans. Bioorg. Med. Chem. Lett., 16, 4512-4514. 
 
Stern.  R. (2008).  Hyaluronidases in cancer biology.  Semin. Cancer Biol., 18, 275-280. 
Stone, M. & Jonatan, P. (1993). Statistical Thinking and technique for QSAR and 
related studies. 1. General Theory.   J. Chemometrics, 7, 455-475. 
 
Su-Ching, K., Pey-Rin, C. (1995). Constituents of roots of Rubia lanceolata Hayata.  
Journal of the Chinese Chemical Society, 42, 869-891. 
 
Suzuki, A., Hasegawa. M., Ishii, M. (2005). Anthraquinone derivatives as a new family 
of protein photocleaVERS.  Bioorg. Med. Chem. Lett., 15, 4624-4627. 
 
Takuya, K., Yukikazu, Y., Masatoshi, I. & Syuichi, O.(2003).  Hyaluronidase-inhibiting 
polysaccharide isolated and purified from hot water extract of sporophyll of Undaria 
pinnatifida. Food Science Technology Research, 9 (1), 25-29. 
 
Tingting, Z, Weiquan, Z., Guorong, F., Yifeng, C. & Yutian, W. (2007). Isolation and 
purification of iridoid glycosides from Gardenia jasminoides Ellis by isocratic reversed-
phase two dimensional preparative high-performance liquid chromatography with 
column switch technology.  Journal of Chromatography B, 858, 296-301. 
 
Toshihiro, M., Mai, W., Yu, T., Toshio, M. & Fumihiko, Y. (2010). Hyaluronidase 
inhibitors from Takuran, Lycopus lucidus. Chem Pharm Bull., 58 (3), 394-397.  
 
Umezawa, T. (2003). Diversity in lignan biosynthesis.  Phytochem. Rev.,  2, 371-390. 
Van den Berg, A.J.J. & Labadie, R.P. (1989). Quinones. In: Methods in Plant 
biochemistry, vol 1 (pp. 451-491). London: Academic Press London. 
 
Venketeshwer, R. (2012). Phytochemicals as Nutraceuticals - Global Approaches to 
Their Role in Nutrition and Health. Rijeka, Croatia: InTech Published. 
 
Verpoorte R. (1999). Chemodiversity and the biological role of secondary metabolites, 
some thoughts for selecting plant material for drug development. In Lars B. & Jan G. B. 
(eds.), Bioassay methods in natural product research and drug development. 
Proceedings of the phytochemical society of Europe. Kluwer: Academic Publishers. 
  
 
  
Vierhuis, E., York, W.S., Kolli, V.S.K., Vincken, J.P., Schols, H.A., Van Alebeek, G.-
J.W.M., Voragen, A.G.J. (2001). Structural analyses of two arabinose containing 
oligosaccharides derived from olive fruit xyloglucan: XXSG and XLSG.  Carbohyd. 
Res., 332, 285-297. 
 
Vincken, J.P., Lynn, H., Aede de,  G. &  Harry, G. (2007).  Saponins, classification and 
occurrence in the plant kingdom.  Phytochem., 68, 275-297. 
 
Von Euler, U.S. (1936). On the specific vaso-dilating and plain muscle stimulating 
substances from accessory genital glands in man and certain animals (prostaglandin and 
vesiglandin).  J. Physiol. 88(2), 213–234. 
 
Wang, S., Wang, Q., Wang, Y. (2008). Novel anthraquinone derivatives: Synthesis via 
click chemistry approach and their induction of apoptosis in BGC gastric cancer cells 
via reactive oxygen species (ROS)-dependent mitochondrial pathway. Bioorg. Med. 
Che. Lett., 18, 6505-6508. 
 
Weiss, U. & Edwards, J.M. (1980). Biosynthesis of aromatic compounds from acetic 
acid-The biosynthesis of aromatic compounds, New York: A Wiley-Interscience.  
 
Werner, S., Nebojsa S., Robert W., Robert, S. & Olaf, K. (2003). Complete assignments 
of 
1
H and 
13
C NMR resonance of oleanolic acid, 18α-oleanolic acid, ursolic acid and 
their 11-oxo derivatives.  Magnetic Resonance in Chemistry, 41, 636-638.  
 
West, D.C., Hampson, I.N., Arnold, F. & Kumar S. (1985). Angiogenesis induced by 
degradation products of hyaluronic acid. Science,  228, 1324-1326. 
 
West, D.C., Kumar, S. (1989). Hyaluronan and angiogenesis, In: The Biology of 
hyaluronan, Vol 143 (pp. 187-207). New York: John Wiley and Sons. 
 
Wiliam, D.W. (1998). The nervous system. In Robert, M.B.(ed.). Physiology (4
th
 ed.) 
(pp. 113) St. Louise: Mosby Inc. 
 
Winter, R.W., Cornell, K.A., Johnson, L.L. (1995). Hydrozy anthraquinones as anti-
malarial agents.  Bioorg. Med. Chem. Lett., 5, 1927-1932. 
 
Wu, M., Wu, P., Liu, M., Xie, H., Jiang, Y. & Wei, X. (2009). Iridoids from Gentiana 
loureirii.  Phytochemistry, 70, 746-750. 
 
www.colby.edu/chemistry/PChem/notes/MOPACinst.pdf  Retrieved on 22 Mac 2012 
 
www.madsci.org/post/archives/2001-04/986571103.Bc.r.html Retrieved on 29 
September 2011. 
 
Ying-Shan, H., Robert van der Heijden, Alfons, W.M. Lafeber, C.E. & Robert, V. 
(2002).  Biosynthesis of anthraquinones in cell cultures of Cinchona robusta proceeds 
via the methylerythritol 4-phosphate pathway.  Phytochem., 59, 45-55. 
 
Zefirov, N.S., Kirpichenok, M.A., Izmailov, F.F. & Trofimoz, M.I. (1987). Dokl Akad. 
Nauk SSSR, 296, 883. 
 
  
 
Zeng, C., Toole, B.P., Kinney, S.D., Kuo, J.W. & Stamenkovic, I. (1998).  Inhibition of 
tumor growth in vivo by hyaluronan oligomers. International journal of cancer, 77, 
396-401. 
 
Zi –Ming, F., Jian-Shuang, J., Ying-Hong, W. & Pei-Cheng, Z. (2005).  Anthraquinones  
from the roots of Prismatomeris tetrandra.  Chem. Pharm. Bull., 53(10), 1330-1332. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX  
Journals, Articles in Seminar, Proceeding and Conferences 
 
1. Khalijah Awang, Nor Hayati Abdullah, Noel F. Thomas and Sek Weng Ng.  
Methyl 3-Dehydroxy-3-Oxoursolate.   Acta Crytallographica (2009).  E65, 
02113 [Doi: 10.1107/S1600536809030669] 
  
2. Nor Hayati Abdullah,Khalijah Awang,  Noel F. Thomas  and Sek Weng Ng. 
Methyl 3-Acetoxy-3-Dehydroxyursolate. Acta Crytallographica (2009).  E65, 
02114 [[Doi: 10.1107/S1600536809030657]  
 
3. Nor Hayati Abdullah, Ling Sui Kiong, Khalijah Awang, Mohd. Faisal Iskandar 
Sukhari.  Effect of Extraction Parameters on Total Triterpenoid Saponins from 
Prismatomeris malayana.  Malaysian Journal Of Science, Vol 28, November 
2008 
 
4. Nor Hayati A., Ibrahim A.N., Noel F. Thomas, Khalijah A., Fadzureena J., 
Mazura Mp.   Pentacylic Triterpenoids Inhibition towards Hyaluronidase 
Activity: Synthesis and Qsar Study, 15th Project Evaluation and Monitoring 
(PEM), 31Oktober-2 November 2012, Hotel Heritage, Cameron Highland 
Pahang. 
 
5. Nor Hayati Abdullah, Khalijah Awang, Noel F. Thomas.  Anti Inflammatory 
Activity of Ursolic Acid and Derivatives.  International Conference on Natural 
Product (ICNP), 13-16 November 2011. 
 
6. Nor Hayati Abdullah, Ling Sui Kiong, Khalijah Awang, Mohd. Faisal Iskandar 
Sukhari.  Effect of Extraction Parameters on Total Triterpenoid Saponins from 
Prismatomeris Malayana.  International Conference on Molecular Chemistry 
2008 - Current Trends in Molecular Chemistry. 25-26 November 2008, 
University Malaya. 
 
7. Nor Hayati Abdullah, Ling Sui Kiong, Mazura Md. Pisar.  Chemical Analysis of 
Prismatomeris malayana and Its Anti-Inflammatory Activity.  Malaysian 
Science and Technology Congress 2008, 16-17 December 2008, Kuala Lumpur 
Convention Centre, Kuala Lumpur. 
 
8. Structure Activity Relationship Study on Isolated Compounds and Standardised 
Extract Preparation from Prismatomeris malayana.    Norhayati, S.K. Ling, 
M.A. Nor Azah, M.P. Mazura, S. Saidatul Husni, J. Fadzureena, B.K. Ong, 
Ihsan Safwan, Zainon Abu Samah, S. Mohd. Faisal Iskandar, A. Khalijah, N. 
Ibrahim Ali.  National Biotechnology Conference, PWTC Kuala Lumpur, May 
2010. 
 
9. Isolation And Structure Modification on the Anti Inflammatory Compound from 
Prismatomeris malayana.  Nor Hayati Abdullah, Mazura Md. Pisar, Fadzureena 
Jamaludin, Khalijah Awang, Ibrahim Ali Noorbatcha.  FRIM Project Evaluation 
Meeting, FRIM, Selangor, April 2010. 
     10. Prismalayanoside, a Novel Iridoid Glycoside from Prismatomeris malayana 
Ridley.  Nor Hayati Abdullah, Yasodha Sivasothy, Nurhanan Murni Yunos, Siti 
Syrifah Mohd Mutalip, Khalijah Awang.  (Submitted to Journal of Biooorganic 
and Medicinal Chemistry) 
  
 
 
 
